12th World Congress of Biological Psychiatry

14 – 18 June 2015 • Athens, Greece
Megaron Athens International Conference Centre

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Hellenic Society for the Advancement of Psychiatry and Related Sciences
12th World Congress of Biological Psychiatry

WFSBP Congress 2015

Smartphone APP
The congress @ your fingertips!

Get it now for your
- iPhone
- iPad
- iPod-Touch
- Android

Quickly find your way through the most up-to-date congress schedule of scientific sessions.

Further information is given at www.wfsbp-congress.org/app.
# Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Invitation to the 12th World Congress of Biological Psychiatry</td>
</tr>
<tr>
<td>3</td>
<td>About WFSBP</td>
</tr>
<tr>
<td>4</td>
<td>About the WFSBP Congress 2015</td>
</tr>
<tr>
<td>4</td>
<td>Congress Administration</td>
</tr>
<tr>
<td>4</td>
<td>WFSBP Executive Committee</td>
</tr>
<tr>
<td>4</td>
<td>Honorary Committee</td>
</tr>
<tr>
<td>4</td>
<td>International Scientific Programme Committee</td>
</tr>
<tr>
<td>5</td>
<td>National Presidents</td>
</tr>
<tr>
<td>6</td>
<td>Local Organizing Committee</td>
</tr>
<tr>
<td>6</td>
<td>WFSBP Administrative Meetings</td>
</tr>
<tr>
<td>7</td>
<td>Floorplan</td>
</tr>
<tr>
<td>9</td>
<td>WFSBP Awards and Grants</td>
</tr>
<tr>
<td>10</td>
<td>Format Descriptions</td>
</tr>
<tr>
<td>11</td>
<td>Scientific Information</td>
</tr>
<tr>
<td>11</td>
<td>CME Accreditation</td>
</tr>
<tr>
<td>12</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>13</td>
<td>Scientific Programme Overview</td>
</tr>
<tr>
<td>13</td>
<td>Structure of the Scientific Programme</td>
</tr>
<tr>
<td>23</td>
<td>Scientific Programme</td>
</tr>
<tr>
<td>23</td>
<td>Saturday, 13 June and Sunday, 14 June 2015</td>
</tr>
<tr>
<td>24</td>
<td>Monday, 15 June 2015</td>
</tr>
<tr>
<td>42</td>
<td>Tuesday, 16 June 2015</td>
</tr>
<tr>
<td>58</td>
<td>Wednesday, 17 June 2015</td>
</tr>
<tr>
<td>74</td>
<td>Thursday, 18 June 2015</td>
</tr>
<tr>
<td>91</td>
<td>Congress Information</td>
</tr>
<tr>
<td>91</td>
<td>Congress Venue</td>
</tr>
<tr>
<td>91</td>
<td>Congress Registration Counter</td>
</tr>
<tr>
<td>91</td>
<td>Name Badges</td>
</tr>
<tr>
<td>91</td>
<td>Congress Language</td>
</tr>
<tr>
<td>91</td>
<td>Certificate of Attendance/CME Certificate</td>
</tr>
<tr>
<td>91</td>
<td>Final Programme</td>
</tr>
<tr>
<td>91</td>
<td>Congress Information System</td>
</tr>
<tr>
<td>91</td>
<td>Wireless Lan/Wi-Fi</td>
</tr>
<tr>
<td>91</td>
<td>Technical Exhibition</td>
</tr>
<tr>
<td>91</td>
<td>WFSBP Congress APP</td>
</tr>
<tr>
<td>92</td>
<td>Speakers Congress APP</td>
</tr>
<tr>
<td>92</td>
<td>Poster Exhibition</td>
</tr>
<tr>
<td>92</td>
<td>Best Poster Awards</td>
</tr>
<tr>
<td>92</td>
<td>Programme Changes</td>
</tr>
<tr>
<td>92</td>
<td>Snack Bars/Venue Restaurant</td>
</tr>
<tr>
<td>92</td>
<td>Cloakroom</td>
</tr>
<tr>
<td>93</td>
<td>Cash Machine</td>
</tr>
<tr>
<td>93</td>
<td>First Aid</td>
</tr>
<tr>
<td>93</td>
<td>Mobile Phones</td>
</tr>
<tr>
<td>93</td>
<td>Currency</td>
</tr>
<tr>
<td>93</td>
<td>Visa</td>
</tr>
<tr>
<td>93</td>
<td>Official Italian Agency</td>
</tr>
<tr>
<td>93</td>
<td>Insurance</td>
</tr>
<tr>
<td>93</td>
<td>Force Majeure</td>
</tr>
<tr>
<td>93</td>
<td>General Conditions</td>
</tr>
<tr>
<td>93</td>
<td>Climate</td>
</tr>
<tr>
<td>92</td>
<td>Housing</td>
</tr>
<tr>
<td>93</td>
<td>Athens Information Counter</td>
</tr>
<tr>
<td>94</td>
<td>How to get to the Megaron Athens International Conference Centre</td>
</tr>
<tr>
<td>94</td>
<td>Car Park</td>
</tr>
<tr>
<td>94</td>
<td>Taxis</td>
</tr>
<tr>
<td>94</td>
<td>Safety</td>
</tr>
<tr>
<td>94</td>
<td>City of Athens</td>
</tr>
<tr>
<td>95</td>
<td>Exhibition Floor Plan/Exhibitors List</td>
</tr>
<tr>
<td>96</td>
<td>Acknowledgements</td>
</tr>
<tr>
<td>97</td>
<td>Industry Sessions</td>
</tr>
<tr>
<td>98</td>
<td>List of Chairpersons, Authors and Co-Authors</td>
</tr>
</tbody>
</table>
Dear Colleagues,

It is our privilege and special pleasure to welcome you to the 12th World Congress of Biological Psychiatry. The World Federation of Societies of Biological Psychiatry (WFSBP) has chosen Athens for its World Congress in June 14th –18th 2015; therefore, the hosting society (Hellenic Society for the Advancement of Psychiatry and Related Sciences) is very thankful.

Today, it is easy to envision a future where psychiatric diagnosis will be based on understanding fundamental defects in thinking, emotional processing, and motivational systems. Psychiatry is now well positioned to take advantage of the major advances achieved in the last few decades in neurobiology and cognitive sciences and to build on them. WFSBP with its unique complementarity between basic neuroscientists and clinical psychiatrists, coming from various cultural and geographical backgrounds, is an important tool for the future of psychiatry.

During the 12th World Congress of Biological Psychiatry, worldwide opinion leaders will share with us the recent innovations in their respective fields which impact on diagnosis, treatment and quality of life of our patients. High scientific level sessions have been organized: plenary lectures, symposia, interactive workshops and debates, while a good number of WFSBP Task Forces will actively participate in the scientific programme through the presentation of Treatment Guidelines they currently publish. Also, young scientists will present their recent findings through free communications and posters presentations. Moreover, the scientific programme of the present congress includes certain novel components such as a round table on the topic “Drug discovery in neuroscience: Why is big pharma reluctant to continue investing?”, and three educational sessions on basic research issues, pharmacological treatments, and brain stimulation methods.

We are looking forward to welcome you in Athens, the heart of European culture and civilization, and to receive you according to the traditional Greek hospitality. Finally, we wish you a joyous and fruitful congress participation and hope that you will take home unforgettable memories and inspiration for your research and everyday clinical practice.

Thank you for joining us!

Prof. Constantin R. Soldatos
Congress President and
Chair of the Local Organizing Committee

Prof. Florence Thibaut
Chair of the International
Scientific Programme Committee
Founded in 1974, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organisation composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its world-wide community, the World Federation has built an international network of over 4,000 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

WFSBP MEMBERS PER CONTINENT

As of May 2015

- Europe 26%
- Africa 4.8%
- Asia 8.6%
- Middle East 1.2%
- South America 0.4%
- Australia 2.2%
- North America 56.8%

THE PRINCIPLE OBJECTIVES OF WFSBP ARE:

- To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- To improve the quality of training spanning all the biological psychiatry sciences
- To promote education and achieve the highest level of knowledge and understanding within the field
- To provide information and guidance to all institutions, societies or individuals with an interest in biological psychiatry
- To establish, build, and maintain solid collaboration with international and national organisations related to biological psychiatry

Educational activities, regional, international and world congresses, the interactive website www.wfsbp.org, and The World Journal of Biological Psychiatry build the World Federation’s portfolio and insure its world-wide influence. The development of world-wide treatment guidelines is one of WFSBP’s main areas of international leadership.

WFSBP MEMBERS PER FIELD OF ACTIVITY

As of May 2015

- Clinicians 88%
- Researchers 12%

Year after year, more and more professionals choose to join the World Federation’s Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward welcoming new eminent member societies from different parts of the world.
About the WFSBP Congress 2015

CONGRESS ADMINISTRATION
The 12th World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)

WFSBP EXECUTIVE COMMITTEE
President (2013 – 2015)  Constantin R. Soldatos, Greece
Vice President (2013 – 2017)  Tudor Udristoiu, Romania
Past President (2013 – 2015)  Florence Thibaut, France
President Elect (2013 – 2015)  Masatoshi Takeda, Japan
Secretary (2013 – 2017)  Lakshmi N. Yatham, Canada
Treasurer (2013 – 2017)  Martin Hatzinger, Switzerland
Vice Secretary (2013 – 2017)  Ladislav Hosak, Czech Republic
Vice Treasurer (2013 – 2017)  Victoria Valdez, Ecuador

HONORARY COMMITTEE (HC)
Jules Angst, Switzerland
Jose Luis Ayuso, Spain
Tetsuo Fukuda, Japan
Gerardo Heinze, Mexico
Florian Holsboer, Germany
Jeffrey Lieberman, USA
Julien Mendlewicz, Belgium
Hans-Jürgen Möller, Germany
Robin Murray, UK
Ahmed Okasha, Egypt
Mitsumoto Sato, Japan
Göran Sedvall, Sweden
Michael Trimble, UK

INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC)
Florence Thibaut, France  Chair
Peter Falkai, Germany  Co-Chair
Shigenobu Kanba, Japan  Co-Chair
Lakshmi N. Yatham, Canada  Co-Chair
Michel Bourin, France  Secretary

Members of ISPC
C. A. Altamura, Italy*
M. Bauer, Germany
A. Benyamina, France*
M. Berk, Australia*
J. Bobes, Spain
C. L. Bowden, USA
J. Bradford, Canada
P. Brambilla, Italy
M. Bras, Croatia
M. S. Buchsbaum, USA
D. Castle, Australia
E. Ceskova, Czech Republic
J. Ciprian-Ollivier, Argentina
P. Cosyns, Belgium
P. Courtet, France*
B. Dean, Australia
K. Fountoulakis, Greece
S. Frangou, UK
W. Gaebel, Germany
F. Duarte Garcia, Brazil
W. F. Gattaz, Brazil*
M. George, USA
B. Glenthoj, Denmark
P. Gorwood, France
G. M. Goodwin, UK
A. Grace, USA
H. Grunze, UK
A. Halaris, USA
A. Hasan, Germany*
C. Hiemke, Germany
E. Holsboer-Trachsler, Switzerland
W. G. Honer, Canada
R. Kahn, The Netherlands
S. Kasper, Austria
T. Kato, Japan
J. Kane, USA
J. Kennedy, Canada
H. R. Kranzler, USA
R. Lanzenberger, Austria
V. Larach, Chile
A. Lopez Mato, Argentina
C. Lyketsos, USA
R. McCarley, USA
M. Maes, Belgium
H. Mayberg, USA
A. Kant Mital, India
E. Mohan Das, India

* Special correspondents of ISPC Core Group
About the WFSBP Congress 2015

Consultants to the ISPC

G. Alexopoulos, USA
C. Arango, Spain*
E. Baca Garcia, Spain
E. Belfort, Venezuela
A. Bozkurt, Cyprus
N. Boutros, USA
P. Boyer, France
A. Burns, UK
R. Castilla-Puentes, USA
M. Cetkovich-Bakmas, Argentina
Y. Hwa Chou, Taiwan
H. Correa, Brazil
J. Costa e Silva, Brazil
P. Cosyns, Belgium
J. de Buitelaar, The Netherlands
M. Dierick, Belgium
B. Dubois, France
P. Gejman, USA
A. Germanavicious, Lithuania
A. H. Glassman, USA
D. Gorelick, USA
G. Hajak, Germany
S. Heckers, USA*
Y. Hirayasu, Japan
E. Hollander, USA
J. Horacek, Czech Republic
A. Jablensky, Australia
C. Katona, UK
W. Kaye, USA
L. Konopka, USA
C. Krieg, Germany
T. Kudo, Japan
J. Soo Kwon, Korea*
S. Lamy, France
M. Leboyer, France
M. Lejoyeux, France
M. So Lee, Korea
B. Leonard, Ireland
Y. Levkovitz, Israel
P. Mc Gorry, Australia
P. Mc Guire, UK
A. Malafosse, Switzerland
J.-L. Martinot, France
H. Y. Meltzer, USA
A. Meyer-Lindenberg, Germany
Z. Nahas, Lebanon
D. Nutt, UK
J. Ospina-Duque, Colombia
N. Ozaki, Japan
G. Parker, Australia
L. Pezewas, Austria
S. G. Potkin, USA
M. Rapaport, USA
E. Richelson, USA
J. Rybakowski, Poland
D. Rujescu, Germany
H. Sackeim, USA
P. Salgado Pineda, Spain
T. Schläfer, Germany
L. Schneider, USA
C. Schulz, USA
E. Seifritz, Switzerland
W. W. Shen, Taiwan
L. Siever, USA
D. St. Clair, UK
M. Taleb, France/Algeria
T. Taneli, USA
J. Treasure, UK
N. A. Uranova, Russia
J. Van Os, The Netherlands
D. Velakoulis, Australia
E. Vieta, Spain
X. Yu, China*
M. Zanarini, USA
J. Zohar, Israel

National Presidents

A. Corrales, Argentina
A. Boyajyan, Armenia
J. Marksteiner, Austria
S. Claeys, Belgium
N. D. Noya-Tapia, Bolivia
A. Kucukalic, Bosnia-Herzegovina
P. Abreu, Brazil
O. Atanasova Mikova-Demireva, Bulgaria
R. R. Lam, Canada
E. Olea, Chile
J. Franco, Columbia
R. Castro, Costa Rica
M. Jakovljevic, Croatia
L. Hosak, Czech Republic
G. Wegener, Denmark
F. Solis de Mendez, Dominican Republic
V. Valdez de Vuibert, Ecuador
A. Okasha, Egypt
M. Meja Pena, El Salvador
J. Harro, Estonia
P. Courtet, France
S. Herpertz, Germany
C. R. Soldatos, Greece
H. Soto Chavez, Guatemala
M. Aguilar Lopez, Honduras
S.-W. Tang, Hong Kong
C. Banki, Hungary
R. Nagpal, India
A. J. Tanra, Indonesia
D. Gothelf, Israel
M. Maj, Italy
T. Nishikawa, Japan
M. Assimov, Kazakhstan
C. Uk Lee, Korea
B. Kupca, Latvia
C. Baddoura, Lebanon
B. Stefanovski, Macedonia
S. Krishnaswamy, Malaysia
D. Moussaoui, Morocco
G. Villanueva Colín, Mexico
H. Lovdahl, Norway
M. Amin, Pakistan
G. Da Costa, Panama
L. Villalba, Paraguay
About the WFSBP Congress 2015

LOCAL ORGANIZING COMMITTEE (LOC)
Chair: C. R. Soldatos
Honorary Chair: C. Stefanis

General Members
D. Anagnostopoulos
C. Androutsos
E. Angelopoulos
N. Bergiannaki
P. Bitsios
G. Diakogiannis
D. Dikeos
A. Douzenis
C. Fokas
K. Fountoulakis
G. Garyfalos
A. Gena
F. Gourzis
J. Hatzimanolis
S. Kaprinis
G. Karantanos
A. Karkanias
G. Kolaitis
S. Kotsopoulos
A. Koumoula
H. Lazaratou
M. Liakopoulou
M. Ramklint, Sweden
M. Hatzinger, Switzerland
Ch.-Y. Liu, Taiwan
B. Taneli, Turkey
A. V. Kalueff, Ukraine
G. Bouza, Uruguay
J. Ibáñez-Dominguez, Venezuela

Honorary Members
N. Angelopoulos
S. Beratis
A. Botsis
G. Christodoulou
I. Giouzepas
C. Ierodiakonou
G. Kaprinis
A. Karavatos
V. Kontaxakis
A. Liakos
I. Liappas
M. Livaditis
M. Madianos
A. Mallis
Y. Papakostas
A. Rabavilas
G. Trikkas
J. Tsiantis
E. Tzebelikos
N. Vaidakis

ADMINISTRATIVE MEETINGS
By invitation only

WJBP Editorial Board Meeting
Monday, 15 June 2015
12:45 – 14:00, Conference Room 4

WFSBP Individual Membership Section Meeting
Tuesday, 16 June 2015
12:30 – 13:30, MC 2 Room

WFSBP Task Force Meeting
Tuesday, 16 June 2015
12:30 – 14:30, Conference Room 4

WFSBP Standing and Operational Committees Meeting
Tuesday, 16 June 2015
14:30 – 16:30, Conference Room 4

WFSBP Council Meeting
Wednesday, 17 June 2015
12:30 – 13:30, MC 3 Room

WFSBP General Assembly
Wednesday, 17 June 2015
13:30 – 15:00, MC 3 Room
Ground Level | Floorplan

- Trianti Hall
- Muses Foyer
- Atrium
- Poster Exhibition
- Coffee Breaks
- Registration
- Allegro Restaurant

**Upstairs - Conference rooms 1 + 4**

**To -1 Level**
- Skalkotas Hall
- MC 2 Room
- MC 3 Room
- MC 3.3 Room
- MC 3.2 Room (Speakers Centre)

**Congress Entrance / Entrance B**
left from Main Music Hall Entrance
WFSBP AWARDS
The Executive Committee will distribute several prizes to honour distinguished scientists for their continuous excellence in clinical and basic research. The awards will be delivered during the Opening Ceremony of the Congress on Sunday, 14 June 2015. The best poster awards will be delivered during the Closing Ceremony on Thursday, 18 June 2015.

WFSBP LIFETIME ACHIEVEMENT AWARD IN BIOLOGICAL PSYCHIATRY
The WFSBP Lifetime Achievement Award in Biological Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has significantly influenced today’s field of biological psychiatry. This award is open to members and non-members of the WFSBP.

Awardee 2015:
Professor Janusz Rybakowski, Poland

WFSBP RESEARCH AWARD
The WFSBP Research Award is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of biological psychiatry.

Awardee 2015:
Professor Rupert Lanzenberger, Austria

WFSBP AWARD FOR EXCELLENCE IN MENTORSHIP
The WFSBP Award for Excellence in Mentorship is to acknowledge outstanding performance in providing guidance and mentorship to colleagues involved in clinical/research work in Biological Psychiatry. This Award is also intended to acknowledge long standing leadership in educational programs related to Biological Psychiatry.

Awardees 2015:
Professor E. Mohandas, India
Professor Bilgen Taneli, Turkey

WFSBP AWARD FOR EXCELLENCE IN EDUCATION
The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Award for Excellence in Education is open to all WFSBP members who have improved education in all fields of Psychiatry.

Awardees 2015:
Professor Philippe Courtet, France
Professor Konstantinos Fountoulakis, Greece

THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY EXCELLENCE IN PUBLICATION PRIZE
The World Journal of Biological Psychiatry (WJBP) is the official journal of the WFSBP (2013 Impact Factor: 4.225). The Chief Editor Prof. Siegfried Kasper awards the 2015 WJBP Excellence in Publication Prize to Prof. Heinz Grunze for his outstanding input to the scientific impact of the journal: four of his WFSBP Treatment Guidelines on Bipolar Disorder are among the top ten of the journal’s most cited papers of all time. This range of influence depicts the high quality of his work, which is based on systematic reviews and thorough evaluation of up-to-date literature.

Awardee 2015:
Professor Heinz Grunze, United Kingdom

WFSBP YOUNG INVESTIGATOR AWARDS FOR THE TEN BEST POSTERS (UNDER 40 YEAR-OLD)
An application for the Young Investigator Award is not necessary. All posters will be evaluated at the congress. The awards will go to those presentations that not only provide evidence of innovative research, but are also well presented.

WFSBP EDUCATIONAL GRANTS
WFSBP is offering an Educational Grant for young investigators (under 40 year-old) to attend the WFSBP biennial congress and the special WFSBP educational sessions. Special educational sessions have been developed and are only open to educational grant winners.
FORMAT DESCRIPTIONS

OPENING LECTURE
The Opening Lecture will be held during the Opening Ceremony on 14 June 2015.

PLENARY LECTURES
Plenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen from among the most prominent researchers in the respective field.

SYMPOSIA
Symposia were selected, covering basic, clinical, interface and conceptual topics of Biological Psychiatry. Symposia are organized and chaired by the experts whose proposals were accepted by the International Scientific Programme Committee.

WORKSHOPS
Workshops are highly interactive sessions with an educational focus. This format is especially designed to give specific regions a platform for presentation and networking.

DEBATES
Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) state their opinions on different subjects.

ROUND TABLE
The round table is a platform for scientists and industry representatives to discuss current and controversial issues.

WFSBP TREATMENT GUIDELINES SESSIONS
WFSBP Treatment Guidelines Sessions are 90-minute sessions with an educational focus. They centre on the WFSBP Treatment Guidelines and include brief presentations by individual panel members, followed by lively and informative discussion. This session type provides for substantial audience participation and should be highly interactive.

FREE COMMUNICATIONS
Authors were invited to submit abstracts on their latest research findings. All submitted abstracts were reviewed and the best were selected and allocated to Free Communication Sessions.

EDUCATIONAL GRANT SESSIONS
These sessions are especially designed for young researchers (under 40 year-old) which were pre-selected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational grant sessions are not open to other congress delegates.

GUIDED POSTER TOURS
Poster Exhibition
The poster exhibition is located in the Muses Foyer on ground level of the Megaron.

Posters are allocated to 26 guided poster tours (P-01 to P-26). Posters will be changed daily and are on display for the entire day of the according poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster exhibition times for P-01 to P-06
Monday, 15 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Poster exhibition times for P-07 to P-13
Tuesday, 16 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Poster exhibition times for P-14 to P-20
Wednesday, 17 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Poster exhibition times for P-21 to P-26
Thursday, 18 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

BEST POSTER AWARDS
All posters will be evaluated on site by the WFSBP Prize Committee. The best poster of each poster tour will be moved to the best poster area in the Muses Foyer where they are displayed throughout the congress. Out of these the 10 best posters of young investigators under 40 years will be awarded with a poster prize. The awards will be handed out during the Closing Ceremony on Thursday, 18 June 2015.
The underlying topics of the congress are as follows:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>Addictive Disorders</td>
</tr>
<tr>
<td>T2</td>
<td>Antidepressants: Basic/Clinical</td>
</tr>
<tr>
<td>T3</td>
<td>Antipsychotics: Basic/Clinical</td>
</tr>
<tr>
<td>T4</td>
<td>Anxiety Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T5</td>
<td>Anxiolytics: Basic/Clinical</td>
</tr>
<tr>
<td>T6</td>
<td>Bipolar Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T7</td>
<td>Childhood &amp; Adolescent Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T8</td>
<td>Cognitive Neuroscience</td>
</tr>
<tr>
<td>T9</td>
<td>Dementia: Basic/Clinical</td>
</tr>
<tr>
<td>T10</td>
<td>Depression: Basic/Clinical</td>
</tr>
<tr>
<td>T11</td>
<td>Eating Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T12</td>
<td>Emergency Psychiatry</td>
</tr>
<tr>
<td>T13</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>T14</td>
<td>Ethics and Psychiatry</td>
</tr>
<tr>
<td>T15</td>
<td>Forensic Psychiatry</td>
</tr>
<tr>
<td>T16</td>
<td>Genetics</td>
</tr>
<tr>
<td>T17</td>
<td>Hypnotics: Basic/Clinical</td>
</tr>
<tr>
<td>T18</td>
<td>Liaison Psychiatry</td>
</tr>
<tr>
<td>T19</td>
<td>Mental Retardation or Chromosomal Aberrations: Basic/Clinical</td>
</tr>
<tr>
<td>T20</td>
<td>Molecular Neurobiology</td>
</tr>
<tr>
<td>T21</td>
<td>Mood Stabilisers: Basic/Clinical</td>
</tr>
<tr>
<td>T22</td>
<td>Neuropathology</td>
</tr>
<tr>
<td>T23</td>
<td>Neuroimaging: Genetic, Functional, Structural</td>
</tr>
<tr>
<td>T24</td>
<td>Neurophysiology</td>
</tr>
<tr>
<td>T25</td>
<td>Obsessive-Compulsive Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T26</td>
<td>Oncopsychiatry</td>
</tr>
<tr>
<td>T27</td>
<td>Pain: Basic/Clinical</td>
</tr>
<tr>
<td>T28</td>
<td>Panic Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T29</td>
<td>Personality Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T30</td>
<td>Pharmacoeconomics</td>
</tr>
<tr>
<td>T31</td>
<td>Pharmacogenetics</td>
</tr>
<tr>
<td>T32</td>
<td>Pharmacology</td>
</tr>
<tr>
<td>T33</td>
<td>Posttraumatic Stress: Basic/Clinical</td>
</tr>
<tr>
<td>T34</td>
<td>Pregnancy, post partum and newborn: Basic/Clinical</td>
</tr>
<tr>
<td>T35</td>
<td>Premenstrual Syndrome: Basic/Clinical</td>
</tr>
<tr>
<td>T36</td>
<td>Psychogeriatrics</td>
</tr>
<tr>
<td>T37</td>
<td>Psychoneuroimmunology</td>
</tr>
<tr>
<td>T38</td>
<td>Psychopathology</td>
</tr>
<tr>
<td>T39</td>
<td>Psychosurgery</td>
</tr>
<tr>
<td>T40</td>
<td>Schizophrenia: Basic/Clinical</td>
</tr>
<tr>
<td>T41</td>
<td>Sexual Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T42</td>
<td>Sleep Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T43</td>
<td>Somatoform Disorders: Basic/Clinical</td>
</tr>
<tr>
<td>T44</td>
<td>Stimulation Methods (ECT, TMS, VNS, DBS)</td>
</tr>
<tr>
<td>T45</td>
<td>Stress: Basic/Clinical</td>
</tr>
<tr>
<td>T46</td>
<td>Suicide: Basic/Clinical</td>
</tr>
<tr>
<td>T47</td>
<td>Violence: Basic/Clinical</td>
</tr>
</tbody>
</table>

**CME ACCREDITATION**

The ‘12th World Congress of Biological Psychiatry’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net).

The ‘12th World Congress of Biological Psychiatry’ is designated for a maximum of (or ‘for up to’) **23 hours** of European external CME credits. Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMACredit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

**EACCME credits**

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMC per hour with a maximum of 3 ECMCs for half a day and 6 ECMCs for a full-day event.
Opening Ceremony

Sunday, 14 June 2015  
Beginning: 18:00

Master of Ceremony  
Professor Dimitris Dikeos, Greece

OPENING ADDRESS  
Professor Constantin R. Soldatos, WFSBP President

WELCOME ADDRESSES  
Georgios Kaminis, Mayor of Athens  
Professor Dimitris Nanopoulos, President of the Academy of Athens  
Professor Georgios Zografos, Vice Rector of the University of Athens

PRESENTATION OF DISTINCTIONS AND AWARDS  
Distinctions presented by Professor Constantin R. Soldatos  
Professor Florence Thibaut, France, being pronounced WFSBP Honorary President  
Professor Lakshmi Yatham, Canada, being presented with Presidential Commendation

Awards presented by Professor Florence Thibaut  
Professor Janusz Rybakowski, Poland / WFSBP Lifetime Achievement Award in Biological Psychiatry  
Professor Rupert Lanzenberger, Austria / WFSBP Research Award  
Professor E. Mohandas, India / WFSBP Award for Excellence in Mentorship  
Professor Bilgen Taneli, Turkey / WFSBP Award for Excellence in Mentorship  
Professor Philippe Courtet, France / WFSBP Award for Excellence in Education  
Professor Konstantinos Fountoulakis, Greece / WFSBP Award for Excellence in Education

Prize presented by Professor Siegfried Kasper  
Professor Heinz Grunze, United Kingdom  
The World Journal of Biological Psychiatry Excellence in Publication Prize

Music by the Athens Municipality Choir

OPENING LECTURE  
“Risk and resilience for psychosis and autism: Do developmental brain changes matter?”  
Speaker: Professor Christos Pantelis, Australia/Greece  
Chair: Professor Constantin R. Soldatos, Greece  
Co-chair: Professor Tudor Udristoiu, Romania

The Opening Ceremony is followed by a Networking Reception in the Megaron Athens International Conference Centre.
SATURDAY, 13 JUNE 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 16:00</td>
<td>Eginition Psychiatric Hospital</td>
<td>PCS-01 Neuroinflammation, neuroprogression, and neuroplasticity: An integrative approach towards understanding psychiatric disorders</td>
</tr>
</tbody>
</table>

**Place:** Eginition Psychiatric Hospital, University of Athens, 72-74 Vassilissis Sofias Ave, Athens

**Auspices:** 1st Department of Psychiatry, University of Athens Medical School

Free of charge for all registered congress delegates.
Congress registration must be done online beforehand:
www.wfsbp-congress.org

The confirmation of congress registration must be shown in order to attend the session.

SUNDAY, 14 JUNE 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 – 17:30</td>
<td>Trianti Hall – Megaron Athens International Conference Centre</td>
<td>SA-01 Industry sponsored symposium</td>
</tr>
<tr>
<td>18:00 – 19:30</td>
<td>Trianti Hall – Megaron Athens International Conference Centre</td>
<td>Opening Ceremony including OL-01: Risk and resilience for psychosis and autism: Do developmental brain changes matter?</td>
</tr>
</tbody>
</table>

**STRUCTURE OF THE SCIENTIFIC PROGRAMME**

The scientific programme is structured by day, by format and within format it is sorted by time. All presenters are listed by name and the title of their presentation. The different formats are highlighted in different colours in order to recognize them throughout the programme:

**FORMATS – COLOUR LEGEND**

<table>
<thead>
<tr>
<th>Format</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS –</td>
<td>Workshops</td>
</tr>
<tr>
<td>PL –</td>
<td>Plenary Lectures</td>
</tr>
<tr>
<td>P –</td>
<td>Poster Presentations</td>
</tr>
<tr>
<td>S –</td>
<td>Symposia</td>
</tr>
<tr>
<td>D –</td>
<td>Debates</td>
</tr>
<tr>
<td>RT –</td>
<td>Round Table</td>
</tr>
<tr>
<td>TG –</td>
<td>Treatment Guideline Sessions</td>
</tr>
<tr>
<td>FC –</td>
<td>Free Communications</td>
</tr>
<tr>
<td>ES –</td>
<td>Educational Grant Sessions</td>
</tr>
<tr>
<td>SA –</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>Time</td>
<td>Hall</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Hall</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
</tr>
<tr>
<td>8:30</td>
<td>8:30</td>
</tr>
<tr>
<td>9:00</td>
<td>9:00</td>
</tr>
<tr>
<td>9:30</td>
<td>9:30</td>
</tr>
<tr>
<td>10:00</td>
<td>10:00</td>
</tr>
<tr>
<td>10:30</td>
<td>10:30</td>
</tr>
<tr>
<td>11:00</td>
<td>11:00</td>
</tr>
<tr>
<td>11:30</td>
<td>11:30</td>
</tr>
<tr>
<td>12:00</td>
<td>12:00</td>
</tr>
<tr>
<td>12:30</td>
<td>12:30</td>
</tr>
<tr>
<td>13:00</td>
<td>13:00</td>
</tr>
<tr>
<td>13:30</td>
<td>13:30</td>
</tr>
<tr>
<td>14:00</td>
<td>14:00</td>
</tr>
<tr>
<td>14:30</td>
<td>14:30</td>
</tr>
<tr>
<td>15:00</td>
<td>15:00</td>
</tr>
<tr>
<td>15:30</td>
<td>15:30</td>
</tr>
<tr>
<td>16:00</td>
<td>16:00</td>
</tr>
<tr>
<td>16:30</td>
<td>16:30</td>
</tr>
<tr>
<td>17:00</td>
<td>17:00</td>
</tr>
<tr>
<td>17:30</td>
<td>17:30</td>
</tr>
<tr>
<td>18:00</td>
<td>18:00</td>
</tr>
<tr>
<td>18:30</td>
<td>18:30</td>
</tr>
<tr>
<td>Hall</td>
<td>Trianti</td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>8:30</td>
<td>S-16</td>
</tr>
<tr>
<td>9:00</td>
<td>PL-02</td>
</tr>
<tr>
<td>10:30</td>
<td>Break</td>
</tr>
<tr>
<td>11:00</td>
<td>S-21</td>
</tr>
<tr>
<td>11:30</td>
<td>12:00</td>
</tr>
<tr>
<td>12:30</td>
<td>13:00</td>
</tr>
<tr>
<td>13:30</td>
<td>14:00</td>
</tr>
<tr>
<td>14:30</td>
<td>15:00</td>
</tr>
<tr>
<td>15:00</td>
<td>15:30</td>
</tr>
<tr>
<td>15:30</td>
<td>16:00</td>
</tr>
<tr>
<td>16:00</td>
<td>16:30</td>
</tr>
<tr>
<td>16:30</td>
<td>17:00</td>
</tr>
<tr>
<td>17:00</td>
<td>17:30</td>
</tr>
<tr>
<td>17:30</td>
<td>18:00</td>
</tr>
<tr>
<td>18:00</td>
<td>18:30</td>
</tr>
</tbody>
</table>
## Tuesday, 16 June 2015 | Scientific Programme Overview

### FC-10
**Addiction**

### FC-11
**Child and Adolescent Psychiatry**

### Registration (Mitropoulos Foyer)
08:00 – 18:00

### Technical Exhibition
09:00 – 17:00

### Poster Exhibition
09:00 – 17:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Kokkali</th>
<th>Conference Room 1</th>
<th>MC 3.3</th>
<th>Muses Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hall</td>
<td>Time</td>
<td>Trianti</td>
<td>Mitropoulos</td>
<td>Skalkotas</td>
</tr>
<tr>
<td>------</td>
<td>------</td>
<td>---------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30</td>
<td>S-31</td>
<td>S-32</td>
<td>S-33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novel biomarkers in mood disorders: Opportunities for translation into clinical practice</td>
<td>Biological markers of cognitive deficits and negative symptoms in schizophrenia</td>
<td>Translational psychiatry in mood disorders and suicide</td>
</tr>
<tr>
<td></td>
<td>9:00</td>
<td>PL-03</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuropsychiatric syndromes of later life: Implications ...</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:00</td>
<td>D-02</td>
<td>S-36</td>
<td>S-37</td>
</tr>
<tr>
<td></td>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SA-04</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Industry sponsored symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S-41</td>
<td>S-42</td>
<td>TG-06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resolving the missing link between physical and mental pain: Basic, clinical, and translational approaches</td>
<td>Computational, cognitive and pharmacological connectomics: Towards understanding mechanisms of psychosis</td>
<td>Task Force on Schizophrenia</td>
</tr>
<tr>
<td></td>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:30</td>
<td>WS-16</td>
<td>WS-11</td>
<td>WS-12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of biological markers for differential diagnosis of dementia in physiological and biochemical strategies</td>
<td>Treatment of schizophrenia: Personalized tailoring to meet patients needs</td>
<td>Task force recommendations for the management of comorbidity in major depressive disorder and bipolar disorder</td>
</tr>
<tr>
<td></td>
<td>16:00</td>
<td>FC-18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brain Stimulation Therapies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16:30</td>
<td>WS-17</td>
<td>WS-12</td>
<td>WS-13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of biological markers for differential diagnosis of dementia in physiological and biochemical strategies</td>
<td>Treatment of schizophrenia: Personalized tailoring to meet patients needs</td>
<td>Interaction between neurobiological and ethno cultural factors in PTSD treatment response, recovery and resilience. Is there a link?</td>
</tr>
<tr>
<td></td>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Hall</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Muses Foyer</td>
<td><strong>Registration</strong> (Mitropoulos Foyer) 08:00 – 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td><strong>Technical Exhibition</strong> 09:00 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td><strong>Poster Exhibition</strong> 09:00 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Kokkali Conference Room 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td></td>
<td><strong>Registration</strong> (Mitropoulos Foyer) 08:00 – 18:00</td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td><strong>Technical Exhibition</strong> 09:00 – 17:00</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td><strong>Poster Exhibition</strong> 09:00 – 17:00</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MC 3.3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td></td>
<td><strong>Registration</strong> (Mitropoulos Foyer) 08:00 – 18:00</td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td><strong>Technical Exhibition</strong> 09:00 – 17:00</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td><strong>Poster Exhibition</strong> 09:00 – 17:00</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Muses Foyer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td></td>
<td><strong>Registration</strong> (Mitropoulos Foyer) 08:00 – 18:00</td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td><strong>Technical Exhibition</strong> 09:00 – 17:00</td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td><strong>Poster Exhibition</strong> 09:00 – 17:00</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Guided Poster Tours**

<table>
<thead>
<tr>
<th>P-14 – P-20</th>
<th>12:45 – 14:15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td>Hall</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>8:30</td>
<td>S-45</td>
</tr>
<tr>
<td></td>
<td>Advances in genetics of affective disorders</td>
</tr>
<tr>
<td>9:00</td>
<td>S-46</td>
</tr>
<tr>
<td></td>
<td>The latest international findings regarding TMS for treating depression</td>
</tr>
<tr>
<td>9:30</td>
<td>S-47</td>
</tr>
<tr>
<td></td>
<td>Defining and re-defining the boundaries of psychotic disorders using neuroimaging</td>
</tr>
<tr>
<td>10:00</td>
<td>S-48</td>
</tr>
<tr>
<td></td>
<td>Understanding psychiatric disorders: Recent advances in postmortem research</td>
</tr>
<tr>
<td>10:30</td>
<td>S-49</td>
</tr>
<tr>
<td></td>
<td>Psychobiology of men’s mental health</td>
</tr>
<tr>
<td>11:00</td>
<td>D-03</td>
</tr>
<tr>
<td></td>
<td>Should anxiety disorders be treated with medication?</td>
</tr>
<tr>
<td>11:30</td>
<td>S-51</td>
</tr>
<tr>
<td></td>
<td>Molecular determinants of suicide</td>
</tr>
<tr>
<td>12:00</td>
<td>S-06</td>
</tr>
<tr>
<td></td>
<td>Major controversies for the treatment of bipolar disorders</td>
</tr>
<tr>
<td>12:30</td>
<td>S-53</td>
</tr>
<tr>
<td></td>
<td>The impact of tobacco and cannabis use on psychosis liability and illness long term outcome: Epidemiological evidence across Europe and Australia</td>
</tr>
<tr>
<td>13:00</td>
<td>FC-20</td>
</tr>
<tr>
<td></td>
<td>schizophrenia</td>
</tr>
<tr>
<td>13:30</td>
<td>FC-21</td>
</tr>
<tr>
<td></td>
<td>schizophrenia</td>
</tr>
<tr>
<td>14:00</td>
<td>FC-22</td>
</tr>
<tr>
<td></td>
<td>schizophrenia</td>
</tr>
<tr>
<td>14:30</td>
<td>FC-23</td>
</tr>
<tr>
<td></td>
<td>Depression</td>
</tr>
<tr>
<td>15:00</td>
<td>S-56</td>
</tr>
<tr>
<td></td>
<td>Development of biomarkers for neuropsychiatric disorders: State-of-the-art and challenges ahead</td>
</tr>
<tr>
<td>15:30</td>
<td>S-57</td>
</tr>
<tr>
<td></td>
<td>Central role of glial cells in the pathogenesis of schizophrenia</td>
</tr>
<tr>
<td>16:00</td>
<td>S-58</td>
</tr>
<tr>
<td></td>
<td>Diagnostic and prognostic stratification of affective disorders based on inflammation biomarkers and immune related neurotransmitter pathways</td>
</tr>
<tr>
<td>16:30</td>
<td>S-59</td>
</tr>
<tr>
<td></td>
<td>Dysregulation of tyrosine transport influence dopamine function and cause cognitive deficits in schizophrenia</td>
</tr>
<tr>
<td>17:00</td>
<td>S-60</td>
</tr>
<tr>
<td></td>
<td>Neural oscillations: Translational research in psychiatry</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Programme Overview

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Conference Room 1</th>
<th>MC 3.3</th>
<th>Muses Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Registration (Mitropoulos Foyer)</td>
<td>08:00 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Poster Exhibition</td>
<td>09:00 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Guided Poster Tours</td>
<td>P-21 – P-26</td>
<td>12:45 – 14:15</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Break</td>
<td>12:30 – 14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td>13:00 – 14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td>13:30 – 14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td>14:00 – 15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td>14:30 – 15:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td>15:00 – 16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td>15:30 – 16:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td>16:00 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td>16:30 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td>17:00 – 17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td>17:30 – 17:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Session Details

- **S-50**
  - **Title**: The importance of pharmacovigilance in psychiatric inpatient populations
  - **Location**: Kokkali Conference Room 1

- **FC-19**
  - **Title**: Anxiety Disorders
  - **Location**: Conference Room 1

- **ES-03**
  - **Title**: Session 3 on brain stimulation methods
  - **Location**: MC 3.3

- **S-54**
  - **Title**: Recent research data in electroconvulsive therapy and how they inform state of the art clinical practice
  - **Location**: Kokkali Conference Room 1

- **S-55**
  - **Title**: New insights of clinical, neurobiological and genetic aspects in mental illness
  - **Location**: MC 3.3

- **Break**

- **S-61**
  - **Title**: A paradigm shift in studies of affective disorders
  - **Location**: Kokkali Conference Room 1

- **FC-24**
  - **Title**: Bipolar Disorder
  - **Location**: Conference Room 1

- **FC-25**
  - **Title**: Violence
  - **Location**: Conference Room 1

- **Break**

- **S-61**
  - **Title**: A paradigm shift in studies of affective disorders
  - **Location**: Kokkali Conference Room 1

- **FC-26**
  - **Title**: Pharmacogenetics
  - **Location**: Conference Room 1
CPO HANSER SERVICE is specialist in the field of Conference, Event, Destination and Association Management organizing events of any size throughout Germany and also abroad for more than 30 years.

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT – IT SOLUTIONS

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- websites and apps
- graphic design
- association management

www.cpo-hanser.de
Saturday, 13 June 2015

**Place**
Eginition Psychiatric Hospital, University of Athens
72-74 Vassilissis Sofias Ave, Athens

**Auspices**
1st Department of Psychiatry, University of Athens Medical School

Free of charge for all registered congress delegates. Congress registration must be done online beforehand:
www.wfsbp-congress.org
The confirmation of congress registration must be shown in order to attend the session.

**PCS-01 PRE-Congress Symposium**
13:00 – 16:00 Eginition Psychiatric Hospital

**Neuroinflammation, neuroprogression, and neuroplasticity: An integrative approach towards understanding psychiatric disorders**
*Chair:* Angelos Halaris, USA
*Co-Chair:* Michael Maes, Thailand

**PCS-01-001**
From activated immune-inflammatory pathways to neuroprogression
*Michael Maes, Thailand*

**PCS-01-002**
Molecular mechanisms by which early life stress increases vulnerability to mental health disorders
*Carmine Pariante, United Kingdom*

**PCS-01-003**
Molecular mechanisms of neuroprogression
*Jussi Jokinen, Sweden*

**PCS-01-004**
Prevention of neuroprogression after a first episode of mania
*Michael Berk, Australia*

**PCS-01-005**
Central and peripheral inflammatory markers in mood disorders and suicide
*Ghanshyam Pandey, USA*

**PCS-01-006**
Inflammation control reverses treatment resistance in bipolar depression
*Angelos Halaris, USA*

*Discussant:* Elias Angelopoulos, Greece

Sunday, 14 June 2015

**OL-01 OPENING CEREMONY**
18:00 – 19:30 Trianti Hall

**Opening Lecture**
*Chair:* Constantin R. Soldatos, Greece
*Co-Chair:* Tudor Udristoiu, Romania

**OL-01-001**
Risk and resilience for psychosis and autism: Do developmental brain changes matter?
*Christos Pantelis, Australia*

*Please see page 12.*

**SA-01 INDUSTRY SPONSORED SYMPOSIUM**
16:00 – 17:30 Trianti Hall

*see page 97.*
Scientific Programme | Monday, 15 June 2015

PL-01 PLENARY LECTURE
10:00 – 10:45 Trianti Hall
Chair: Lakshmi Yatham, Canada

PL-01-001
DSM, ICD and RDQc and the future of psychiatric diagnosis
Mario Maj, Italy

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

S-01 SYMPOSIUM
08:30 – 10:00 Trianti Hall

Advances in child psychiatry research
Chair: Joseph Biederman, USA
Co-Chair: Gagan Joshi, USA

S-01-001
Are autistic traits clinically meaningful?
Joseph Biederman, USA

S-01-002
Resting state functional connectivity analysis of social networks in adolescents and young adults with high-functioning autism spectrum disorder
Gagan Joshi, USA

S-01-003
Resting state functional connectivity in a longitudinal study of ADHD children grown up
Mai Uchida, USA

S-01-004
Memantine in the treatment of adults with ADHD
Thomas Spencer, USA

T3: ANTIPSYCHOTICS: BASIC/CLINICAL

S-02 SYMPOSIUM
08:30 – 10:00 Mitropoulos Hall

A better use of antipsychotics to improve the prognosis of schizophrenia
Chair: Miquel Bernardo, Spain
Co-Chair: Philippe Courtet, France

S-02-001
Pharmacogenetic of antipsychotics, as a tool to improve response to cognitive remediation
Roberto Cavallaro, Italy

S-02-002
Advantages of long-acting injectable antipsychotics (in everyday life)
Dieter Naber, Germany

S-02-003
Relapse prevention and long-acting injectable antipsychotics in early phases of schizophrenia
Eduard Parellada, Spain

S-02-004
Interest of guidelines to improve the everyday use of antipsychotics: Methodological, and implementation aspects
Pierre-Michel Llorca, France

T24: NEUROPHYSIOLOGY

S-19 SYMPOSIUM
08:30 – 10:00 Skalkotas Hall

Serotonin and neuroplasticity
Chair: Rupert Lanzenberger, Austria
Co-Chair: Christoph Kraus, Austria

S-19-001
Effects of serotonin on neurostimulation induced cortical plasticity
Walter Paulus, Austria

S-19-002
Serotonin and neuroplasticity
Eero Castren, Finland

S-19-003
Serotonin and neuroplasticity investigated in vivo with neuroimaging
Christoph Kraus, Austria
S. Kasper, R. Lanzenberger

S-19-004
Neural plasticity in the etiology and therapy of psychiatric disorders
Tilo Kircher, Germany

T1: ADDICTIVE DISORDERS

S-04 SYMPOSIUM
08:30 – 10:00 MC 3 Room

Alcohol, nicotine and metamphatamine addiction, progress at basic and clinical fronts
Chair: Yousef Tizabi, USA
Co-Chair: Rosario Moratalla, Spain

S-04-001
Alcohol and nicotine interactions: Implications for drinking-smoking co-morbidity
Yousef Tizabi, USA

S-04-002
Metamphatamine damage of dopaminergic neurons and motor consequences
Rosario Moratalla, Spain
S-04-003
Imaging and clinical intervention in metamphetamine addiction
Hamed Ekhtiari, Iran

S-04-004
Clinical intervention in drinking-smoking co-morbidity
Bo Söderpalm, Sweden

S-05-001
Sex-dependent vulnerability and response of brain circuits in affective disorders and treatment: Evidence from preclinical models
Ioannis Sotiropoulos, Portugal

S-05-002
Sex differences: Gonadal hormone modulation of fear extinction
Lisa Maeng, USA

S-05-003
Stress and emotional learning in humans: Does sex make a difference?
Oliver Wolf, Germany
C. Merz

S-05-004
Influence of estrogen on the neural correlates of fear extinction across species
Kelimer Lebron-Milad, USA

S-52-003
Genese: Pharmacogenetic response to antidepressant treatment in the general population treated for depression
Nicolas Ramoz, France
Y. Le Strat, P. Courtet, P. Gorwood

S-52-004
CANBIND–Update on the progress so far
Sidney Kennedy, Canada

S-38-001
Clinical efficacy of high dose of baclofen in reducing alcohol consumption
Philippe Jaury, France

S-38-002
Impact of chronic cannabinoid adolescent exposure on prefrontal structure and function
Therese Jay, France
G. Le Pen, M.-O. Krebs, J. Renard

S-38-003
New challenges for forensic toxicology from the “New Psychoactive Substances”
Franco Tagliaro, Italy

S-38-004
Acute human effects of synthetic cannabinoids: How are they related to cannabinoid receptor ligand properties?
David Gorelick, USA

S-08-001
Hypersexuality: Obsession or addiction?
Florence Thibaut, France

S-08-002
A personal status, legal, economic and psychological comparison of types of adult male gamblers
Pinhas Dannon, Israel
S-08-003
Does food addiction exist?
Marc Potenza, USA

S-08-004
Exercise addiction—brain and behavior
Aviv Weinstein, Israel
M. Gavriel, Y. Weinstein

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

S-09 SYMPOSIUM
11:00 – 12:30 Kokkali Room
Major psychopathology during adolescence and early adulthood: The dynamic developmental interplay between protective and risk factors
Chair: Paolo Brambilla, Italy
Co-Chair: Jair C. Soares, USA

S-09-001
Grin2b mediates susceptibility to affective problems in children and adolescents
Maria Nobile, Italy

S-09-002
Developmental imaging and cognitive markers of pediatric Parkinson’s disease
Jair C. Soares, USA

S-09-003
Functional imaging markers of psychosis during adolescence
Vaibhav Diwadkar, USA

S-09-004
Risk and protective factors for psychopathology detected in the Mannheim Study of Children at Risk (MARS)
Katrin Zohsel, Germany
M. Laucht

T3: ANTIPSYCHOTICS: BASIC/CLINICAL

S-10 SYMPOSIUM
11:00 – 12:30 Conference Room 1
D-amino acids and D-amino acid oxidase (DAAO) based modulation of NMDAR neurotransmission: Diagnostic and therapeutic implications
Chair: Kenji Hashimoto, Japan
Co-Chair: Hsien-Yuan Lane, Taiwan

S-10-001
Preclinical study of D-serine signaling in schizophrenia
Kenji Hashimoto, Japan

S-10-002
D-aspartate based modulation of NMDAR neurotransmission: Clinical implication
Alessandro Usiello, Italy

S-10-003
D-amino acid oxidase (DAAO) based modulation of NMDAR neurotransmission: Therapeutic implication
Hsien-Yuan Lane, Taiwan

S-10-004
D-amino acid oxidase (DAAO) activator levels in peripheral blood: Diagnostic implication
Chieh-Hsin Lin, Taiwan
H.-Y. Lane

T23: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-11 SYMPOSIUM
15:00 – 16:30 Trianti Hall
Biological overlaps between schizophrenia and autism spectrum disorders: Neuroimaging and neurophysiology
Chair: Serge Mitelman, USA
Co-Chair: Monte Buchsbaum, USA

S-11-001
Neural correlates in autism spectrum disorders and schizophrenia
Junko Fukushima, Japan
T. Miyamoto, A. Toyomaki, N. Hashimoto, I. Kusumi

S-11-002
Positron emission tomography in patients with schizophrenia and autism spectrum disorders
Marie-Cécile Bralet, France

S-11-003
Srgap3-/- mice present a neurodevelopmental disorder with schizophrenia-related and autism-related intermediate phenotypes: Implications for psychiatry
Robert Waltereit, Germany

S-11-004
MRI and diffusion tensor imaging assessment in patients with schizophrenia and autistic disorder
Monte Buchsbaum, USA
S. Mitelman
T16: GENE TiCs

S-12 SYMPOSIUM
15:00 – 16:30 Mitropoulos Hall
Epigenetic acquisitions in mood disorders: Implication for pathophysiology and treatment
Chair: Carlo Altamura, Italy

S-12-001
Biological targets for epigenetic modulations in psychiatric disorders
Nicolas Ramoz, France

S-12-002
Epigenetic regulation of BDNF gene in bipolar vs. unipolar depressive disorders
Bernardo Dell’Osso, Italy

S-12-003
Epigenetic mechanisms and endocannabinoid signaling: A putative treatment target for psychiatric disorders?
Mauro Maccarrone, Italy

T44: Stimulation Methods (ECT, TMS, VNS, DBS)

S-13 SYMPOSIUM
15:00 – 16:30 MC 3 Room
Identifying the biological targets of treatment response to neuromodulation in resistant psychiatric disorders
Chair: Zafiris Daskalakis, Canada
Co-Chair: Aristotle Voineskos, Canada

S-13-001
Neurophysiological and symptomatic changes induced by magnetic seizure therapy in depression
Zafiris Daskalakis, Canada

S-13-002
Cognitive, structural and connectivity changes from repetitive magnetic stimulation to the prefrontal cortex in schizophrenia
Aristotle Voineskos, Canada
Z. J. Daskalakis, D. Blumberger, N. Neufeld, C. Hawco, T. Rajji

S-13-003
ECT-induced changes in functional connectivity in treatment resistant depression
Georgios Petrides, USA
M. Argyalen, S. Kaliara

S-13-004
Neurobiological predictors of response to dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation in depression
Daniel Blumberger, Canada

T20: Molecular Neurobiology

S-14 SYMPOSIUM
15:00 – 16:30 MC 2 Room
Neuron-Glia interactions and neuropsychiatric disease: Implications for novel therapeutics
Chair: Thomas Sedlak, USA
Co-Chair: Jean-Pierre Mothe, France

S-14-001
D-serine and glycine in gliotransmission: Synaptic and extra-synaptic targets
Jean-Pierre Mothe, France
M. Le Bail, S. Sacchi, I. Pollegioni, J.-M. Billard

S-14-002
Neuron-astrocyte interactions – a critical juncture where gene-environment interactions increase risk of psychiatric disease
Mikhail Pletnikov, USA

S-14-003
Relationship between inflammatory cytokines, oxidative stress and astrogliosis markers and prefrontal grey matter volume in schizophrenia subgroups
Vibeke Catts, Australia
Y. Zhang, S. Fillman, J. Wong, S. Fung, C. Shannon Weickert

S-14-004
Interplay of neurons and glia for glutamate and glutathione cycling – new avenues to target excitatory neurotransmission abnormalities in neuropsychiatric disorders
Thomas Sedlak, USA

T8: CogniTive Neuroscience

S-15 SYMPOSIUM
15:00 – 16:30 Kokkali Room
Convergent approaches to impulsivity: The role of noradrenaline in ADHD and Parkinson’s disease
Chair: Ulrich Müller, United Kingdom
Co-Chair: Angie Kehagia, United Kingdom

S-15-001
The involvement of the noradrenergic system in impulsivity associated with ADHD and Parkinson’s disease
Manfred Gerlach, Germany

S-15-002
PET imaging of the noradrenergic system in ADHD and Parkinson’s disease
Rupert Lanzenberger, Austria

S-15-004
Noradrenergic modulation of impulsivity in Parkinson’s disease
Angie Kehagia, United Kingdom
T6: Bipolar Disorders: Basic/Clinical

TG-01 WFSBP Treatment Guidelines
11:00 – 12:30 MC 3 Room
Task Force on Bipolar Disorders: Improving longitudinal treatment for bipolar disorders including mixed states guidelines
Chair: Siegfried Kasper, Austria
Co-Chair: Heinz Grunze, United Kingdom

TG-01-001
Bipolar mixed state guideline development
Heinz Grunze, United Kingdom

TG-01-002
Long term illness trajectories and their management
Eduard Vieta, Spain

TG-01-003
Multistate outcome and persistent benefit analysis
Charles L. Bowden, USA

T16: Genetics

TG-02 WFSBP Treatment Guidelines
15:00 – 16:30 Skalkotas Hall
Task Force on Genetics
Chair: Dan Rujescu, Germany
Co-Chair: Mick C. O’Donovan, United Kingdom

TG-02-001
Genomics of schizophrenia: Results from the largest association study so far
Mick C. O’Donovan, United Kingdom

TG-02-002
The genetics of schizophrenia: Back to family studies
Lynn Delisi, USA

TG-02-003
Genetics of intermediate phenotypes: Focus on cognition
Dan Rujescu, Germany

TG-02-004
Clinical application of psychiatric pharmacogenetic testing
James Kennedy, Canada

T32: Pharmacology

RT-01 Round Table
11:00 – 12:30 Trianti Hall
Drug discovery in neuroscience: Why is big pharma reluctant to continue investing?
Chair: Lakshmi Yatham, Canada
Co-Chair: Shigenobu Kanba, Japan
Discussants: Carlos A. Zarate, USA
Michel Bourin, France
Raimund Buller, Denmark
Maeda Kenji, Japan
Sanjeev Pathak, USA
Matcheri S. Keshavan, USA

T6: Bipolar Disorders: Basic/Clinical

WS-01 Workshop
16:30 – 18:00 Skalkotas Hall
Lithium phobia: Science or superstition?
Chair: Digvijay Goel, New Zealand
Co-Chair: Mohan Isaac, Australia

WS-01-001
Lithium: Science or superstition?
Digvijay Goel, New Zealand

WS-01-002
Lithium: The magic ion
Shailesh Kumar, New Zealand

WS-01-003
Lithium vs. sodium valproate: Understanding the dilemma
Rajesh Nagpal, India

WS-01-004
Lithium: The way forwards
Mohan Isaac, Australia
## WFSBP 2015

### Monday, 15 June 2015 | Scientific Programme

#### T6: Bipolar Disorders: Basic/Clinical

<table>
<thead>
<tr>
<th>Workshops</th>
<th>Workshop</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS-02</strong></td>
<td>Workshop</td>
<td>16:30–18:00</td>
<td>MC 3 Room</td>
</tr>
<tr>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
</tr>
<tr>
<td><strong>Mood disorders and bipolar spectrum: How to get over diagnostic problems</strong></td>
<td><strong>Bipolarity during the adolescence: When do we treat them?</strong></td>
<td><strong>Depression and work related stress problems, with notes of comparative law</strong></td>
<td><strong>Neurocognitive and functional impairment in mood disorders</strong></td>
</tr>
<tr>
<td>Chair: Giuseppe Tavormina, Italy</td>
<td>Nicholas Zdanowicz, Belgium</td>
<td>Marilisa Amorosi, Italy</td>
<td>Sagar Parikh, Canada</td>
</tr>
<tr>
<td>Co-Chair: Nicolas Zdanowicz, Belgium</td>
<td>D. Jacques, C. Reynaert</td>
<td>R. Pettinelli</td>
<td>Roumen Milev, Canada</td>
</tr>
</tbody>
</table>

**WS-02-001**
Bipolarity during the adolescence: When do we treat them?
Nicolas Zdanowicz, Belgium
D. Jacques, C. Reynaert

**WS-02-002**
Depression and work related stress problems, with notes of comparative law
Marilisa Amorosi, Italy
R. Pettinelli

**WS-02-003**
Depressive disorders and resilience
Sandro Elisei, Italy
R. Quartesan, S. Anastasi, N. Verdelini

**WS-02-004**
Evaluation of cases reports of bipolar spectrum mixed states: A diagnostic-therapeutic approach
Giuseppe Tavormina, Italy

#### T7: Childhood & Adolescent Disorders: Basic/Clinical

<table>
<thead>
<tr>
<th>Workshops</th>
<th>Workshop</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS-04</strong></td>
<td>Workshop</td>
<td>16:30–18:00</td>
<td>Kokkali Room</td>
</tr>
<tr>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
</tr>
<tr>
<td><strong>Evaluation and management of youth with autism spectrum disorders and co-morbid behavioral and neurologic symptoms</strong></td>
<td><strong>Multidisciplinary team evaluation of youth with autism</strong></td>
<td><strong>Treatment of disruptive behavior and aggression in autism</strong></td>
<td><strong>Recognition and management of epilepsy in autism</strong></td>
</tr>
<tr>
<td>Chair: Adelaide Robb, USA</td>
<td>Peter T. Daniolos, USA</td>
<td>Adelaide Robb, USA</td>
<td>William Gaillard, USA</td>
</tr>
<tr>
<td>Co-Chair: Peter Daniolos, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WS-04-001**
Multidisciplinary team evaluation of youth with autism
Peter T. Daniolos, USA

**WS-04-002**
Treatment of disruptive behavior and aggression in autism
Adelaide Robb, USA

**WS-04-003**
Recognition and management of epilepsy in autism
William Gaillard, USA

**WS-04-004**
Use of telehealth to increase accessibility of evidence-based intervention for children with PDD
Todd Kopelman, USA

#### T8: Cognitive Neuroscience

<table>
<thead>
<tr>
<th>Workshops</th>
<th>Workshop</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS-03</strong></td>
<td>Workshop</td>
<td>16:30–18:00</td>
<td>MC 2 Room</td>
</tr>
<tr>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
</tr>
<tr>
<td><strong>Neurocognitive and functional impairment in mood disorders</strong></td>
<td><strong>Neurocognitive deficits in mood disorders: Biological underpinnings</strong></td>
<td><strong>Clinical assessment of neurocognition: The basis for improved clinical outcomes</strong></td>
<td><strong>Neurocognitive and functional outcomes in depression</strong></td>
</tr>
<tr>
<td>Chair: Sagar Parikh, Canada</td>
<td>Benicio Frey, Canada</td>
<td>Michael Berk, Australia</td>
<td>Arun Ravindran, Canada</td>
</tr>
<tr>
<td>Co-Chair: Roumen Milev, Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WS-03-001**
Neurocognitive deficits in mood disorders: Biological underpinnings
Benicio Frey, Canada

**WS-03-002**
Clinical assessment of neurocognition: The basis for improved clinical outcomes
Michael Berk, Australia

**WS-03-003**
Neurocognitive and functional outcomes in bipolar disorders
Serge Beaulieu, Canada

**WS-03-004**
Neurocognitive and functional outcomes in depression
Arun Ravindran, Canada

#### T10: Depression: Basic/Clinical

<table>
<thead>
<tr>
<th>Workshops</th>
<th>Workshop</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS-05</strong></td>
<td>Workshop</td>
<td>16:30–18:00</td>
<td>Conference Room 1</td>
</tr>
<tr>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
<td><strong>16:30–18:00</strong></td>
</tr>
<tr>
<td><strong>Role of aldosterone and mineralocorticoid receptor function in emotion-regulation</strong></td>
<td><strong>Aldosterone in stress related depression models</strong></td>
<td><strong>Sodium deficiency and mood: The brain renin-angiotensin-aldosterone system in the craving for salt and in anhedonia</strong></td>
<td><strong>The role of mineralocorticoid receptors in emotional regulation in borderline personality disorder</strong></td>
</tr>
<tr>
<td>Chair: Mike Franklin, United Kingdom</td>
<td>Mike Franklin, United Kingdom</td>
<td>Alan Kim Johnson, USA</td>
<td>Katja Wingenfeld, Germany</td>
</tr>
<tr>
<td>Co-Chair: Alan Kim Johnson, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WS-05-001**
Aldosterone in stress related depression models
Mike Franklin, United Kingdom

**WS-05-002**
Sodium deficiency and mood: The brain renin-angiotensin-aldosterone system in the craving for salt and in anhedonia
Alan Kim Johnson, USA

**WS-05-003**
Aldosterone and mineralocorticoid function as predictors of antidepressant response
Matthias Buettner, Germany

**WS-05-004**
The role of mineralocorticoid receptors in emotional regulation in borderline personality disorder
Katja Wingenfeld, Germany
## FORUM-01

**13:00 – 14:30**

**Kokkali Room**

**Achieving interaction among Greek scientists involved in Biological Psychiatry worldwide**

**Chair:** Nikos C. Stefanis, Greece  
**Co-Chair:** Antonis Politis, Greece  
**Secretaries:** Alexander Hatzimanolis, Greece  
Rigas Soldatos, Greece  
**Presenters:**  
- V. Brakoulias, Australia  
- P.T. Daniolos, USA  
- M. Filiou, Germany  
- A. Halaris, USA  
- C. Lyketsos, USA  
- M. Mavrikaki, USA  
- K. Patas, Germany  
- C. Pantelis, Australia  
- G. Petrides, USA  
- C. Phassouliotis, Australia  
- Y. Trakadis, Canada  
- D. Velakoulis, Australia  
- N. Venizelos, Sweden

**Discussion among all participants**

## ES-01

**14:00 – 18:00**

**MC 3.3 Room**

### Session 1 on basic research issues

**Chairs:** Florence Thibaut, France  
Tudor Udristoiu, Romania  
**Co-Chairs:** Victoria Valdez de Vuibert, Ecuador  
Anu Kant Mital, India

| **ES-01-001** | What do we learn from genetics (the example of schizophrenia) | Florence Thibaut, France |
| **ES-01-002** | What do we learn from genetics (the example of schizophrenia) | Dan Rujescu, Germany |
| **ES-01-003** | What do we learn from pharmacology (the example of anxiolytics mechanism of action) | Michel Bourin, France |
| **ES-01-004** | Biomarkers in psychiatry | Peter Riederer, Germany |
| **ES-01-005** | What do we learn from meta-analysis | Alessandro Serretti, Italy |

## ES-01

**08:30 – 10:00**

**Kokkali Room**

### Schizophrenia

**Chair:** Brian Dean, Australia  
**Co-Chair:** Nikos C. Stefanis, Greece

| **ES-01-001** | Meta-analysis of treatments for anxiety disorders | Borwin Bandelow, Germany |
| **ES-01-002** | Structural, functional and molecular brain imaging in psychiatry | Rupert Lanzenberger, Austria |
| **ES-01-003** | How to get grants and publish papers | Siegfried Kasper, Austria |

## FC-01

**08:30 – 10:00**

**Kokkali Room**

### Schizophrenia

**Chair:** Brian Dean, Australia  
**Co-Chair:** Nikos C. Stefanis, Greece

| **FC-01-001** | Social brain activity during theory of mind in first episode psychosis: Comparison with healthy controls and link to symptoms | Cali Bartholomeusz, Australia  
| **FC-01-002** | Genetic influences on multivariate cognitive endophenotypes of positive symptom schizophrenia | Narayan R. Mutalik, India  
H. HN, S. Jain, J. P. John |
| **FC-01-003** | Ketamine as a model for schizophrenia deficits | Erica Neill, Australia  
S. Rossell, C. Morgan, O. Carter, N. Joshua |
| **FC-01-004** | Prefrontal glutamate and cortical structure in schizophrenia: A combined brain metabolic and neuroanatomical study in antipsychotic naïve patients | Carl Christoph Schultz, Germany  
A. Gusew, I. Nenadic, H. Sauer, S. Smesny |
| **FC-01-005** | Similar age-related decline in cortical activity over frontotemporal regions in schizophrenia: A multi-channel near-infrared spectroscopy study | Po Han Chou, Taiwan  
S. Koike, Y. Nishimura, Y. Satomura, A. Kinoshita, R. Takizawa, K. Kasai |
| FC-01-006 | Social anhedonia and gamma band oscillations in remitted schizophrenia patients and their first degree relatives: A high resolution EEG study  
Shreekantiah Umesh, India  
S. H. Nizamie, N. Goyal |
| FC-01-007 | Sixteen biomarkers for schizophrenia and schizoaffective disorder from a case-control study, yield a clinically-meaningful five domain working model with predictive diagnostic accuracy  
Stephanie Fryar-Williams, Australia  
S. Jorg |
| FC-02 | FREE COMMUNICATIONS  
08:30 – 10:00  
Conference Room 1  
Depression  
Chair: Siegfried Kasper, Austria  
Co-Chair: John Nimatoudis, Greece (TBC) |
| FC-02-001 | Predicting treatment outcome in treatment resistant depression using a large set of 53 clinical and demographic predictors and machine learning  
Alexander Kautzky, Austria  
P. Baldinger, D. Souery, S. Montgomery, J. Mendlewicz, J. Zohar, A. Serretti, R. Lanzenberger, S. Kasper |
| FC-02-002 | The specific pattern of gray matter alterations in major depressive disorder and panic disorder: A diagnosis-specific endophenotype model  
Chien-Han Lai, Taiwan  
Y.-T. Wu |
| FC-02-003 | Role of melatonin MT1 receptor in melancholic depression and circadian rhythm: Insights from MT1 receptor knockout mice  
Stefano Comai, Canada  
R. Ochoa-Sanchez, S. Dominguez-Lopez, F. Rodriguez Bambico, G. Gobbi |
| FC-02-004 | The 6-year longitudinal association between telomere length & depression and anxiety disorders  
Josine Verhoeven, The Netherlands  
P. van Oppen, D. Révész, B. Penninx |
| FC-02-005 | The patterns of fractional amplitude of low-frequency fluctuations in depression patients: The dissociation between temporal regions and fronto-parietal regions  
Chien-Han Lai, Taiwan  
Y.-T. Wu |
| FC-02-006 | Cognitive ability in childhood and the chronicity and suicidality of depression  
Galen Chin-Lun Hung, Taiwan |
| FC-03 | FREE COMMUNICATIONS  
13:00 – 14:30  
Mitropoulos Hall  
Antidepressants  
Chair: Heinz Grunze, United Kingdom  
Co-Chair: Konstantinos Fountoulakis, Greece |
| FC-03-001 | Stress and antidepressant-induced effects on DNA methylation and DNA methyltransferase expression in limbic regions of rats submitted to learned helplessness  
Samia Joca, Brazil  
A. Sales |
| FC-03-002 | The novel antidepressant spadin: Absence of side effects and neurogenesis action mechanism  
Marc Borsotto, France  
J. Veyssiere, C. Devader, S. Moreno, C. Heurteaux, J. Mazella, H. Moha ou Maati |
| FC-03-003 | Fluoxetine alleviates behavioral impairments and soluble beta-amyloid production in app/ps1 mice  
Yanbo Zhang, Canada  
J. Wang, Q. Huang, H. Zhang, H. Xu, J. Kong, X.-M. Li |
| FC-03-004 | Effect of ketamine in patients of treatment resistant depression  
Bharti Talreja, India  
S. Reddy |
| FC-03-005 | Ketamine and 3beta-methoxy-pregnenolone exhibit an antidepressant effect in the endogenously “depressed” Wistar-Kyoto rat: A microtubular mechanism?  
Jack Prenderville, Ireland  
J. Rouine, M. Campion, S. O’Mara, M. Bianchi |
### Seasonal variation of placebo effect in antidepressant clinical trial: Very preliminary data

Joël Gailledreau, France  
B. Gailledreau, S. Becque

### Pharmacogenetic polymorphisms and antidepressant adverse effects or nonresponse

Rajnish Mago, USA  
S. Gupta, K. Huhn, R. Shah

### Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly

Hyun Kook Lim, Republic of Korea  

### Neuronal origin plasma exosomes provide novel biomarkers of neuronal intracellular dysfunction in Alzheimer's disease

Dimitrios Kapogiannis, USA  
M. Mustapic, E. Eitan, A. Boxer, J. Schwartz, E. Abner, R. Petersen, B. Miller, E. Goetzl

### Co-morbid medical conditions in vascular dementia: A matched case-control study

Ruby Castilla-Puentes, USA  
M. Habeych

### Effects of serum IL-10 and IL-1β levels on intestinal endotoxemia on Alzheimer's disease rat and in Chinese sample of Alzheimer's disease patients and healthy controls

Bai Han, People's Republic of China  
F. Wu, H. Li, C. Li, K. Liu, Q. Sun, Y. Gao, L. Ma, X. Shan

### The potential role of nanotechnology in the diagnosis and treatment of Alzheimer's disease

Jerzy Leszek, Poland  
J. Zhang

### Gene expression profiling of 70 suicide victims with psychosis by using DNA microarray

Arvin Haghighatfard, Iran  
S. Jokari

### Functional state of c-Fos, c-Jun, and Ier5 transcription factors in schizophrenia

Roksana Zakharyan, Armenia  
G. Mkrtchyan, S. Atshemyan, A. Chavushyan, A. Boyajyan

### The nrg1 polymorphism is a genetic modifier of age at onset in schizophrenia

Shiau Foon Tee, Malaysia  
P. Y. Tang, T. J. Chow

### TCF4 gene polymorphism and the risk of schizophrenia in relation to age at onset, gender and family history

Tze Jen Chow, Malaysia  
S. F. Tee, P. Y. Tang

### The 5-HTTLPR genotype modulates autonomic reactivity after pharmacological stress challenge in healthy men

Agorastos Agorastos, Germany  
M. Kellner, O. Stiedl, K. Wiedemann, C. Demiralay

### Genetic variant of FK506 binding protein-5 predicts negative affectivity in Serbian schizophrenia spectrum patients

Marina Mihaljevic, Serbia  
S. Andric, T. Mirjanic, I. Soldatovic, I. Novakovic, J. van Os, N. Maric

### Parenting, gender and the polygenic risks for depression in adolescents

Evelien Van Assche, Belgium  
### FC-06  FREE COMMUNICATIONS  13:00–14:30  MC 2 Room

**Eating/Sleeping/Personality Disorders**  
Chair: Grigoris Vaslamatzis, Greece  
Co-Chair: Eleftheria Varsou, Greece

| FC-06-001 | Effect of different REM sleep-suppressing strategies on learning and memory consolidation in rats | Lia Maisuradze, Georgia  
N. Lortkipanidze, N. Oniani |
| --- | --- | --- |
| FC-06-002 | Central nervous system responses to thermoregulatory challenge: Differences between lean and obese subjects | Otto Muzik, USA  
V. Diwadkar |
| FC-06-003 | White matter changes at the early stages of anorexia nervosa in adolescents | Santino Gaudio, Italy  
C. Piervincenzi, F. Carducci, C. C. Quattrocchi |
| FC-06-004 | Optogenetic and dread manipulation of sleep-active neurons: Implications for insomnia | Peter Shiromani, USA  
R. R. Konadhod, D. Pelluru, T. Uhde |
| FC-06-005 | Polymorphism-g308a gene tnf-a and sleep disturbance in open populations men 25-64 years of Siberia (program who monica-psychosocial) | Valery Gafarov, Russia  
E. Gromova, A. Gafarova, I. Gagulin, D. Panov |
| FC-06-006 | The imagination of aggressive behavior down-regulates limbic activation in female patients with borderline personality disorder | Sabine Herpertz, Germany  
K. Nagy, F. Mancke, R. Schmitt, A. Gäbel, K. Bertsch |
| FC-06-007 | Towards best practice outcomes in clozapine therapy in forensic settings | Guna Kanniah, New Zealand |

### FC-07  FREE COMMUNICATIONS  13:00–14:30  Conference Room 1

**Neuroimaging**  
Chair: Rupert Lanzenberger, Austria  
Co-Chair: Nikos Smyrnis, Greece

| FC-07-001 | Serotonin-1A and -2A receptor binding measured by PET in vivo correlates with mRNA expression in postmortem brains | Arkadiusz Komorowski, Austria  
C. M. James, G. Gryglewski, S. Kasper, R. Lanzenberger |
| FC-07-002 | Increased cortical gray/white matter intensity contrast in schizophrenia and bipolar disorder compared to healthy controls | Kjetil Nordbo Jørgensen, Norway  
| FC-07-003 | Attenuated serotonin transporter binding with increased age in patients with attention deficit/hyperactivity disorder investigated by pet and [11c]dasb | Thomas Vanicek, Austria  
| FC-07-005 | Genetic modulation of dopamine system and the response to methylphenidate: An [18F]FDOPA-PET study | Ingo Vernaleken, Germany  
| FC-07-006 | Involuntary interference in emotion dysregulation: Hyper-modulation of brain networks by the amygdala and orbitofrontal cortex | Kristy Abraham, USA  
V. Diwadkar, P. Soloff |
### Scientific Programme | Monday, 15 June 2015

<table>
<thead>
<tr>
<th>FC-08</th>
<th>FREE COMMUNICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>15:00 – 16:30</strong></td>
<td>Conference Room 1</td>
</tr>
<tr>
<td><strong>Antipsychotics</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: Yuan Hwa Chou, Taiwan</td>
<td></td>
</tr>
<tr>
<td>Co-Chair: Charalambos Papageorgiou, Greece</td>
<td></td>
</tr>
<tr>
<td><strong>FC-08-001</strong></td>
<td>Antipsychotic polypharmacy in severe mental disorders: Efficacy and metabolic side effects</td>
</tr>
<tr>
<td></td>
<td>José M. Pelayo-Terán, Spain</td>
</tr>
<tr>
<td></td>
<td>Y. Zapico-Merayo, J. Martínez-Díez, N. Martín-Navarro</td>
</tr>
<tr>
<td><strong>FC-08-002</strong></td>
<td>Three-year follow-up after a first episode of psychosis: Adherence and relapse</td>
</tr>
<tr>
<td></td>
<td>José M. Pelayo-Terán, Spain</td>
</tr>
<tr>
<td></td>
<td>V. Gajardo-Galán, V. Ortiz-García de la Foz, O. Martínez-García, M. Gómez, B. Crespo-Facorro</td>
</tr>
<tr>
<td><strong>FC-08-003</strong></td>
<td>The effect of aripiprazole on hippocampal volume in first-episode psychosis: A one year longitudinal neuroimaging study</td>
</tr>
<tr>
<td></td>
<td>Martin Lepage, Canada</td>
</tr>
<tr>
<td></td>
<td>B. Michael, R. Joober, A. Malla</td>
</tr>
<tr>
<td><strong>FC-08-004</strong></td>
<td>Reduction of neuroinflammation by antipsychotic treatment in a virus model for schizophrenia</td>
</tr>
<tr>
<td></td>
<td>Hans Klein, The Netherlands</td>
</tr>
<tr>
<td><strong>FC-08-006</strong></td>
<td>Monitoring antipsychotic drugs in psychiatric patients from Epirus, northwestern Greece</td>
</tr>
<tr>
<td></td>
<td>Vassiliki Boumba, Greece</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FC-09</th>
<th>FREE COMMUNICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>16:30 – 18:00</strong></td>
<td>Mitropoulos Hall</td>
</tr>
<tr>
<td><strong>Depression</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: Angelos Halaris, USA</td>
<td></td>
</tr>
<tr>
<td>Co-Chair: Konstantinos Papageorgiou, Austria</td>
<td></td>
</tr>
<tr>
<td><strong>FC-09-001</strong></td>
<td>Increased NPY and decreased DPP4 plasma levels are associated with stress system alterations in children and adolescents with affective disorders</td>
</tr>
<tr>
<td></td>
<td>Yulia Golub, Germany</td>
</tr>
<tr>
<td></td>
<td>A. Eichler, F. Canneva, O. Kratz, G. Moll, R. Funke</td>
</tr>
<tr>
<td><strong>FC-09-002</strong></td>
<td>Risk of cancer after suicide attempt—a nationwide cohort study in Sweden</td>
</tr>
<tr>
<td></td>
<td>Jussi Jokinen, Sweden</td>
</tr>
<tr>
<td></td>
<td>F. Mattsson, K. Lagergren, J. Lagergren, R. Ljung</td>
</tr>
<tr>
<td><strong>FC-09-004</strong></td>
<td>Correlation between depression and cardiovascular diseases</td>
</tr>
<tr>
<td></td>
<td>Peter László, Hungary</td>
</tr>
<tr>
<td></td>
<td>K. Schweitzer</td>
</tr>
<tr>
<td><strong>FC-09-005</strong></td>
<td>Gamma power and theta-gamma coupling enhancement in resting state electroencephalogram (EEG) following repetitive transcranial magnetic stimulation (rTMS) in patients with treatment-resistant depression (TRD)</td>
</tr>
<tr>
<td></td>
<td>Yoshihiro Noda, Canada</td>
</tr>
<tr>
<td></td>
<td>R. Zomorrodí, D. Blumberger, Z. J. Daskalakis, M. Nakamura</td>
</tr>
<tr>
<td><strong>FC-09-006</strong></td>
<td>Plasma anti-oxytocin autoantibodies concentration is associated with postpartum depression</td>
</tr>
<tr>
<td></td>
<td>Frederico Garcia, Brazil</td>
</tr>
<tr>
<td></td>
<td>G. de Faria, T. Couto, M. Brancaglio, S. Caligiorno, A. A. Corrêa de Freitas, H. Corrêa</td>
</tr>
<tr>
<td><strong>FC-09-007</strong></td>
<td>Standardizing and validation of a specialized examination for the assessment of testamentary capacity in patients with dementia: Preliminary results</td>
</tr>
<tr>
<td></td>
<td>Panagiota Voskou, Greece</td>
</tr>
<tr>
<td></td>
<td>A. Douzenis, A. Economou, S. Papageorgiou</td>
</tr>
</tbody>
</table>

### SA-02 INDUSTRY SPONSORED SYMPOSIUM

| **17:00 – 18:30** | Trianti Hall |

see page 97.
P-01-001
Functional and structural connectivity in the cingulate cortex in the habitual internet game users
Jihye Choi, Republic of Korea

P-01-002
Attentional bias and poor inhibitory control as risk factors for relapse in patients diagnosed with bipolar disorder and alcohol use disorders
Marta Marin Mayor, Spain

P-01-003
Effects of chronic or acute cocaine on the AMPK system in the rat frontal cortex and dorsal striatum
Shijie Xu, Republic of Korea
U. G. Kang

P-01-004
The peptide origin anxiolytics as possible tools in treatment of opiate addiction: An experimental study
Mark Konstantinopolsky, Russia
L. G. Kolik, T. A. Gudasheva

P-01-005
Association between NPY gene polymorphisms and alcohol dependence in Turkish sample
Hayriye Akel, Turkey
S. C. Curel, Y. Ayhan, B. Diclenur Ulug, B. Demir, C. Karaaslan

P-01-006
The alterations of systemic neuroinflammatory cytokine levels during early alcohol withdrawal
Min Shan Li, Taiwan
M.-C. Huang

P-01-007
The role of serotonin transporter polymorphisms in anxiety sensitivity: An investigation in a South African adolescent population
Sian Hemmings, South Africa
R. Benecke, L. Martin, S. Seedat

P-01-008
Acute restraint and unpredictable chronic mild stress differentially activate dorsal and median raphe nuclei
Milena Viana, Brazil
D. A. Lopes, J. A. Lemes, I. C. Céspedes

P-01-009
Blockade of D2-like dopamnergic receptor corrects anxiety-like behaviour in gonadectomized male rats of middle age treated with low dose of testosterone
Julia Fedotova, Russia

P-01-010
D-cycloserine-augmented exposure therapy in patients with agoraphobia
Lena Pyrkosch, Germany
J. Mumm, J. Plag, T. Fydrich, L. Fehm, A. Ströhle

P-01-011
Endophenotypes and transcriptional markers of different stress reactivity in two inbred mouse strains
Klaudia Szkarczyk-Smolana, Poland
M. Korostynski, S. Golda, R. Przewlocki

P-01-012
Psychiatry and primary care: Obstacles faced by general practitioners in Singapore in managing patients with mental disorders
Arnab Kumar Ghosh, Singapore
P. Gangaram, H. Jayaraman

P-01-013
Effect of SSRIs on gray matter volume in obsessive-compulsive disorder: A prospective study of treatment-naïve patients
Janardhanan Narayanaswamy, India
D. Jose, S. M. Agarwal, S. Kalmady, B. Shrinivasa, V. Shivakumar, G. Venkatasubramanian, Y. C. Reddy

P-01-014
Exploring the familiality of obsessive-compulsive symptoms
Vlasis Brakoulis, Australia

P-01-015
Bipolar disorder (BD) comorbidity in patients with a primary diagnosis of obsessive compulsive disorder (OCD)
Gayatri Sarat, India
I. Paul, B. Viswanath, S. Bada Math, Y. C. Reddy

P-01-016
Increased levels of plasma oxytocin in untreated adult OCD patients
Donatella Marazziti, Italy
S. Baroni, G. Massimetti, L. Dell’Osso

P-01-017
A systematic review of the association between the serotonin receptor 2a polymorphisms and obsessive-compulsive disorder
Meir Steiner, Canada
G. Mattina

P-01-018
Comorbidity between obsessive compulsive disorder, autism spectrum disorder and alcohol
Mikel Ruiz Feliu, Spain
C. Campos Mangas, A. B. Rodríguez Aliste, M. Haba Sanchez
**P-01-019**

**Association between obsessive compulsive disorder and diogenes syndrome**

Mikel Ruiz Feliu, Spain
C. Campos Mangas, A. B. Rodriguez Aliste, M. Haba Sanchez

**P-02-008**

Mood disorders are associated with an increased atherogenic index of plasma

Marta Martin-Subero, Spain
H. Odebrecht, S. Odebrecht, D. Sabbatini, S. Dodd, M. Berk, M. Maes

**P-02-009**

Polarity of first episode and neurocognitive functioning in bipolar disorder

Kalliopi Tournikioti, Greece
D. Dikeos, A. Douzenis, I. Michopoulos, P. Ferentinos, M. Alevizaki, C. R. Soldatos

**P-02-010**

The correlation between the clinical symptoms, serum uric acid levels, and quantitative electroencephalography (QEEG) findings in recently manic patients with bipolar I disorder

Sunmi Kim, Republic of Korea
S. Park, Y. Kim, D. Han, K. Min, C. Na

**P-02-001**

Decreased levels of cerebral lactate in patients with bipolar disorder after treatment with lithium

Alana Costa, Brazil
R. Machado-Vieira, M. C. García Otaduy, M. V. Zanetti, R. T. de-Sousa, W. F. Gattaz

**P-02-003**

Bipolar misdiagnosis in a 10-year study: How age may influence the way bipolarity is perceived in primary care

Andrée Daigneault, Canada
S. Saury, C. Duclos, J. Paquet, D. Dumont, S. Beaulieu

**P-02-004**

Comparison of cognitive changes between older people with major depression and those with bipolar disorder after two-year follow-up

Chih-Chiaung Chiu, Taiwan

**P-02-005**

Continuous circular cycling in bipolar disorders as a predictor of poor response to short-term antidepressant treatment

Antonio Tundo, Italy
J. Calabrese, L. Prietti, R. de Filippis

**P-02-006**

Continuous cycling bipolar disorders: Clinical characteristics and response to long-term treatment

Antonio Tundo, Italy
J. Calabrese, L. Dell’Osso, L. Prietti, R. de Filippis

**P-02-007**

Distinct patterns of amygdala resting state functional connectivity in remitted bipolar disorder and major depressive disorder patients

Giannis Lois, Germany
M. Wessa

**P-02-002**

**POSTER PRESENTATION**

12:45 – 14:15 Muses Foyer

**Bipolar Disorders/Depression/Suicide**

Chair: Artemios Pehlivanidis, Greece
Co-Chair: Athanasios Karkanias, Greece

**P-02-008**

Mood disorders are associated with an increased atherogenic index of plasma

Marta Martin-Subero, Spain
H. Odebrecht, S. Odebrecht, D. Sabbatini, S. Dodd, M. Berk, M. Maes

**P-02-009**

Polarity of first episode and neurocognitive functioning in bipolar disorder

Kalliopi Tournikioti, Greece
D. Dikeos, A. Douzenis, I. Michopoulos, P. Ferentinos, M. Alevizaki, C. R. Soldatos

**P-02-010**

The correlation between the clinical symptoms, serum uric acid levels, and quantitative electroencephalography (QEEG) findings in recently manic patients with bipolar I disorder

Sunmi Kim, Republic of Korea
S. Park, Y. Kim, D. Han, K. Min, C. Na

**P-02-002**

**POSTER PRESENTATION**

12:45 – 14:15 Muses Foyer

**Bipolar Disorders/Depression/Suicide**

Chair: Artemios Pehlivanidis, Greece
Co-Chair: Athanasios Karkanias, Greece

**P-02-001**

Decreased levels of cerebral lactate in patients with bipolar disorder after treatment with lithium

Alana Costa, Brazil
R. Machado-Vieira, M. C. García Otaduy, M. V. Zanetti, R. T. de-Sousa, W. F. Gattaz

**P-02-003**

Bipolar misdiagnosis in a 10-year study: How age may influence the way bipolarity is perceived in primary care

Andrée Daigneault, Canada
S. Saury, C. Duclos, J. Paquet, D. Dumont, S. Beaulieu

**P-02-004**

Comparison of cognitive changes between older people with major depression and those with bipolar disorder after two-year follow-up

Chih-Chiaung Chiu, Taiwan

**P-02-005**

Continuous circular cycling in bipolar disorders as a predictor of poor response to short-term antidepressant treatment

Antonio Tundo, Italy
J. Calabrese, L. Prietti, R. de Filippis

**P-02-006**

Continuous cycling bipolar disorders: Clinical characteristics and response to long-term treatment

Antonio Tundo, Italy
J. Calabrese, L. Dell’Osso, L. Prietti, R. de Filippis

**P-02-007**

Distinct patterns of amygdala resting state functional connectivity in remitted bipolar disorder and major depressive disorder patients

Giannis Lois, Germany
M. Wessa
P-02-017
Parental history of psychiatric diagnoses and unipolar depression: A Danish national register-based cohort study
Trine Munk-Olsen, Denmark
K. L. Musliner, B. Trabjerg, B. Waltoft, T. Munk Laursen, P. B. Mortensen

P-02-018
Serum IgG response to 43 food antigens in major depression indicates lower IgG response to dairy proteins in depressed patients
Agata Szulc, Poland
L. Rudzi, D. Pawlak, N. Waszkiewicz, A. Malus, M. Galecka, P. Szlachta, B. Konarzewska

P-02-019
Aerobic exercise as add-on treatment improves alertness and working memory in depressed patients: Preliminary results from a randomized controlled multicentre-trial
Christian Imboden, Switzerland

P-02-020
Androgen receptor increases resistance to depressive-like phenotypes in chronic unpredictable mild stress through maintaining brain-derived neurotrophic factor
Yi-Yung Hung, Taiwan

P-02-021
Cortical inhibition in the pathophysiology and treatment of major depressive disorder
Daphne Voineskos, Canada
A. Levinson, D. Blumberger, Z. J. Daskalakis

P-02-023
Association between plasma brain-derived neurotrophic factor levels and impulsiveness in recent suicide attempters
Liviu Ambrus, Sweden
Å. Westrin

P-02-024
Factors associated with suicide completion: A comparison between suicide attempters and completers
Woong Hahm, Republic of Korea
S. H. Joo, I. H. Paik

P-02-025
A comparative study of permissive attitudes toward suicide in South Korea, Japan, and the U.S.: A cross-national analysis
Hyeyoung Kim, Republic of Korea
B. Kim, S. S. Lee, C.-j. Baek, Y.-M. Ahn

P-02-026
The impact of alcohol problems on depressive symptoms
Masaya Tayama, Japan
M. Yamamoto, T. Saito

P-03 PoSTER PreSentation
12:45 – 14:15 muses Foyer
Schizophrenia/Dementia
Chair: Charalambos Touloumis, Greece
Co-Chair: Thomas Matsoukas, Greece

P-03-002
Cerebrospinal fluid and plasma concentrations of Non-Phosphorylated Tau protein as a novel potential biomarker of Alzheimer’s disease
Piotr Lewczuk, Germany
N. Lelental, I. Lachmann, A. Perret-Liaudet, J. Kornhuber

P-03-003
Aberrant gray matter structure associated with sleep disturbance in the drug naïve subjects with Alzheimer’s disease
Soo Hyun Joo, Republic of Korea
J. Y. Nam, H. K. Lim, I. H. Paik, W. Hahm, C. U. Lee

P-03-004
Development of Abeta-42 surrogate marker in peripheral blood
Shinji Tagami, Japan
S. Sano, K. Yanagida, T. Kodama, N. Mizuta, T. Tomonaga, M. Takeda, M. Okochi

P-03-005
Exploring the effect of adducins genetic variability on cognition in schizophrenia
Alessandro Pigoni, Italy

P-03-006
Functional genetic and epigenetic analyses reveal rare mutations and hypermethylation of the ARC associated with schizophrenia
Yang-An Chuang, Taiwan

P-03-007
Oxidative stress and treatment response in schizophrenia: Acute relapse and chronic stable stage
Yi-Ling Chien, Taiwan
C.-M. Liu, S.-Y. Lin-Shiau, H.-G. Hwu

P-03-008
PET study of thalamic dopamine D2-receptors in drug-naïve patients with schizophrenia
Pauliina Ikonen, Sweden
P-03-011
Disrupted frontal-thalamic connectivity as a marker of risk for schizophrenia: Dynamic causal modeling applied to fMRI data collected in vivo
Pranav Jagtap, USA
V. Diwadkar

P-03-012
Identification of rare mutations of postsynaptic scaffolding protein genes associated with schizophrenia using targeted resequencing analysis
Min-Chih Cheng, Taiwan

P-03-013
Interaction between memory retrieval and emotion in schizophrenic patients
Sang-Keun Chung, Republic of Korea
J.-C. Yang

P-03-014
Interaction of EAATs genotype and clozapine on cognitive remediation outcome
Alessandro Pigoni, Italy
M. Spangaro, M. Bosia, M. Buonocore, A. Pirovano, C. Lorenzi, E. Smeraldi, R. Cavallaro

P-03-016
Affective and non-affective first episode psychosis; DUP, substance abuse and clinical outcome
Alba Tolf, Spain
A. Mané, D. Bergé, V. Pérez-Solà

P-03-017
Antipsychotics prescribing patterns in schizophrenic patients with comorbid substance use disorder
Gerard Mateu-Codina, Spain

P-03-019
Clinical predictors of a first psychosis in subjects at high risk for schizophrenia
Maryna Skuhareuskaya, Belarus
N. Buyskaya, O. Skugarevsky

P-04-001
Role of m2 muscarinic receptors in the development of self directedness in children and adolescents
Maria Nobile, Italy

P-04-002
Convergent changes in fronto-cingulate cortex function and structure in adolescent: Multi-modal analyses of fMRI and sMRI data and their implications for neurodevelopment models of psychiatric disease
Ani Madurkar, USA
V. Diwadkar, A. Burgess

P-04-003
Latent classes of emotional and behavioral problems in different samples and their relations to DSM-IV diagnoses
Maria Nobile, Italy
V. Bianchi, P. Brambilla, M. Garzitto, L. Fornasari, P. Colombo, C. Bonivento, S. Piccin, M. Bellina, A. Tesei, M. Molteni

P-04-004
Clinical management of agitation in child and adolescent psychiatric patients
Luis San, Spain
D. Munoz, M. Pardo, X. Alvarez, B. Sanchez

P-04-005
Future directions concerning the impact of childhood and adolescent adversities in the field of men's mental health: The New York declaration
Leo Sher, USA
T. Rice, Z. Rihmer, J. Golier

P-04-006
Genetic polymorphism effect of FTO, AKT1 and AKTIP in childhood obesity in a Brazilian population
Patricia Pereira, Brazil

P-04-007
A study on cytogenetic analyses and MECP2 mutation with Gamma-amino butyric acid (GABA) and serotonin in Rett syndrome (RTT) twins
Balachandar Vellingiri, India
A. Meyyazhagan, S. Kathanan, B. Balasubramaniam, D. Shanaz, S. Keshavarao
P-04-008
Impact of fibromyalgia and presence of anxious and depressive symptoms
María Del Pino Ordovás González, Spain
E. Rodríguez Jiménez, J. Alcalá Partera

P-04-010
Study about Munchhausen syndrome
Mikel Ruiz Feliu, Spain
C. Campos Mangas, A. B. Rodriguez Aliste, M. Haba Sanchez

P-04-012
A rare case of hematohidrosis with schizophrenia
Chytanya Ponangi, India
M. Gowri Devi

P-04-013
Fahr’s syndrome: A case report
Emilce Blanc, Argentina
M. C. Ballarino, O. A. Porta

P-04-014
Functional impairment, religiosity and depression: A mixed-methodology study of spinal cord injury patients in Sri Lanka
Arun Ravindran, Canada
S. Xue, S. Arya, A. Embuldeniya, H. Narammalage, T. da Silva, S. Williams

P-04-016
New onset anxiety disorder in a patient with possible neurocysticercosis
Andrea Bulbena-Cabre, USA
N. Ramos Dunn, R. Gorman Swift

P-04-019
„I tried to get a bug out of my ear“: A case report of a patient with delusions of parasitic infestation and the review of relevant literature
Magdalena Spariosu, USA
D. Coira

P-04-020
„It’s all in your head“: The psychiatrist’s role in the diagnosis and management of conversion disorder in medical settings: Case series and literature review
Magdalena Spariosu, USA
D. Coira

P-05-001
Concentrations of venlafaxine, mirtazapine and citalopram in serum and cerebrospinal fluid--a naturalistic approach
Sarah Lammertz, Germany
G. Grünert, S. Tauber, T. Veselinovic, C. Hiemke, M. Paulzen

P-05-003
Serotonin transporter binding ratios predict outcome and nonadherence to antidepressant in patients with major depression: A naturalistic follow-up study
San-Yuan Huang, Taiwan
C.-C. Huang, Y.-W. Yeh

P-05-004
Beta-arrestin1&2 are inversely affected by antidepressants through alterations in ERK1/2-regulated transcription
Sofia Schreiber-Avissar, Israel
M. Golan, G. Schreiber

P-05-005
The optimal dopamine D2/3 receptor occupancy by antipsychotics in patients with late-life schizophrenia: A [11C]-Raclopride PET study
Shinichiro Nakajima, Canada

P-05-006
Effectiveness and tolerability of high doses of paliperidone palmitate in patients with severe schizophrenia
Juan J. Fernández-Miranda, Spain
S. Díaz-Fernandez, E. Tubio-Arcos, A. C. Gamon-Cantero

P-05-007
Serum Orexin-A levels in antipsychotic-treated schizophrenic patients and their correlation with metabolic profile
Po-Yu Chen, Taiwan
P-05-009
Valerian, melissa, passion flower and their combination STW 32 in experimental models of anxiety
Jürgen Müller, Germany
S. N. Okpanyi, O. Kelber, C. Kolb

P-05-010
Valerian: Safety confirmed
J. Müller, Germany
K. Kraft, O. Kelber, K. Nieber

P-05-011
BDNF gene in bipolar disorder: Case-control association study in South Indian sample and relationship to lithium treatment response
Ravi Kumar Nadella, India
P. Paul, S. Sen, L. N. Kota, V. Kapur, G. Saraf, B. Viswanath, M. Purushottam, M. D. Zompo, A. Squassina, S. Jain

P-05-012
Genetic variants in telomerase-pathway genes are associated with antidepressant response
Sandra Scheuer, Germany
T. Brückl, H. Pfister, M. Uhr, S. Kloiber, S. Lucae, F. Wilhelm, M. Ising

P-05-013
Transcranial magnetic stimulation at 5Hz as an antidepressant response accelerator: Clinical and QEEG analysis
Jorge Julio González Olvera, Mexico
E. Reyes Zamorano, J. Ricardo Garcell, E. Miranda-Terres, M. D. Lourdes García-Anaya, F. Pellicer-Graham

P-05-014
Repetitive Transcranial Magnetic Stimulation modification of the neural processing of emotional stimuli
Virginie Moulier, France
C. Gaudeau, N. Bouaziz, M. Thomas, P. Schenin-King Andrianisaina, E. Bertasi, D. Januel

P-05-015
Clinical effectiveness of electroconvulsive therapy in a university hospital setting in South Korea
Hee-Cheol Kim, Republic of Korea
Y.-M. Choi, K.-S. Kim

P-06
POSTER PRESENTATION
12:45 – 14:15 Muses Foyer

P-06-001
Anti-social behaviour neurobiology
Guillermo Nicolas Jemar, Argentina

P-06-002
The effect of cross-sex hormone treatment on resting state functional connectivity in transsexuals assessed using network-based statistics
Marie Spies, Austria
A. Hahn, G. Kranz, M. Kühlböck, H. Allan, S. Ganger, K. Ulrike, C. Windischberger, D. Winkler, S. Kasper, R. Lanzenberger

P-06-003
The role of peripheral tumor necrosis factor genes in cognitive deficits—preliminary study
Piotr Galecki, Poland
M. Talarowska

P-06-004
Brexpiprazole, a novel serotonin-dopamine activity modulator, has the beneficial effects on NMDA related cognitive dysfunction model in mice: Novel object recognition test in chronic PCP model
Noriko Yoshimi, Japan
K. Hashimoto, Y. Fujita, Y. Ohgi, T. Futamura, T. Kikuchi

P-06-005
Brexpiprazole, a novel serotonin-dopamine activity modulator, has the beneficial effects on NMDA related cognitive dysfunction model in mice: Social recognition test in acute dizocilpine model
Noriko Yoshimi, Japan
T. Futamura, T. Kikuchi, K. Hashimoto

P-06-006
Comparison of facial emotion recognition deficits and cerebral laterality in patients with schizophrenia versus bipolar disorder, their first degree relatives and healthy controls
Rishikesh Behere, India
U. Thonse, P. Sharma

P-06-007
Social brain activity during theory of mind in first episode psychosis: Comparison with healthy controls and link to symptoms
Cali Bartholomeusz, Australia
P-06-008  
Molecular mechanisms of posttraumatic stress disorder  
Alma Dzubur Kulenovic, Bosnia and Herzegovina  
J. Deckert, K. Domschke, A. Kucukalic, E. Avdibegovic, M. Jakovljevic, D. Babic, F. Agani

P-06-009  
Genomewide investigation of copy number variants in relation to Tourette syndrome in a Danish cohort  
Shannmukha Sampath Padmanabhuni, Greece  
A. Juan Ignacio Rodriguez, P. Paschou, Z. Turner

P-06-010  
The role of neurotrophic system genes and environmental factors in depression and individual differences in personality  
Anastasiya Kazantseva, Russia  
T. Noskova, S. Koks, T. Traks, S. Malykh, M. Lobaskova, E. Khusnutdinova

P-06-011  
Association of CCL11 gene polymorphisms with schizophrenia in Korean population  
Jong Woo Kim, Republic of Korea  
W. S. Kang, J.-W. Paik, J. Choi, Y. J. Kim

P-06-012  
Aberrant activation of epigenetic repressive genes is involved in the pathophysiology of major depressive disorder  
Romain Rey, France  
J.-R. Teysier, S. Ragot, J.-C. Chauvet-Gelinier, B. Bonin

P-06-013  
Association between GNA1 gene polymorphisms and risk of schizophrenia in Korean population  
Jong Woo Kim, Republic of Korea  
W. S. Kang, J.-W. Paik, J. Choi, Y. J. Kim

P-06-015  
Associations of white matter hyperintensities with post-stroke depression: A one year longitudinal study  
Kyungyeol Bae, Republic of Korea

P-06-016  
Disruption of thalamofrontal circuitry are linked to neurocognitive deficits in untreated schizophrenic patients  
Mingli Li, People’s Republic of China  
W. Cheng, W. Deng, Q. Wang, X. Ma, J. Feng, T. Li

P-06-017  
Acute effects of SSRI and tryptophan depletion on functional connectivity of amygdala in MAOA-high and MAOA-low carriers: A pharmaco-fMRI study  
Patrick Schelenz, Germany  
M. Klasen, D. Wolf, K. Zerres, T. Eggermann, A. Eisert, F. Zepl, K. Mathiak

P-06-018  
Hypothalamic grey matter volume alterations in alcohol dependence and the effects of the GATA4 genotype: Associations to relapse  
Evangelos Zois, Germany  
S. Hoffmann, S. Vollstädt-Klein, H. Nakovics, F. Kiefer

P-06-019  
Structural brain changes in first episode psychosis – A longitudinal MRI study  
Unn Kristin Haukvik, Norway  

P-06-020  
Structural brain correlates of xenomelia  
Bernd Kraemer, Switzerland  
J. Hänggi, L. M. Hilti, P. Brugger

P-06-021  
Altered function of ventrolateral prefrontal cortex in peer verbal abused adolescents  
Jeewook Choi, Republic of Korea  
S. W. Lee, J. H. Yoo, K. W. Kim, B. Jeong

P-06-022  
Analytical q-ball imaging in euthymic patients with bipolar I disorder  
Bianca Kollmann, Germany  
J. Houenou, V. Scholz, C. Poupon, M. Wessa

P-06-023  
Childhood physical abuse and neglect predict pituitary gland volume in first episode psychosis patients  
Christina Phassoulitis, Australia  

P-06-024  
Inter-hemispheric transfer leads to hyper-activation of macroscopic brain networks in first episode psychosis  
Karthik Ramaseshan, USA  
F. Badaoui, E. Penta, M. Bellani, C. Marzi, P. Brambilla, V. Diwadkar
T6: Bipolar Disorders: Basic/Clinical

S-16  SYMPOSIUM
08:30 – 10:00  Trianti Hall

Biological and clinical aspects of mood disorders with psychotic features
Chair: Thomas Schlaepfer, Germany
Co-Chair: Peter Falkai, Germany

S-16-001
Biomarkers associated with psychotic symptoms in major depression
Alan Schatzberg, USA

S-16-002
Visualization techniques and psychotic patterns
Peter Falkai, Germany

S-16-003
Immunological and neuroimaging patterns associated with psychotic dimension in bipolar disorder
Massimiliano Buoli, Italy

S-16-004
Pharmacological treatment of psychotic mood disorders
Heinz Grunze, United Kingdom

T34: Pregnancy, Post Partum and New Born: Basic/Clinical

S-17  SYMPOSIUM
08:30 – 10:00  Mitropoulos Hall

Recent advances in understanding and treating psychiatric disorders in pregnancy and postpartum
Chair: Simone Vigod, Canada
Co-Chair: Meir Steiner, Canada

S-17-001
Investigating the phenotypic and genotypic heterogeneity of postpartum depression in an international perinatal psychiatry consortium
Samantha Meltzer-Brody, USA
A. Viktorin

S-17-002
Preeclampsia and risk of postpartum psychiatric episodes
Trine Munk-Olsen, Denmark
V. Bergink, T. Munk Laursen, B. M. Winther Johannsen, S. Kushner, S. Meltzer-Brody

S-17-003
Pregnancy outcomes among women using antipsychotic drugs
Simone Vigod, Canada

S-17-004
Transcranial magnetic stimulation for pregnant women with major depressive disorder
Deborah Kim, USA

T1: Addictive Disorders

S-18  SYMPOSIUM
08:30 – 10:00  Skalkotas Hall

Metabotropic glutamate receptors in drug and alcohol dependence
Chair: Athina Markou, USA
Co-Chair: Angela Attwood, United Kingdom

S-18-001
mGluR and mGluR7 activation, and mGluR5 blockade modulate conditioned behavioral and neurochemical effects of psychostimulants in rats
Athina Markou, USA

S-18-002
Rescue of infralimbic mGluR2 deficit restores control of drug seeking in alcohol dependent rats consistent with decreased mGluR2 function in alcoholic patients and alcohol-dependent rats
Rainer Spanagel, Germany

S-18-003
Reduction in mGluR5 receptor binding in human smokers and ex-smokers determined by positron emission tomography
Gregor Hasler, Switzerland

S-18-004
Cognitive attentional bias for drug and alcohol-related cues: Studies in nicotine and alcohol dependent human subjects
Angela Attwood, United Kingdom

T2: Antidepressants: Basic/Clinical

S-03  SYMPOSIUM
08:30 – 10:00  MC 3 Room

Novel mechanisms of action of antidepressant treatment
Chair: Rainer Rupprecht, Germany
Co-Chair: Mark Rasenick, USA

S-03-001
Lipid rafts and signalling cascades as targets for antidepressants
Rainer Rupprecht, Germany
S-03-002
The role of lipid rafts for antidepressant mediated G-protein signalling
Mark Rasenick, USA

S-03-003
The role of p-glycoprotein for the effects of antidepressants on HPA axis
Carmine Pariante, United Kingdom

S-03-004
The cytoskeleton as a target for antidepressants
Massimiliano Bianchi, Ireland

S-20-001
Nitric oxide and zinc levels in limbic regions in pre- and post-pubertal rats after neonatal lesions of the ventral hippocampus
Gonzalo Flores, Mexico

S-20-002
NOS1-NOS1AP interaction at the glutamatergic post-synapse as a candidate mechanism in the pathogenesis of schizophrenia
Andreas Reif, Germany

S-20-003
The glutamate receptor complex in schizophrenia pathogenesis and treatment
David Bredt, USA

S-20-004
The islands of Calleja: The substrate for the glutamate-nitric oxide-dopamine link in schizophrenia?
Dragos Inta, Germany
A. Meyer-Lindentberg, P. Gass

S-21-002
CANMAT’s role in developing and implementing guidelines for clinical practice
Sagar Parikh, Canada

S-21-003
CANMAT/ISBD guidelines: 2013 update
Roumen Milev, Canada
R. Milev

S-21-004
The future of CANMAT/ISBD guidelines
Lakshmi Yatham, Canada

---

T40: SCHIZOPHRENIA: BASIC/CLINICAL

S-20
SYMPOSIUM

08:30 – 10:00
MC 2 Room

Nitric oxide, glutamate and schizophrenia: New insights
Chair: Dragos Inta, Germany
Co-Chair: Andreas Reif, Germany

S-22
SYMPOSIUM

11:00 – 12:30
Skalkotas Hall

Biomarkers in psychiatric disorders
Chair: Peter Riederer, Germany
Co-Chair: Florence Thibaut, France

T20: MOLECULAR NEUROBIOLOGY

S-22-001
Biomarkers in schizophrenia
Peter Falkai, Germany

S-22-002
Biomarkers in ADHD
Edna Grünblatt, Switzerland

S-22-003
Biomarkers in alcoholism
Toshikazu Saito, Japan

S-22-004
Biomarkers in Alzheimer’s disease
Markus Schwarz, Germany

T13: EPIDEMIOLOGY

S-23
SYMPOSIUM

11:00 – 12:30
MC 2 Room

Latency to pharmacological treatments in psychiatric disorders: Epidemiological, biological and clinical aspects
Chair: Carlo Altamura, Italy

S-23-002
Assessing latency to pharmacological treatments in psychiatric disorders: Differences between affective and psychotic disorders
Bernardo Dell’Osso, Italy

S-23-003
Immunological findings in relation to untreated schizophrenia
Elif Weidinger, Germany
S-23-004
The effect of prolonged duration of untreated depression on antidepressant treatment outcome
Lars Vedel Kessing, Denmark

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

S-24 SYMPOSIUM
11:00–12:30 Kokkali Room
Oxytocin and social cognition: From social attachment and reward to novel treatments for autism
Chair: Larry Young, USA
Co-Chair: Adam Guastella, Australia

S-24-001
Oxytocin and social attachment: Implications for novel therapies for autism
Larry Young, USA

S-24-002
Interactions of oxytocin and serotonin in the striatum mediate social reward
Gul Dolen, USA

S-24-003
Common polymorphism in the oxytocin receptor gene (OXTR) is associated with human social recognition skills
David Skuse, United Kingdom
E. Binder, J. Cubells, K. Conneely, I. Lee, A. Lori, L. Young, T. Lehtimaki

S-24-004
Oxytocin therapies to treat core social impairments in autism: Clinical treatment trials in toddlers and youth
Adam Guastella, Australia

S-25 SYMPOSIUM
15:00–16:30 Trianti Hall
Sleep, spindles, and schizophrenia
Chair: Robert McCarley, USA
Co-Chair: Fabio Ferrarelli, USA

S-25-001
Sleep spindle deficits point to thalamic reticular nucleus dysfunction in schizophrenia
Fabio Ferrarelli, USA
G. Tononi

S-25-002
Optogenetic studies of the role of the thalamic reticular nucleus in spindles: Implications for schizophrenia
Robert McCarley, USA
J. McNally, J. McKenna, R. Strecker, F. Katsuki, R. Brown, S. Thankachan

S-25-003
Sleep spindles, magnetic resonance spectroscopy in the thalamus and cognitive functioning
Reto Huber, Switzerland

S-26 SYMPOSIUM
11:00–12:30 Conference Room 1
Neuroimaging in people at ultra high risk for psychosis
Matthew Kempton, United Kingdom
J. van Os, L. Valmaggia, P. McGuire

S-26-001
Mechanisms underlying brain changes in early psychosis
Christos Pantelis, Australia

S-26-002
Early childhood brain development in children at risk for schizophrenia
John Gilmore, USA

S-26-003
New white matter biomarkers of schizophrenia risk
Marek Kubicki, USA
O. Pasternak, P. Savadjiev, L. Delisi, L. Seidman, M. Shenton
### T32: Pharmacology

**S-27**

**SYMPOSIUM**

**15:00 – 16:30**

**Mitropoulos Hall**

**Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for improving pharmacotherapy**

*Chair:* Christoph Hiemke, Germany  
*Co-Chair:* Chin Bin Eap, Switzerland

**S-27-001**

**Pharmacogenetics for improving pharmacotherapies**

*Chin Bin Eap, Switzerland*

**S-27-002**

**Therapeutic drug monitoring for improving pharmacotherapies**

*Christoph Hiemke, Germany*

**S-27-003**

**Brain imaging technologies in psychiatry**

*Gerhardt Gründer, Germany*

**S-27-004**

**Tools for improving pharmacotherapy in psychiatry:**  
*The opinion of a clinician*  
*Andreas Conca, Germany*

### T20: Molecular Neurobiology

**S-28**

**SYMPOSIUM**

**15:00 – 16:30**

**MC 3 Room**

**Glutamatergic mechanisms in schizophrenia: From ketamine to genetic models**

*Chair:* Peter Gass, Germany  
*Co-Chair:* Kazutoshi Nakazawa, USA

**S-28-001**

**Ketamine reversal: Towards empirical discovery of antipsychotics with neuroimaging**

*Philip Corlett, USA*

**S-28-002**

**Expression analysis of a NMDA MK-801 rat model identifies novel candidate genes for schizophrenia**

*Dan Rujescu, Germany*

**S-28-003**

**Mechanisms of neuronal synchrony deficits in NMDAR-hypofunction-mediated schizophrenia mouse model**

*Kazutoshi Nakazawa, USA  
K. Nakao*

**S-28-004**

**Inducible genetic mouse models to study the onset of schizophrenia during late adolescence**

*Dragos Inta, Germany  
H. Elkin, P. Gass*

### T40: Schizophrenia: Basic/Clinical

**S-29**

**SYMPOSIUM**

**15:00 – 16:30**

**MC 2 Room**

**Alpha4beta2-nicotinic acetylcholine receptors in schizophrenia: Implications for smoking cessation and therapeutics**

*Chair:* Deepak Cyril D’Souza, France  
*Co-Chair:* Eden Evins, USA

**S-29-001**

**Nicotine dependence treatment in schizophrenia: Evidence for effectiveness of maintenance pharmacotherapy**

*Eden Evins, USA*

**S-29-002**

**Neuroscience of nicotine addiction vulnerability in schizophrenia**

*Andrew Chambers, USA*

**S-29-003**

**In vivo evidence for beta2-nAChR upregulation in smokers with schizophrenia**

*Deepak Cyril D’Souza, France  
I. Esterlis, M. Ranganathan, F. Bois, B. Pittman, M. Picciotto, L. Shearer, A. Anticevic, J. Carlson, M. Niciu, K. Cosgrove*

**S-29-004**

**Nicotinic CHRNA4 genotype predicts clinical outcome in schizophrenia and neuroleptic drug treatment response**

*Georg Winterer, Germany*

### T9: Dementia: Basic/Clinical

**S-30**

**SYMPOSIUM**

**15:00 – 16:30**

**Kokkali Room**

**Clinical neurochemistry in the early diagnosis of dementia disorders**

*Chair:* Piotr Lewczuk, Germany  
*Co-Chair:* Henrik Zetterberg, Sweden

**S-30-001**

**Current status and new developments for Alzheimer’s disease biomarkers**

*Kaj Blennow, Sweden*

**S-30-002**

**Diagnostic approaches in frontotemporal lobar degeneration (FTLD)**

*Markus Otto, Germany*

**S-30-003**

**Biomarkers for the diagnosis and progression of motor and premotor Parkinson’s disease**

*Brit Mollenhauer, Germany*

**S-30-004**

**Blood biomarkers for neurodegenerative disorders – feasible or too much of a challenge?**

*Henrik Zetterberg, Sweden*
**T10: DEPRESSION: BASIC / CLINICAL**

**TG-03**  
**WFSBP TREATMENT GUIDELINES**  
11:00 – 12:30  
MC 3 Room

**Guidelines on Depression: Globalization or localization**
Chair: Michael Bauer, Germany  
Co-Chair: Raymond W. Lam, Canada

**TG-03-001**  
**WFSBP guidelines for unipolar depression**
Emanuel Severus, Germany

**TG-03-002**  
**Guidelines for major depressive disorder in Korea**
Kang Seob Oh, Republic of Korea

**TG-03-003**  
**Global guidelines for psychiatrists, local guideline for general practitioners – MDD guidelines in Taiwan**
Chia-Yih Liu, Taiwan

**TG-03-004**  
**CANNMAT depression guidelines: The next generation of progress**
Raymond W. Lam, Canada

**T41: SEXUAL DISORDERS: BASIC / CLINICAL**

**TG-04**  
**WFSBP TREATMENT GUIDELINES**  
15:00 – 16:30  
Skalkotas Hall

**Task Force on Paraphilic Disorders: Paraphilia treatment for adults and adolescents**
Chair: Florence Thibaut, France  
Co-Chair: Peer Briken, Germany

**TG-04-001**  
**The proposed diagnostic criteria of paraphilic disorders for ICD-11**
Peer Briken, Germany

**TG-04-002**  
**WFSBP treatment guidelines on paraphilias**
John M. W. Bradford, Canada

**TG-04-003**  
**Ethical considerations of hormonal treatment of paraphilic disorders or sex offenders**
Paul Cosyns, Belgium

**T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL**

**D-01**  
**DEBATE**  
11:00 – 12:30  
Trianti Hall

**Are children overmedicated?**
Chair: Joseph Biederman, USA  
Proponent: Maria Nobile, Italy  
Opponent: Robert Post, USA

**T24: NEUROPHYSIOLOGY**

**WS-06**  
**WORKSHOP**  
16:30 – 18:00  
Skalkotas Hall

**Transcranial magnetic stimulation studies of neurophysiology, neuroplasticity, and neurocognition in psychiatric disorders**
Chair: Paul Croarkin, USA  
Co-Chair: Zafiris J. Daskalakis, Canada

**WS-06-001**
Overview of transcranial magnetic stimulation studies in severe psychiatric disorders  
Zafiris Daskalakis, Canada

**WS-06-002**
A review of the use of repetitive Transcranial Magnetic Therapy in the treatment of chronic pain and borderline personality disorder  
Shirlene Sampson, USA

**WS-06-003**
**rTMS studies of neurocognition in schizophrenia**
Stephanie Ameis, Canada  
A. Voineskos, Z. Daskalakis, D. Blumberger

**WS-06-004**
The neurochemistry of TMS: Magnetic resonance spectroscopy studies  
John D. Port, USA
### T40: Schizophrenia: Basic/Clinical

**WS-07**  
**Workshop**

16:30 – 18:00  
MC 3 Room

**Metabolic disturbances in schizophrenia: Epidemiology, pathophysiology and antipsychotics—towards clinical application of genetic risk models and new treatment strategies**  
Chair: Wiepke Cahn, The Netherlands  
Co-Chair: Bjørn H. Edbrud, Denmark

**WS-07-001**  
**Nationwide studies of diabetes in psychiatric populations**  
René E. Nielsen, Denmark

**WS-07-002**  
**Antipsychotic-induced glucose disturbances: From mice to men**  
Margaret Hahn, Canada  
G. Remington, M. Guenette, A. Chintoh, A. Giacca, G. Remington

**WS-07-003**  
**GWAS in antipsychotic-induced weight gain dissecting the CATIE sample**  
Daniel J. Müller, Canada

**WS-07-004**  
**Antipsychotic-associated dysmetabolism: Glucometabolic hormones, cardiovascular risk markers and potential physiological benefits of glucagon-like peptide-1 receptor agonist treatment**  
Bjørn H. Edbrud, Denmark  

### T25: Obsessive-Compulsive Disorders: Basic/Clinical

**WS-09**  
**Workshop**

16:30 – 18:00  
Kokkali Room

**Biological approaches toward clarifying heterogeneities of obsessive-compulsive disorder**  
Chair: Tomohiro Nakao, Japan  
Co-Chair: Hisato Matsunaga, Japan

**WS-09-001**  
**Altered frontostriatal connectivity in obsessive-compulsive disorder**  
Takashi Nakamae, Japan

**WS-09-002**  
**Neurobiological heterogeneities of OCD**  
Tomohiro Nakao, Japan

**WS-09-003**  
**Cross-cultural aspects of symptom dimension of OCD**  
Hisato Matsunaga, Japan  
K. Yamanishi, K. Mukai, A. Nakajima, Y. Yamagisawa

**WS-09-004**  
**Does the neurobiology of obsessions and compulsions differ?**  
Damiaan Denys, The Netherlands

### T25: Obsessive-Compulsive Disorders: Basic/Clinical

**WS-09**  
**Workshop**

16:30 – 18:00  
Kokkali Room

**Biological approaches toward clarifying heterogeneities of obsessive-compulsive disorder**  
Chair: Tomohiro Nakao, Japan  
Co-Chair: Hisato Matsunaga, Japan

**WS-09-001**  
**Altered frontostriatal connectivity in obsessive-compulsive disorder**  
Takashi Nakamae, Japan

**WS-09-002**  
**Neurobiological heterogeneities of OCD**  
Tomohiro Nakao, Japan

**WS-09-003**  
**Cross-cultural aspects of symptom dimension of OCD**  
Hisato Matsunaga, Japan  
K. Yamanishi, K. Mukai, A. Nakajima, Y. Yamagisawa

**WS-09-004**  
**Does the neurobiology of obsessions and compulsions differ?**  
Damiaan Denys, The Netherlands

### T8: Cognitive Neuroscience

**WS-10**  
**Workshop**

16:30 – 18:00  
Conference Room 1

**Patient’s response to treatment: A neurobiological approach**  
Chair: Jorge Tellez-Vargas, Colombia  
Co-Chair: Policarpo Rebollo, Chile

**WS-10-001**  
**Inflammatory and metabolic dysregulation as predictor of antidepressant response**  
Jorge Tellez-Vargas, Colombia

**WS-10-002**  
**Effects of parental anxiety, traumatic events, and hormonal influences on developmental changes in neural circuits associated with PTSD in children**  
Ruby Castilla-Puentes, USA

**WS-10-003**  
**Pharmacogenetics studies in Latin America**  
Hernan Silva, Chile

**WS-10-004**  
**Genetic and psychiatric diagnosis**  
Veronica Larach, Chile  
L. Varela
Session 2 on pharmacological treatment
Chair: Lakshmi Yatham, Canada
Co-Chair: David Castle, Australia

Pharmacological treatment of anxiety disorders
Christer Allgulander, Sweden

Pharmacological treatment of unipolar disorders
Michael Bauer, Germany

Pharmacological treatment of bipolar disorders
Lakshmi Yatham, Canada

Pharmacological treatment of psychotic disorders
Peter Falkai, Germany

How to manage metabolic disorders associated to psychotropic drugs
David Castle, Australia

Methamphetamine induces dopamine neurons degeneration evidenced by silver staining and causes motor defects in mice
Rosario Moratalla, Spain
S. Ares-Santos, N. Granado

Dopaminergic modulation of value-based decision making and subjective well-being
Nikolina Skandali, United Kingdom
R. Rutledge, P. Dayan, R. Dolan

The glucocorticoid receptor system is altered in cocaine-withdrawn adolescent rats
Lucia Calfino, Italy
G. Giuseppe, C. Malpighi, C. Michilli, F. Fumagalli

Type of benzodiazepine and clinical presentation of benzodiazepine dependence
Olivera Zikic, Serbia
V. Djordjevic, J. Kostic, G. Nikolic

Psychosis: Clinical evaluation of 130 patients for inborn errors of metabolism
Yannis Trakadis, Canada
J. Mitchell

Alterations of functional responses to glutamate in human neural progenitors in fragile X syndrome
Maija Castrén, Finland
V. S. Achuta, N. Putkonen

The glucocorticoid receptor system is altered in cocaine-withdrawn adolescent rats
Lucia Calfino, Italy
G. Giuseppe, C. Malpighi, C. Michilli, F. Fumagalli

Executive dysfunction in autism spectrum disorders: A meta-analysis
Eleni Demetriou, Australia
A. Lampit, A. Guastella

Acute and maintenance electroconvulsive therapy for catatonia in autism spectrum disorders
Lee Wachtel, USA

The effect of support group therapy on parentally bereaved adolescents: A randomized controlled trial
Hesham Abuhegazy, Egypt
H. Elkeshishi

Adverse childhood experiences, depressive symptoms, and food security status: Cross-sectional analysis of mothers of children under age 4
Mohini Prasad, USA
A. Evans, M. Chilton
FC-12  FREE COMMUNICATIONS
15:00–16:30  Conference Room 1
Schizophrenia
Chair: Wolfgang Gaebel, Germany
Co-Chair: Charalampos Touloumis, Greece

Baseline grey matter volume of non-transitioned ultra high risk cases with and without attenuated psychotic symptoms at long term follow up
Vanessa Cropley, Australia

Cognitive functions in schizophrenia: A randomized controlled trial of yoga and physical exercise
Triptish Bhatia, India
S. Mazumdar, J. Wood, F. He, R. Gur, R. Gur, V. Nimgaonkar

Clinical course and risk factors for psychotic relapses in patients diagnosed with delusional disorder: A 24-month follow-up study
Alexandre González-Rodríguez, Spain
O. Molina-Andreu, R. Penadés, A. Pons, R. Catalán, M. Bernardo

Microglial activation: A pet study in schizophrenia
Vanessa Cropley, Australia

Sub-threshold negative symptoms and brain network sensitivity to emotional salience: Potential predictors of psychosis in adolescence
Harinder Rai, USA
V. Divadkar

FC-13  FREE COMMUNICATIONS
16:30–18:00  Mitropoulos Hall
Depression
Chair: Bilgen Taneli, Turkey
Co-Chair: Venetsanos Mavreas, Greece

Predictors of gestational depression
Mayra Brancaglione, Brazil
T. Couto, F. García, R. Nicolato, H. Corrêa

Pathogenesis of Cotard’s syndrome
João Malhadas Martins, Portugal
D. Durães, J. Chainho, A. Paiva

Cognitive function following recovery from a major depressive episode: Systematic review and meta-analysis
Maria Semkovska, Ireland

Who is who: Depression in attention-deficit/hyperactivity disorder in adults—a clinical approach
Vanessa Vila Nova, Portugal
J. Martins, C. Cotta

SA-03  INDUSTRY SPONSORED SYMPOSIUM
13:30–15:00  Skalkotas Hall
see page 97.

P-07  POSTER PRESENTATION
12:45–14:15  Muses Foyer
Addictive Disorders/Anxiety Disorders/Panic Disorders/Stress/Childhood and Adolescent Disorders
Chair: Ioanna-Despoina Bergiannaki, Greece
Co-Chair: Christos Androutsos, Greece

Increased dorsomedial prefrontal cortex in response to emotional face inducing cognitive conflict in smartphone overusers
Chun Ji-Won, Republic of Korea
D.-J. Kim, P. Arom, J. Choi
P-07-002  
Neurobiological characteristics of teenage internet addiction: A resting state EEG study  
Yunna Kwan, Republic of Korea  
I.-J. Lee, D.-B. Yang, S. Choi

P-07-003  
Simulating alcohol use behavior: Pathophysiology and mechanism of therapeutic measures  
Ung Gu Kang, Republic of Korea  
H. S. Kim

P-07-004  
Cardiac autonomic dysregulation in opioid-dependent patients: Treatment matters  
Sheng-Chang Wang, Taiwan  

P-07-005  
Curcuminoids decreased nicotine self-administration in rats  
Marina Sagnou, Greece  
P. Alexiou, A. Markou, M. Pelecanou, X. Li

P-07-006  
Gender differences in the use of prohibited substances in prison  
Oscar Sanz-Garcia, Spain  
M. P. Ibáñez, A. Muro

P-07-008  
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and plasma levels in road traffic accident survivors  
Leigh van den Heuvel, South Africa  
S. Suliman, S. Hemnings, S. Malan, S. Seedat

P-07-009  
Can we predict the treatment response of escitalopram in social anxiety disorder?  
Karg Seob Oh, Republic of Korea  
S. Lim

P-07-010  
Eye movement desensitization and reprocessing for facilitating post-traumatic growth  
Sang Won Jeon, Republic of Korea  
C. Han, S.-H. Kim

P-07-012  
Identification of chromosomal alteration and association study of NRXN3 gene mutations in autism  
Arun Meyyazhagan, India  
B. Balasubramanian, P. Krishnan, D.S.N., S. Keshavarao, B. Vellingiri

P-07-014  
(Re)Introducing psychodynamics into medical school education: Regulation focused psychotherapy for children as a teaching tool  
Timothy Rice, USA  
L. Hoffman, T. Prout, E. Gaines, F. Oluyadi

P-07-015  
Children’s drawings as a window into creativity in play: Systematic ratings of disrupted emotionality in human figure drawings predict creativity in symbolic play  
Timothy Rice, USA  

P-07-016  
Does prenatal exposure to phthalate alter early neurodevelopment and neurogenesis in rodents?  
Yeni Kim, Republic of Korea  

P-07-017  
Latrophilin-3 gene and side effect of OROS methylphenidate in children with attention-deficit/hyperactivity disorder  
Ki-Hwan Yook, Republic of Korea  
J. Song, K.-H. Yook, H. J. Hong

P-07-018  
Effect of emotion regulation training in patients with panic disorder  
Sheng-Min Wang, Republic of Korea  
H.-K. Lee, Y.-S. Kweon, C.-T. Lee, K.-U. Lee

P-07-019  
Methylation effects of early-life stress (ELS)  
Fabian Streit, Germany  
M. Lang, J. Treutlein, M. Gilles, S. Witt, M. Rietschel, M. Deuschle

P-07-020  
Combined effects of social defeat stress and methamphetamine on behavioral sensitization and dopamine receptor mRNA levels in mice  
Yin Cui, Republic of Korea  
H.-M. Jin, T. R. Bagalkot, Y.-C. Chung

P-07-021  
Recent—but not early—psychosocial life stress associated with shorter telomere length  
Josine Verhoeven, The Netherlands  
E. Puterman, B. Elzinga, B. Penninx, P. van Oppen
<table>
<thead>
<tr>
<th>P-08</th>
<th>POSTER PRESENTATION</th>
<th>12:45 – 14:15</th>
<th>Muses Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bipolar Disorders/Depression/Suicide</strong></td>
<td><strong>Chair:</strong> George Papadimitriou, Greece</td>
<td><strong>Co-Chair:</strong> Georgios Moussas, Greece</td>
<td></td>
</tr>
</tbody>
</table>

**P-08-001**  
Compensatory up-regulation of glucose utilizations for mitochondria-related CNS energy insufficiency as an endophenotype of bipolar disorders  
Cheng-Ta Li, Taiwan  

**P-08-002**  
Elucidation of the molecular mechanisms involved in bipolar disorder based on fibroblasts gene expression analysis  
Marianthi Logotheti, Sweden  
N. Venizelos, O. Papadodima, A. Chatziioannou, R. Kolisis

**P-08-004**  
Dysfunctional bottom-up modulation by the amygdala during episodic memory formation associated with emotion dysregulation: fMRI evidence  
Megha Jagannathan, USA  
K. Ramaseshan, R. White, P. Soloff, V. Diwadkar

**P-08-005**  
Enhanced treatment adherence in bipolar II disorder: A 1-year prospective follow-up study using Taiwanese life-chart methodology  
Kuo-Hsuan Chung, Taiwan  

**P-08-006**  
Prescribing patterns of antidepressants and other drugs in Korean bipolar affective disorder patients  
Da-Ye Baek, Republic of Korea  
W. Yoon, J.-S. Lee, Y.-H. Joo

**P-08-009**  
Short-term antidepressant treatment of bipolar depression: Are the International Society for Bipolar Disorder’s Guidelines effective?  
Antonio Tundo, Italy  
J. Calabrese, L. Proietti, R. de Filippis

**P-08-010**  
Study of fMRI activation pattern during associative learning in patients with bipolar disorder  
Eleonora Maggoni, Italy  
P. Brambilla, V. Diwadkar, R. A. Paoli, C. Cinnante, E. Caletti, M. Cigliobianco, G. Cabras, F. Triulzi, C. Altamura

**P-08-011**  
Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3b in platelets of patients with late-life major depression  
Helena Joaquim, Brazil  
L. Talib, B. Diniz, W. Gattaz

**P-08-012**  
Risk factors of recurrence in major depressive disorders  
Ilyes Marrag, Tunisia  
K. Hajji, W. Chebbi, R. Ben Soussia, M. Nasr

**P-08-014**  
Body composition in elderly patients with depression  
Adam Wysokinski, Poland  
J. Kazimierski, T. Sobow

**P-08-016**  
Efficacy of ECT in ultrasound induced depression in rats  
Anna Morozova, Russia  
Z. Eugen, V. P. Chekhonin

**P-08-017**  
Further insights in the mode of action of hypericum perforatum: The postsynaptic downregulation of β1-adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside  
Christiane Kolb, Germany  
H. Häberlein, D. Jakobs, A. Hage-Hülsmann

**P-08-019**  
Is serum 25-hydroxyvitamin D associated with depressive symptoms and suicidal ideation in Korean adults?  
Sang-Keun Chung, Republic of Korea  
J.-I. Park, J.-C. Yang, T. W. Park

**P-08-020**  
Mechanistic understanding of spatial estrogen receptor beta function during brain development: Implications for depressive behavior  
Ivan Nalvarte, Sweden  
M. Varshney, J.-A. Gustafsson

**P-08-021**  
Molecular analyses of the mouse brain exposed to chronic mild stress; the relation between depression and physiological dyshomeostasis  
Kaoru Ikubo, Japan  
K. Yamanishi, N. Doe, Y. Watanabe, M. Yoshida, W. Li, H. Okamura, H. Matsunaga, H. Yamanishi

**P-08-022**  
Thyroid stimulating hormone (TSH) and serum, plasma, and platelet brain-derived neurotrophic factors (BDNF) during a three month follow-up in patient  
Hong Jin Jeon, Republic of Korea  

**P-08-023**  
An 8-week open-label flexible-dose study of desvenlafaxine as monotherapy in the treatment of dysthymia  
Arun Ravindran, Canada  
G. Abraham, M. McKay, G. Curran, A. Hassan, J. Ratz, M. Boucher
P-08-025
Body mass index of psychiatric patients after a recent suicide attempt
Athanassia Papadopoulou, Greece
C. Christodoulou, A. Douzenis, R. Gournellis, C. Papageorgiou, M. Markianos

P-08-026
Suicidal ideation and mental disorders in primary care
Narseta Mickuviene, Lithuania
J. Pecelioniene, V. Kasiulevicius, A. Bunevicius

P-09-001
Sex-related differences in cerebral laterality between patients with schizophrenia and controls
Yu Sang Lee, Republic of Korea
B.-H. Choi

P-09-002
Telomere shortening in the hippocampus is associated with negative symptom-like behavioral deficits and cognitive impairment in schizophrenia
Kazuya Toriumi, Japan

P-09-003
A cross sectional study of angular gyrus and supramarginal gyrus in patients at first-episode of schizophrenia
Paolo Brambilla, Italy

P-09-004
Altered intrinsic connectivity networks between the cerebrum and cerebellum during rest: A clinical ultra-high risk study
Minji Bang, Republic of Korea
M. Yoon, K. Park, H.-J. Park, S. K. An

P-09-005
BDNF serum levels and Val66Met polymorphism in schizophrenia patients evaluated with MATRICS consensus cognitive battery
Rodrigo Nieto, Chile
H. Silva, M. Kukuljan, L. Bustamante, A. Armijo, A. Gonzalez, R. Nachar, C. P. Castaneda, T. Lopez, C. Montes, V. Salinas, V. De Angel

P-09-006
Cerebral hemodynamics in male schizophrenia patients during the trail making test: A functional transcranial doppler sonography study
Grammato Amexi, Germany
S. Egger, J. Ernst, S. Grimm, S. Vetter, E. Seifritz, D. Schüpbach

P-09-007
EEG characteristics of auditory verbal hallucinations in schizophrenia
In Won Chung, Republic of Korea

P-09-009
Epigenetics in schizophrenia and association with antipsychotic response to clozapine: Preliminary findings
Alessandro Pigoni, Italy

P-09-010
Evaluation of the metabolic parameters of a novel antipsychotic agent „PGW5” in a rat model of atypical antipsychotics induced metabolic side-effect
Michal Taler, Israel
L. Shibo, I. Vered, A. Weizman, A. Weller, I. Gil-Ad

P-09-011
Frequency of somatic illnesses in patients with schizophrenia–age and gender distribution
Srebrenka Bise, Bosnia and Herzegovina
D. Begic, B. Kurtovic, O. Cemalovic

P-09-012
Frontal brain activity in the individuals at risk for schizophrenia: A brain electrical topography study
Aleksandra Aleksandrowicz, Switzerland

P-09-013
In vivo long-term kinetics by planar imaging studies of radiolabelled N,N-dimethyltryptamine, serotonin and tryptamine in rabbits
Jorge Ciprian Olívier, Argentina
A. Vitale, C. Cañellas, M. Vitale, A. Pomilio

P-09-014
Increased calcium-independent lipoprotein phospholipase A2 but not protein S100 in patients with schizophrenia
Ante Silic, Croatia
D. Ostojic, A. Savic, A. Bacekovic, A. Puljic, D. Karlovic

P-09-015
Inefficient DLPFC recruitment in delusion-prone subjects during a working memory task
Yu Fukuda, Germany
T. Katthagen, L. Deserno, F. Schlagenhaft
P-09-016
Inefficient brain network modulations by the responding motor cortex during inter-hemispheric transfer: Pronounced effects of right-hand dominance in chronic schizophrenia
Amanda Martin, USA
M. Bellani, K. Ramaseshan, C. Marzi, P. Brambilla, V. Diwadkar

P-09-018
Investigating serum mean platelet volume in patients with schizophrenia
Murat Beyazyüz, Turkey
E. Soydas Akyol, Y. Albayrak, B. Bilić, N. Albayrak, M. Kuloglu

P-09-019
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) levels in patients with schizophrenia
Tevfik Kalelioglu, Turkey
N. Durak, N. Karamustafalioglu, A. Cenc, M. Akkus, A. Tasdemir, M. Emul

P-09-020
Preliminary study for the effect of open adjunctive molindone to weight loss in obese and overweight patients with schizophrenia
Kyuyoung Lee, Republic of Korea
E.-J. Joo

P-09-022
Quality of life and chronic psychiatric diseases
Illes Marrag, Tunisia
K. Hajji, W. Chebbi, L. Zarrouk, M. Nasr

P-09-023
IQ, the urban environment and schizophrenia risk
Timothea Touloupolou, Hong Kong
P. B. Mortensen, C. B. Pedersen, V. Ehrenstein, M. Picchioni, L. Petersen

P-09-024
Reciprocal causation models of superior temporal gyrus and childhood social personality in twin and siblings with schizophrenia
Xiaowei Zhang,
P. C. Sham, S. S. Cherny, M. Picchioni, R. Murray, T. Touloupolou

P-09-025
Schizophrenia and variations in cognition-associated genes
Roksana Zakharyan, Armenia
S. Atshemyan, A. Boyajyan

P-10-001
Differences of peripheral inflammatory markers in Alzheimer’s disease and mild cognitive impairment
Kang Joon Lee, Republic of Korea
H. W. Shin, H. Kim

P-10-002
Donepezil decreases β-secretase BACE1 expression in platelets of Alzheimer disease patients
Tamires Alves Sarno, Brazil

P-10-003
Donepezil increases iPLA2 activity and inactivates GSK3β in platelets of Alzheimer’s
Leda Talib, Brazil
S. R. Hototian, H. Joaquim, O. Forlenza, W. Gattaz

P-10-004
Glutamate complex and BDNF concentration of depressive patients with cognitive dysfunction
Changsu Han, Republic of Korea
H.-K. Yoon, S. Yoon

P-10-005
Physical exercising is reducing anxiety, depression and memory deficits associated with a MPTP-induced rat model of Parkinson’s disease
Alin Ciobica, Romania
R. Lefter, M. Paulet, F. Trofin

P-10-006
Attentional functions in elderly with and without Attentional Deficit and Hyperactivity Disorder (ADHD): Preliminary results
Mario Louzã Neto, Brazil
M. Klein, A. K. Menezes, T. M. Alves,

P-10-008
A systematic evaluation of impulsive-aggressive behavior of geriatric-psychiatric in-patients using the Staff Observation Aggression Scale-Revision (SOAS-R)
Myrella Paschali, Germany
C. Reichmann, D. Kamp, M. Jaenner, T. Supprian

P-10-009
Finding high risk patients for delirium in orthopaedic elderly patients
Jung-Seo Yi, Republic of Korea
J. J. Kim, N. Hong
P-10-010
The prevalence of bipolar spectrum disorder in elderly patients with recurrent depression
Young-Eun Jung, Republic of Korea

P-10-011
Libidinal increase induced by memantine
Jaehyun Kim, Republic of Korea
Y. Paik

P-10-012
Safety of quetiapine for treatment of geriatric psychosis
Gorana Sulejmanpasic-Arslanagic, Bosnia and Herzegovina
S. Fisekovic, A. Kucukalic, S. Ler

P-10-013
Improving wellness and quality of life of mental health consumers: An eight-year naturalistic evaluation of the CHU de Quebec-IUSMQ Mieux-Etre Wellness Program
Christian Shriqui, Canada
I. Lachance, A. Aubin, S. Bonneville, I. Paradis

P-10-014
Comparison of depressive symptoms of the Hamilton Depression Rating Scale between elderly and non-elderly outpatients with major depressive disorder
Ikki Yoo, Republic of Korea

P-11-001
Deficient assessment and reporting of adverse events in antidepressant clinical trials
Rajnish Mago, USA
J. Chaves, S. Kaur

P-11-002
Detect neural dynamics across acute, chronic and discontinuation SSRI administration
Shahak Yariv, Israel
R. Perets, Y. Shohat, R. Paz

P-11-003
Involvement of 5-HT1A receptors of the dorsal hippocampus in the anxiogenic effect caused by acute antidepressant administration in rats
Helio Zangrossi Junior, Brazil
A. B. Sant'ana do Nascimento, H. H. Vilela-Costa, T. de Andrade

P-11-004
Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder
Chi-Un Pae, Republic of Korea
C. Han, A. Serretti

P-11-005
Smoothing spline regression as a modern tool for the analysis of observational data—moderate depression under hypericum extract STW3-VI (900 mg daily) compared to selective serotonin reuptake inhibitors in routine outpatient treatment
Juergen Mueller, Germany
C. Kolb, O. Kelber, C. Theurer

P-11-006
St John’s wort: What is the key for the bioavailability of a phytomedicine active in mild to moderate depression?
Christiane Kolb, Germany
V. Butterweck, O. Kelber, S. Verjee, H. Abdel-Aziz

P-11-007
Brain state-dependent abnormal LFP activity in the auditory cortex of a schizophrenia mouse model
Kazutoshi Nakazawa, USA
K. Nakao

P-11-008
Gender differences regarding prolactin levels, ASEX and PANSS scales in schizophrenic patients
Christina Kalkavoura, Greece
I. Michopoulos, P. Arvanitakis, P. Theodoropoulou, K. Dimopoulou, E. Tzebelikos

P-11-009
Metabolic syndrome risk of antipsychotics: One year follow-up study
Ayse Nur Inci Kenar, Turkey
E. Hanci, K. Saricay

P-11-010
Does aripiprazole augmentation reduce prolactine levels and relieves related symptoms in women patients treated with amisulpride?
Sarpe Marcel, Romania
P. Dan, P. Ruxandra, L. Maria

P-11-011
Therapeutic dose range of valproate-induced hyperammonemic encephalopathy: A case report
Chul Eung Kim, Republic of Korea
S. Maeng, J. H. Rho
P-11-012
ABCBI polymorphism may be related to refractoriness in a sample of mood disorders patients undergoing ECT: A pharmacogenetics approach
Carolina Prado, Brazil
M. van de Bilt, B. Valim de Nicola, L. Rigonatti, S. Rigonatti, L. Talib, W. Gattaz

P-11-013
Are HTR1A and HTR2A polymorphisms related to treatment response? A pharmacogenetics study of ECT patients
Bruna Nicola, Brazil
C. Prado, M. van de Bilt, L. Rigonatti, L. Talib, S. Rigonatti, W. Gattaz

P-11-014
Deep brain stimulation alters expression of blood brain barrier transporters as a mechanism to enhance CNS drug effects
Ziad Nahas, Lebanon
L. Devane, M. Doumit, P. Zhang

P-11-015
Efficacy of repetitive transcranial magnetic stimulation (rTMS) in post traumatic stress disorder (PTSD) and panic disorder: A meta-analysis
Deepa Nathan, India
M. S. Keshavan

P-11-016
Longitudinal efficacy of TMS treatment in depression
Oguz Karamustafaloğlu, Turkey
M. Cevik, O. Tankaya

P-12-001
Ketamine as a model for schizophrenia deficits
Erica Neill, Australia
S. Rossell, C. Morgan, O. Carter, N. Joshua

P-12-002
Emotion processing in schizophrenia patients and their unaffected mothers
Natallia Khamenka, Belarus
M. Skuhareuskaya, O. Skugarevsky

P-12-004
Mentalizing in schizophrenia: Abnormal activation of theory of mind areas during implicit perspective taking
Lisa Mayrhofer, Austria

P-12-005
Neurocognition and serotonin transporter 5-HTTLPR polymorphism in high-risk for psychosis individuals
Maryna Skuhareuskaya, Belarus
I. Halayenka

P-12-006
The modulatory role of serotonin in model-based and model-free choice behaviour
Nikolina Skandali, United Kingdom
V. Voon, A. Bruhl, J. Rowe, T. Robbins, B. Sahakian

P-12-007
Co-prescription of antipsychotics with other psychotropics and medication for somatic disorders: A total population study in Austria
Heinz Katschnig, Austria
F. Endel, C. Strassmayr

P-12-008
Genetic ancestry of psychosis in the population of the Central Valley of Costa Rica
Javier Contreras, Costa Rica
R. Barrantes, H. Raventos

P-12-009
Pattern of gene expression in different stages of schizophrenia: A pilot comparison of human induced pluripotent stem cell-derived neurons with post mortem cerebral cortex
Mirko Manchia, Italy
I. S. Piras, C. C. Zai, J. Kennedy, B. Carpiniello

P-12-011
Linkage and association analyses of schizophrenia with genetic variations on chromosome 22q11 in Korean population
Yu Sang Lee, Republic of Korea
K. S. Hong

P-12-012
Polymorphisms in the serotonin transporter gene and the risk of stroke: An association study
Janne Kaergaard Mortensen, Denmark
H. Buttenschön, O. Mors, G. Andersen
P-12-013
The role of non-coding RNAs in fear extinction
Stefanie Malan-Müller, South Africa
L. Fairbairn, W. Daniels, M. Jalali Sefid Dashti, E. Oakeley,
M. Altorfer, J. Harvey, S. Seedat, J. Gamieldien, S. Hemmings

P-12-014
Mice, traumatic brain injury, and cognitive effects of enriched environment
Shaul Schreiber, Israel
R. Lin, V. Rubovitch, C. Pick

P-12-015
Gene expression profile of PARK2 CNV carriers with adult ADHD
Sarah Kittel-Schneider, Germany
D. Gersic, M. Frank, C. Lorenz, J. Auer, A. Reif, K.-P. Lesch,
S. Winkler, S. Klebe

P-12-016
Alzheimer's disease, Parkinson's disease and schizophrenia are not inflammatory diseases while inflammation is recognizable beyond organ borders
Michaela Filiou, Germany
A. S. Arefin, P. Moscati, M. Graeber

P-13-001
Morphological and functional connectivity change of basal ganglia in amnestic mild cognitive impairment
Chang Uk Lee, Republic of Korea
C. Lee, S.-H. Joo, C. Hahn, H.-K. Lim

P-13-002
Neural correlates of hallucinations in bipolar disorder
Maila Neves, Brazil
F. Garcia, M. Albuquerque, R. Nicolato, F. Silva Neves, F. L.
De Souza Duran, G. Busatto, H. Corrêa

P-13-003
Prediction of depression in youth at high familial risk for bipolar disorder using diffusion tensor imaging
Rossana Ganzola, Canada
A. McIntosh, T. Nickson, S. Giles, A. Macdonald, J. Sussmann, S. Duchesne, H. C. Whalley

P-13-004
Proton magnetic resonance spectroscopy measures related to a long-time symptomatic outcome in first-episode schizophrenia
Agata Szulc, Poland
B. Galinska-Skok, E. Tarasow, N. Waszkiewicz, A. Mosiolek

P-13-005
Regional cerebral glucose metabolism in acute and transient psychosis–comparison with schizophrenia
Srinivas Balachander, India
S. Malhotra, D. Basu, A. Bhattacharya

P-13-006
Reward susceptibility distinctly mediates salience effects on functional connectivity during expectancy and perception condition
Shijia Li, Germany
L. R. Demenescu, B. Zhang, A. Kraus, C. Metzger, M. Walter

P-13-007
Similar white matter but opposite grey matter alterations in schizophrenia and high-functioning autism
Julien Katz, France
**P-13-008**
Studying neuroimaging in patients with first episode of acute psychosis. A retrospective study comparing patients with abnormal neuroimaging results and patients with normal neuroimaging results
Fengyuan Yao, Singapore
J. Rajesh, G. Kunjithapatham, S. P. Lee

**P-13-009**
The dorsal prefrontal cortex mediates attention to social reward in adolescents: Implications for childhood onset psychiatric conditions
Vaibhav Diwadkar, USA
B. Chepuri, M. Nobile, K. Ramaseshan, P. Brambilla

**P-13-010**
Novel multi-feature vs oddball paradigm in evaluating auditory change detection in schizophrenia
Michał Jarkiewicz, Poland
L. Okruszek, W. Jernajczyk, M. Jarema, A. Wichniak

**P-13-011**
The effect of different routes of administration of THC in rats
Libor Uttl, Czech Republic
P. Nováková, T. Hložek, L. Kaderábek, F. Tyls, E. Lhotkova, C. Vejsnola, T. Palenicek, M. Balikova, D. Ripova

**P-13-012**
The impact of acute cannabis intoxication on eLORETA functional connectivity of the brain
Filip Tyls, Czech Republic
T. Palenicek, M. Viktorinova, R. Androvicova, M. Fujakova, T. Melicher, M. Brunovsky, J. Horacek

**P-13-013**
Auditory event-related potentials differentiate patients with schizophrenia and autism spectrum disorders
Yi-Ling Chien, Taiwan
M. Hsieh, Y.-H. Sheu, S. Gau, H.-G. Hwu

**P-13-014**
GABA metabolism and its role in gamma-band oscillatory activity during auditory processing
Christine Wyss, Switzerland

**P-13-015**
Auditory P300 event related potentials in acute and transient psychosis in remission-comparison with schizophrenia in remission
Swapnajeet Sahoo, India
S. Malhotra, D. Basu, M. Modi

**P-13-016**
Attentional and sensory gating abnormalities in schizophrenia: A neuropsychopharmacologic approach for the treatment of schizophrenia
Leslie Kiraly, Canada
Z. Elbaz

---

**POSTER EXHIBITION**
Please visit the Poster Exhibition located in the Muses Foyer on the ground level of the Megaron.

**OPENING HOURS**
- **Monday, 15 June 2015** 09:00 – 17:00
- **Tuesday, 16 June 2015** 09:00 – 17:00
- **Wednesday, 17 June 2015** 09:00 – 17:00
- **Thursday, 18 June 2015** 09:00 – 17:00
PL-03-001
Neuropsychiatric syndromes of later life: Implications for the study and treatment of major psychiatric diseases
Constantine Lyketsos, USA

T10: DEPRESSION: BASIC/CLINICAL

S-31
08:30 – 10:00
Trianti Hall
Novel biomarkers in mood disorders: Opportunities for translation into clinical practice
Chair: Bernhard Baune, Australia
Co-Chair: Kenji Hashimoto, Japan

S-31-001
A translational perspective on the neurotrophin hypothesis of depression
Marc L. Molendijk, The Netherlands

S-31-002
BDNF and its precursor proBDNF as biomarkers for mood disorders
Kenji Hashimoto, Japan

S-31-003
Apoptosis as new biomarker for mood disorders
Yakup Albayrak, Turkey

S-31-004
Genetic and serum immune biomarkers in depression
Bernhard Baune, Australia

T46: SUICIDE: BASIC/CLINICAL

S-33
08:30 – 10:00
Skalkotas Hall
Translational psychiatry in mood disorders and suicide
Chair: Julio Licinio, Australia
Co-Chair: Philippe Courtet, France

S-33-001
Imaging and cognitive markers of suicidal behavior
Fabrice Jollant, Canada

S-33-002
Omics predictors of suicidal behaviour
Enrique Baca Garcia, Spain

S-33-003
The role of neuroinflammation and immunity on suicidality
Philippe Courtet, France

S-33-004
Serotonin and endocannabinoid system in mood disorders: Animal and clinical studies
Gabriella Gobbi, Canada

T32: PHARMACOLOGY

S-34
08:30 – 10:00
MC 3 Room
Cross species studies of psychedelic drugs—relevance to psychiatric disorders
Chair: Franz Vollenweider, Switzerland
Co-Chair: Mark A. Geyer, USA

S-34-001
Behavioral and pharmacological studies of psychedelics in animals
Mark A. Geyer, USA
S-34-002
Disruption of thalamocortical activity in psychedelic models in animals
Francesc Artigas, Spain

S-34-003
EEG power spectra and connectivity changes as biomarkers of psychedelic effects in animal models
Tomas Palenicek, Czech Republic

S-34-004
Neuroimaging and behavioral studies of cognitive and emotional effects of serotonergic hallucinogens in humans
Franz Vollenweider, Switzerland
R. Krähenmann, E. Seifritz, K. Preller

T44: Stimulation Methods (ECT, TMS, VNS, DBS)

S-35 SYMPOSIUM
08:30 – 10:00 MC 2 Room
Clinical applications and technical foundations of transcranial Direct Current Stimulation (tDCS), a non-invasive brain stimulation therapy, in psychiatric disorders
Chair: Andre Brunoni, Brazil
Co-Chair: Emmanuel Poulet, France

S-35-001
TDCS in psychiatry: Mechanistic foundations and current challenges
Frank Padberg, Germany

S-35-002
TDCS for neuromodulation of decision-making: Implications for the addictive brain
Shirley Fecteau, Canada
S. Fecteau

S-35-003
Clinical and biological evidence for using TDCS in schizophrenia
Jerome Brunelin, France
E. Poulet

S-35-004
TDCS in major depressive disorder: Results from randomized clinical trials and follow-up studies
Andre Brunoni, Brazil

T23: Neuroimaging: Genetic, Functional, Structural

S-36 SYMPOSIUM
11:00 – 12:30 Mitropoulos Hall
Brain imaging and treatment response
Chair: Siegfried Kasper, Austria
Co-Chair: Lars Farde, Sweden

S-36-001
Multimodal imaging and treatment response in depression
Siegfried Kasper, Austria

S-36-002
Targets for deep brain stimulation in depression
Thomas Schlaepfer, Germany

S-36-003
D2-receptor occupancy and treatment response in schizophrenia revisited
Lars Farde, Sweden

S-36-004
Imaging of the glutamatergic neuroreceptors, a new target?
Erich Seifritz, Switzerland

T16: Genetics

S-37 SYMPOSIUM
11:00 – 12:30 Skalkotas Hall
Immunogenetics: Exploring new territory in schizophrenia
Chair: James Kennedy, Canada
Co-Chair: Jennie Pouget, Canada

S-37-001
Common variation does not support involvement of immune loci in schizophrenia
Jennie Pouget, Canada
V. Goncalves, J. Kennedy, J. Knight

S-37-002
The schizophrenia and bipolar polygenic scores: Association with clinical and serologic markers
Faith B. Dickerson, USA

S-37-003
An extreme form of structural variation in the human HLA locus
Steven McCarroll, USA

S-37-004
The viral microbiome: The missing link in the pathogenesis of schizophrenia
Robert Yolken, USA
F. B. Dickerson
## Scientific Programme | Wednesday, 17 June 2015

### T4: Anxiety Disorders: Basic/Clinical

**S-07**

**SYMPOSIUM**

11:00–12:30

MC 2 Room

**Anxiety disorders—clinical and biological markers in diagnosis and treatment**

Chair: Borwin Bandelow, Germany  
Co-Chair: Katharina Domschke, Germany

**S-07-001**

Patho- and therapy-genetics of anxiety disorders  
Katharina Domschke, Germany

**S-07-002**

Childhood anxiety as a precursor of other psychiatric disorders in adulthood  
Christer Allgulander, Sweden

**S-07-003**

Efficacy of treatments for anxiety disorders: A meta-analysis  
Borwin Bandelow, Germany  
M. Reitt, C. Röver, S. Michaelis, Y. Görlich, D. Wedekind

**S-07-004**

The need for new targets in anxiety disorders: From neurobiology to treatment  
Nic J.A. van der Wee, Germany

### T10: Depression: Basic/Clinical

**S-39**

**SYMPOSIUM**

11:00–12:30

Kokkali Room

**Molecular and genetic substrates underpinning diagnosis of major depression**

Chair: Yogesh Dwivedi, USA  
Co-Chair: Dan Rujescu, Germany

**S-39-001**

MicroRNA-mediated reorganization of gene expression networks and its role in depression pathogenesis  
Yogesh Dwivedi, USA

**S-39-002**

Neurotrophic- and GABA-related corticolimbic pathology in depression  
Etienne Sibille, USA

**S-39-003**

DNA methylation in childhood maltreatment and major depression  
Gustavo Turecki, Canada  

**S-39-004**

Neuroticism: Role in negative mood states and internalizing depressive conditions  
Dan Rujescu, Germany

### T44: Simulation Methods (ECT, TMS, VNS, DBS)

**S-40**

**SYMPOSIUM**

11:00–12:30

Conference Room 1

**Advances in repetitive Transcranial Magnetic Stimulation (rTMS) as treatment for psychiatric disorders**

Chair: David Gorelick, USA  
Co-Chair: Christos Theleritis, Greece

**S-40-001**

Functional and structural neuroplasticity possibly induced by a series of prefrontal rTMS for major depression  
Motoaki Nakamura, Japan  

**S-40-002**

Deep transcranial magnetic stimulation in major depression: From animal models to clinical application  
Yechiel Levkovitz, Israel

**S-40-003**

Intermittent theta burst protocol for restricted and repetitive behavior on high function autistic spectrum disorder  
Marco Marcolin, Brazil  
C. Abujadi

**S-40-004**

Neuroplastic effects of standard and deep TMS treatment as measured by EEG in individuals with attention-deficit hyperactivity disorder (ADHD)  
Abraham Zangen, Israel  
U. Alyagon, H. Shahar, H. Shalev

### T27: Pain: Basic/Clinical

**S-41**

**SYMPOSIUM**

15:00–16:30

Trianti Hall

**Resolving the missing link between physical and mental pain: Basic, clinical, and translational approaches**

Chair: Shigenobu Kanba, Japan  
Co-Chair: Tim Salomons, United Kingdom

**S-41-001**

Comorbidity of psychiatric disorders in chronic pain  
Ryota Hashimoto, Japan  

**S-41-002**

Microglia as a pain maker in neuropathic pain: Rodent studies  
Masato Tsuda, Japan

**S-41-003**

Therapeutic and neuroimaging approaches to physical and mental pain  
Tim Salomons, United Kingdom
S-41-004
Microglia as a possible key player to bind physical and psychological pain: Translational approach
Takahiro Kato, Japan
M. Ohgodani, M. Hosoi, S. Kanba

T40: Schizophrenia: Basic/clinical

S-42
Computational, cognitive and pharmacological connectomics: Towards understanding mechanisms of psychosis
Chair: Alan Anticevic, USA
Co-Chair: Deanna Barch, USA

S-42-001
Integrating pharmacology, computation and connectivity to understand schizophrenia onset and progression
Alan Anticevic, USA

S-42-002
Connectomics of psychosis: Cross diagnostic similarities, differences and relationships to RDoC dimensions
Deanna Barch, USA

S-42-003
Neural oscillations in MEG-Data: A translational perspective
Peter Uhlhaas, United Kingdom

S-42-004
Action-based paradigms reveal predictive coding failures in psychotic patients
Judith Ford, USA

S-43
Sleep and neuroplasticity: Clinical implications for depression
Chair: Edith Holsboer-Trachsler, Switzerland
Co-Chair: Axel Steiger, Germany

S-43-001
Animal models of sleep disruption
Tarja Porkka-Heiskanen, Finland

S-43-002
Sleep and synaptic dysfunction in depression
Anne Eckert, Switzerland

S-43-003
Sleep as predictor of emotional regulation in children
Martin Hatzinger, Switzerland

S-44
Inflammation and mitochondrial dysfunction: Relevance to depression
Chair: Michael Berk, Australia
Co-Chair: Michael Maes, Thailand

S-44-001
Differential changes in TNF alpha signalling pathways in schizophrenia, major depressive disorders and bipolar disorders
Brian Dean, Australia

S-44-002
The role of inflammation in the biology and aetiology of depression
Michael Maes, Thailand

S-44-003
Novel therapies for depression: Anti-inflammatory treatments
Michael Berk, Australia

T38: Psychopathology

TG-05
Task Force on Nosology: Psychopathology – past, present and future
Chair: Wolfgang Gaebel, Germany
Co-Chair: Veronica Larach, Chile

TG-05-001
Psychopathology and neuroscience: A modularity approach
Wolfgang Gaebel, Germany

TG-05-002
After Jaspers, what else?
Michael Musalek, Austria

TG-05-003
Gene-environment interaction and psychopathology
George N. Papadimitriou, Greece

TG-05-004
Teaching psychopathology today
Veronica Larach, Chile
Scientific Programme | Wednesday, 17 June 2015

T40: Schizophrenia: Basic/Clinical

WG-06 WFSBP Treatment Guidelines

15:00–16:30 Skalkotas Hall
Task Force on Schizophrenia
Chair: Peter Falkai, Germany
Co-Chair: Alkomiet Hasan, Germany

TG-06-001 WFSBP Guidelines on the acute treatment of schizophrenia
Alkomiet Hasan, Germany

TG-06-002 WFSBP Guidelines on the long-term treatment of schizophrenia
Thomas Wobrock, Germany

TG-06-003 Treatment guideline for the early phase of schizophrenia/psychosis
Eric Chen, People’s Republic of China

T1: Addictive Disorders

D-02 Debate
11:00–12:30 Trianti Hall
Behavioral addictions—normality or deviance?
Chair: Florence Thibaut, France
Co-Chair: Victoria Valdez de Vuibert, Ecuador
Proponent: Marc Potenza, USA
Opponent: Pier Vincenzo Piazza, France

T9: Dementia: Basic/Clinical

WS-16 Workshop
16:30–18:00 Mitropoulos Hall
Development of biological markers for differential diagnosis of dementia in physiological and biochemical strategies
Chair: Toshihisa Tanaka, Japan
Co-Chair: Fernando Maestu, Spain

WS-16-001 Magnetoencephalography for diagnose and evaluation of dementia
Fernando Maestu, Spain

WS-16-002 Functional connectivity in EEG for diagnosis of Alzheimer disease
Leonides Canuet, Spain

WS-16-003 Screening of cognitive impairment and diagnosis of dementia
Katsuya Urakami, Japan

WS-16-004 CSF biomarkers in differential diagnosis of dementia
Toshihisa Tanaka, Japan
M. Terada, M. Sato, M. Takeda

WS-11 Workshop
16:30–18:00 Skalkotas Hall
Treatment of schizophrenia: Personalized tailoring to meet patients needs
Chair: Konstantinos Fountoulakis, Greece
Co-Chair: Cyril Hoschl, Czech Republic

WS-11-001 Antipsychotics: Differences and specificity
Alessandro Serretti, Italy

WS-11-002 Information technology aided relapse prevention in schizophrenia (ITAREPS)
Cyril Hoschl, Czech Republic
F. Spaniel

WS-11-003 Computer-assisted treatment pathway for schizophrenia: Development and first results in over 200 patients
Georg Juckel, Germany

WS-11-004 The optimization effect in schizophrenia: Why we see different things in everyday clinical practice
Konstantinos Fountoulakis, Greece

T10: Depression: Basic/Clinical

WS-12 Workshop
16:30–18:00 MC 3 Room
Task force recommendations for the management of comorbidity in major depressive disorder and bipolar disorder
Chair: Roumen Milev, Canada
Co-Chair: Serge Beaulieu, Canada

WS-12-001 The comorbidity of mental and bone health: A fracture line ready to break?
Michael Berk, Canada

WS-12-002 Management of patients with comorbid mood and anxiety disorders
Roumen Milev, Canada
A. Schaffer
### WS-12-003
Managing substance use in mood disorders  
Serge Beaulieu, Canada

### WS-12-004
Treating bipolar disorder in the real world integrating comorbidity into treatment decisions  
Serge Beaulieu, Canada

### T33: POSTTRAUMATIC STRESS: BASIC/CLINICAL

<table>
<thead>
<tr>
<th>Topic</th>
<th>Workshop</th>
<th>Time and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interaction between neurobiological and ethno cultural factors in PTSD treatment response, recovery and resilience. Is there a link?</td>
<td>WS-13-001</td>
<td>16:30 – 18:00, MC 2 Room</td>
</tr>
<tr>
<td>Contribution of ethno cultural, genetic and biological factors to increasing or decreasing PTSD treatment response— an Asian experience</td>
<td>WS-13-002</td>
<td>16:30 – 18:00, MC 2 Room</td>
</tr>
<tr>
<td>Contribution of ethno cultural, genetic and biological factors to increasing or decreasing a person’s risk for developing PTSD once he or she has been exposed to trauma— an African experience</td>
<td>WS-13-003</td>
<td>16:30 – 18:00, MC 2 Room</td>
</tr>
<tr>
<td>A model of suicidal behavior among immigrants with PTSD</td>
<td>WS-13-004</td>
<td>16:30 – 18:00, MC 2 Room</td>
</tr>
</tbody>
</table>

### WS-14-003
Genetic neuroimaging study to find the neurobiology of depressive disorders  
Byunggool Ham, Republic of Korea  
M.-S. Lee

### WS-14-004
Neurobiology of impulsive behaviors and behavioral addictions  
Dai-Jin Kim, Republic of Korea  
J. E. Jeong

### T46: SUICIDE: BASIC/CLINICAL

<table>
<thead>
<tr>
<th>Topic</th>
<th>Workshop</th>
<th>Time and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suicide and behavioral addiction in Korea: Searching for the biopsychosocial basis in the fast changing society</td>
<td>WS-14-001</td>
<td>16:30 – 18:00, Kokkali Room</td>
</tr>
<tr>
<td>Crosscultural differences in the attitude toward suicide: Multi-countries comparison study</td>
<td>WS-14-002</td>
<td>16:30 – 18:00, Kokkali Room</td>
</tr>
<tr>
<td>Postvention program for suicide attempters in Seoul</td>
<td>WS-14-003</td>
<td>16:30 – 18:00, Kokkali Room</td>
</tr>
</tbody>
</table>

### WS-15-001
Kraepelin model in bipolar disorders  
Jaime Vengoechea, Colombia

### WS-15-002
Addictive disorders and bipolarity  
Guillermo Dorado, Argentina

### WS-15-003
Bipolar II disorders and sudden episodic depression  
Eugenio Vargas Pena, Paraguay

### WS-15-004
Comments on brain-SPECT and bipolar disorders  
Enrique Galli, Peru

### FC-14-001
Non-invasive brain stimulation: A modern approach to improved therapy of nicotine addiction?  
Andreas J. Fallgatter, Germany  
A. Dieter, M. J. Herrmann, T. Dresler

### FC-14-002
Playing video games while intoxicated  
Gabriel Thorens, Switzerland  
S. Rothen, S. Achab, Y. Khazaal, D. Zullino
FC-14-003
Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users
Chih-Ken Chen, Taiwan
S.-K. Lin, M.-C. Huang, Y.-C. Chen, L.-J. Wang

FC-14-004
Addiction: The burden of cyclothymic temperament
Andreas Erfurth, Austria
G. Sachs, O. Lesch

FC-14-005
Aerobic exercise as treatment for tobacco cravings in college students who are quitting smoking
Carmen Lara, Mexico
M. T. Baez, A. Reyes

FC-14-006
Perceived pain, dissociation and its relation to history of sexual abuse among methadone maintenance and non-addicted patients
Einat Peles, Israel
Z. Seligman, D. Potik, M. Bloch, A. Sason, S. Schreiber, M. Adelson

FC-15-003
Patterns of salivary cortisol level in anxiety disorders and personality disorders and changes in salivary cortisol level after psychotherapy
Edyta Dembińska, Poland
K. Rutkowski, K. Tokarz, J. Sobanski, K. Cyran, L. Muldner-Nieckowski, M. Mielimaka

FC-15-001
Obsessive symptoms and clozapine
Esteban Rodriguez Jiménez, Spain
J. Alcalá Partera, M. d. Pino Ordovás González, A. Benito Duarte

FC-15-004
Tau protein is important for stress-driven depressive pathology and cognitive deficits
Ioannis Sotiropoulos, Portugal

FC-15-005
Hair cortisol and subjective stress in patients with schizophrenia and bipolar disorder
Lejla Hasandedi, Germany

FC-15-006
Can body dysmorphic disorder be classified an obsessive spectrum disorder? Evidence from neuroimaging
Susan Rossell, Australia
B. Buchanan, J. Muller, W. L. Toh, D. Castle

FC-16-001
Utilization and predictors of post-stroke antidepressant treatment
Janne Kaergaard Mortensen, Denmark
S. P. Johnsen, H. Larsson, G. Andersen

FC-16-002
Depressive disorders in patients with coronary heart disease associated with arterial hypertension and metabolic disorders of carbohydrate and fat metabolism
Alexander Rozin, Russia
E. Schastnyy, N. Garageeva

FC-16-003
Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease
Caroline Stokes, Germany
F. Gruenhage, C. Baus, D. Volmer, S. Wagenpfeil, M. Riemenschneider, F. Lammert

FC-16-004
Parkinson's disease depression, the pieces of the puzzle: Suggestions for a practical approach
Emmanuelle Pourcher, Canada

FC-16-005
The role of consultation-liaison psychiatrist in preventing, identifying and treating Wernicke's encephalopathy
Magdalena Spariosu, USA
D. Coira, C. Wassef, J. Emolo

FC-16-006
Executive dysfunction in psychosis following traumatic brain injury
Rachel Batty, Australia
A. Francis, N. Thomas, M. Hopwood, J. Ponsford, S. Rossell
FC-17  
**Free Communications**  
15:00 – 16:30  
**Conference Room 1**  

**Depression / Psychopharmacology**  

Chair:  
Janusz Rybakowski, Poland  
Co-Chair:  
Constantinos Fokas, Greece  

**FC-17-001**  
Long-term escitalopram blunts autonomic reactivity to pharmacological stress challenge in healthy men  
Agorastos Agorastos, Germany  
M. Kellner, O. Stiedl, K. Wiedemann, C. Demiralay  

**FC-17-002**  
Effect of short-term escitalopram treatment on neural activation during emotional processing  
Eduard Maron, United Kingdom  

**FC-17-003**  
Antidepressant and neurocognitive effects of single ketamine infusion in bipolar depression  
Janusz Rybakowski, Poland  
A. Permoda-Osip, J. Kiselevski, A. Bartkowska-Sniatkowska  

**FC-17-004**  
Comparison of the effect of mood stabilizers on proliferation and apoptosis of peripheral T lymphocytes from bipolar disorder patients  
Krzysztof Pietruczuk, Poland  
K. Lisowska, J. Witkowski, K. Grabowski, J. Landowski  

**FC-17-005**  
Psychopharmacotherapy during pregnancy: Therapeutic drug monitoring (TDM) in maternal blood, amniotic fluid and umbilical cord blood  
Michael Paulzen, Germany  
S. Lammertz, T. Veselinovic, T. Goecke, C. Hiemke, G. Gründer  

**FC-18  **  
**Free Communications**  
16:30 – 18:00  
**Trianti Hall**  

**Brain Stimulation Therapies**  

Chair:  
Mark George, USA  
Co-Chair:  
Pavlos Sakkas, Greece  

**FC-18-003**  
Comparative efficacy of intermittent theta-burst versus conventional 10 Hz left dorsolateral prefrontal rTMS in major depression: A multi-site non-inferiority trial  
Jonathan Downar, Canada  

**FC-18-004**  
Assessing the antidepressant effect of two and three HF-rTMS sessions per day  
Christos Theleritis, Greece  
P. Sakkas, T. Paparrigopoulos, C. Tzavara, S. Bonaccorso, A. Politis, C. R. Soldatos, C. Psarros  

**FC-18-006**  
Changes in BDNF blood levels after antidepressant treatment with non-pharmacological therapies: A systematic review and meta-analysis  
Andre Brunoni, Brazil  
C. Baeken, R. Machado-Vieira, W.Gattaz, M.-A. Vanderhasselt  

**FC-18-007**  
Non-invasive brain stimulation in psychiatry  
Andreas J. Follgatter, Germany  
T. Dresler, A.-C. Ehlis, C. Plewnia  

**SA-04  **  
**Industry Sponsored Symposium**  
13:30 – 15:00  
**Skalkotas Hall**  

see page 97.  

**P-14  **  
**Poster Presentation**  
12:45 – 14:15  
**Muses Foyer**  

**Addictive Disorders / Stress Related Disorders / Childhood and Adolescent Disorders**  
Chair:  
Ioanna Giannaopoulou, Greece  

**P-14-001**  
Life skills and substance related knowledge among adolescent school students in Malaysia  
Ahmad Hatim Sulaiman, Malaysia  
M. A. Said, S. Hajár, W. A. Irnee, R. Rashid, M. H. Habil  

**P-14-002**  
Orexin level in methamphetamine users: Comparison between health controls and methamphetamine addicts in Taiwan  
Wen Yin Chen, Taiwan  
C.-F. Kao, S.-K. Lin, M.-C. Huang
P-14-003
Prevalence, characteristics and severity of alcohol consumption among pregnant women in Sabah, Malaysia
Mas Ayu Said, Malaysia
A. H. Sulaiman, N. Ain

P-14-004
Change of plasma adiponectin level after smoking cessation
Wangyoun Won, Republic of Korea

P-14-005
The development of neurofeedback protocol for the reduction of impulsivity in internet addiction: A case study
Sunhye Chung, Republic of Korea
S. Choi

P-14-006
The efficacy of the rehabilitation of the dual diagnosis patients
Joanna Zofia Waniek, Poland

P-14-007
Recurrent depression and somatic-vegetative correlates in children
E. Mykhailova, Ukraine
T. Proskurina, T. Matkovska, N. Reshetovska

P-14-008
Effect of phenytoin and cyclosprine on IL-17 production by gingival fibroblast of adult and child
Surena Vahabi, Iran

P-14-009
Use of youth restraints in psychiatric care and its impact on organizational climate and culture
Catherine N. Dalmus, USA
D. A. Patterson Silver Wolf, M. Cristalli

P-14-011
The role of dopamine in fear extinction of adolescent rats
Despina Ganella, Australia
H. Madsen, L. Lee-Kardashyan, I. Zbukvic, S. Luikinga, R. Coulthard, A. Lawrence, J. H. Kim

P-14-012
Methylphenidate use and appearance of peripheral vasculopathy
María Del Pino Ordovás González, Spain
R. De Burgos Marín, E. Rodríguez Jiménez

P-14-013
Prevalence of acute traumatic events in women
Victoria Valdez de Viubert, Ecuador
D. Vasquez, D. Rueda, H. Palma, J. Veloz

P-14-015
Women are more likely to develop PTSD following trauma exposure than men: A prospective study
Vasiliki Michopoulos, USA
A. Rothbaum, H. Grinstead, B. Rothbaum, K. Ressler

P-14-016
New medical therapy and the effect mechanism that the central anticholinergic drug Trihexyphenidyl reduces flashback in patients with posttraumatic stress disorder (PTSD)
Katsumasa Sogou, Japan

P-14-017
A memory is my lighthouse
Ada Tadevosyan, USA
L. Grygoryan

P-14-018
Impact of occupational stress on frontotemporal cortical activity during a verbal fluency test: A near-infrared spectroscopy
Wei-Hao Lin, Taiwan

P-14-019
Tau missorting as part of glucocorticoid-triggered synaptic pathology
Ioannis Sotiropoulos, Portugal
S. Pinheiro, J. Silva, C. Mota, J. Vaz Silva, A. Veloso, V. Pinto, N. Sousa, J. Cerqueira

P-14-020
Decreased medial prefrontal cortex gray matter volume in male conscripts with adjustment disorder
Kyoung-Sae Na, Republic of Korea
W. Myung, S. M. Bae, S.-J. Cho

P-14-021
Health-related quality of life and type d personality in coronary artery disease patients with heart failure: A longitudinal observational study
Julius Burkauskas, Lithuania
M. Staniute, J. Brozaiiteene, N. Kazukauskiene, N. Mickuviene, R. Bunevicius

P-14-022
The effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on occupational stress among health care workers
Jaeyoung Ahn, Republic of Korea
Y. Kim, S. Y. Park, S. M. Kim, D. H. Han, Y. S. Lee, B. S. Kee, C. Na
P-15-001
Combined antidepressant treatment with tranylcypromine and s-ketamine in a severely depressed treatment-resistant patient: A case report
Lucie Bartova, Austria
S. Vogl, M. Stamenkovic, S. Kasper, M. Willeit

P-15-002
Multi-isotope imaging mass spectrometry reveals hippocampal protein turnover alterations in response to antidepressant treatment
Michaela Filiou, Germany
C. Webhofer, C. Guillermer, C. Poczatek, M. Wang, C. Turck, C. Lechene

P-15-003
The efficacy of aripiprazole augmentation for incomplete response in late-life depression: A retrospective study
Hyungseok So, Republic of Korea

P-15-004
Results of the depression disorders medical treatment with sertralin in the primary health protection
Nebojsa Ilic, Serbia
V. Ilic

P-15-006
Modern view on the issue of bipolar affective disorder (psychopathological characteristics and efficiency of psychoeducation in the complex therapy)
Volodymyr Korostiy, Ukraine
H. Kozhyna, O. Rezunenko

P-15-007
Neurocognitive impairments in bipolar disorder patients
Nozomi Isihaka, Japan

P-15-008
Paliperidone for the treatment of bipolar disorder
Christos Istikoglou, Greece
E. Liapis, A. Aivatides, R. Malamou, M. Economou, M. Vassaliadou, N. Polofinis, P. Kanellos, I. Liappas, D. Vlissides

P-15-009
A case report – psychiatric sequale following two episodes of anti-NMDA receptor encephalitis
Jun Xiao, Singapore
G. Kunjithopatham, E. Wuan

P-15-010
Affective symptoms as a diagnostic tool in first psychotic episodes
Marta Arrasate, Spain
A. González-Pinto, M. Martínez, I. González, S. Alberich, F. Mosquera, M. Gutiérrez

P-15-011
Bipolar I disorder and the quality of life
Kilani Hajji, Tunisia
I. Marrag, M. Nasr

P-15-012
Blood-brain barrier dysfunction in bipolar disorder: Less protection to the brain?
Benicio Frey, Canada
J. Patel

P-15-013
ECT and lithium in old age bipolar depression – cause or treatment of ultra-rapid cycling?
Jacqueline Huber, Australia
D. Burke

P-15-015
Neurocognitive remediation therapy for depression: A pilot study
Maria Semkovska, Ireland
E. Ahern

P-15-016
Steroid hormones in the dynamics of therapy of depressive disorders
Lyudmila Levchuk, Russia
N. Vyalo, G. Simutkin, E. Lebedeva, S. Ivanova

P-15-017
Use of statins in the treatment of depression in patients with acute coronary syndrome
Sung-Wan Kim, Republic of Korea
C. Park, Y.-H. Lee, K.-Y. Bae, J.-M. Kim, I.-S. Shin, Y. J. Hong, M. H. Jeong, M. Berk, J.-S. Yoon

P-15-018
Comparative efficacy of bupropion and duloxetine in depressive disorder due to Parkinson's disease
Daniel Vasile, Romania
O. Vasiliu, D. G. Vasiliu, F. Androne, F. Vasile

P-15-019
Depression in the elderly: Description and analyses of four subtypes of geriatric depression
Carol Dillon, Argentina
G. Vazquez, A. Corrales, F. Taragano, R. Allegri
P-15-020 Dynamic interactions between the G protein, galphas, lipid rafts and adenylyl cyclase reveal a potential biomarker for depression and for therapeutic response
Mark Rasenick, USA
R. Donati, J. Schappi, C. Czysz

P-15-021 Heart rate variability in dysthymia before and after treatment with desvenlafaxine
Arun Ravindran, Canada
M. McKay, K. Udupa

P-15-022 Improved voltammetric determination of neurotransmitters as biochemical markers in psychiatric diseases
Anton Ciucu, Romania
A. Gheorghiu

P-15-023 Systematic review of the influence of neurostimulation therapies on heart rate variability in major depressive disorder: A potential predictor of treatment response?
Nisha Ravindran, Canada
M. McKay, Z. J. Daskalakis

P-15-024 Therapeutic drug monitoring, application into clinical practice
Maria Radziwon-Zaleska, Poland
M. Skalski, B. Ryszewska-Pokrasniewicz, J. Skrzeszewski, E. Drozdowicz

P-15-025 Use of pharmaco-electroencephalography in the treatment of depression
Michal Skalski, Poland
B. Ryszewska-Pokrasniewicz, E. Drozdowicz, J. Skrzeszewski, G. Nowak, A. Pilec, M. Radziwon-Zaleska

P-15-026 Depression improves after carbon monoxide poisoning
Jaisung Noh, Republic of Korea
Y. Kwon, M. Cho, S. Kim, S. Hong, M. Jang, S. Son

P-16-003 Off-label prescribing of atypical antipsychotics for non-psychotic disorders – a significant rise in six years
Marko Saje, Slovenia
B. Novak Sarotar

P-16-004 Pharmacogenetic of antipsychotics, as a tool to improve response to cognitive remediation
Roberto Cavallaro, Italy
M. Bosia

P-16-005 Diffusion tensor imaging of catatonic and non-catatonic schizophrenia patients
Amir Krivoy, Israel
S. Shrot, M. Avrahami, D. Last, Y. Mardor, T. Fischel, D. Guez, C. Hoffman

P-16-006 Response to clozapine treatment and serum neurotrophins level among schizophrenia patients
Amir Krivoy, Israel
E. Hochman, A. Weizman, S. Hollander, M. Taler

P-16-007 Sub-threshold negative symptoms and brain network sensitivity to emotional salience: Potential predictors of psychosis in adolescence
Harinder Rai, USA
V. Diwadkar

P-16-008 Suicide attempt in schizophrenia and first-episode psychosis: Clinical and biological associations
Ahmed Mhalla, Tunisia
R. Mensi, A. Mrad, I. Azizi, A. Messaoud, W. Douki, F. Najjar, L. Gaha

P-16-010 The long-term psychosocial intervention effect on the reduction in hospital stay of patients with schizophrenia
Kyuyoung Lee, Republic of Korea
H. J. Oh

P-16-011 The prefrontal and anterior cingulate cortices exert exaggerated modulation during successful cognitive control in schizophrenia
Nino Papale, USA
S. Singh, K. Ramaseshan, A. Omari, R. White, C. Walker, V. Diwadkar, R. Cho

P-16-012 The use of antidepressants in the management of patients with schizophrenia with and without depressive symptoms in Greece: Outcomes of the ELPS study
Christina Kalkavoura, Greece
S. Kogkas, A. Roussidis, A. Giannopoulou
P-16-013  
Tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate in patients hospitalized for an exacerbation of schizophrenia  
Andreas Schreiner, Germany  
L. Hargarter, M. Lahaye, P. Cherubin

P-16-015  
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice  
Francesco Errico, Italy  

P-16-016  
Biomarker profiles decode symptoms of psychosis: Evidence for a new age of biological psychiatry  
Stephanie Fryar-Williams, Australia

P-16-017  
Characterising language comprehension in schizophrenia and its relationship with language production problems  
Eric Tan, Australia  
G. Yelland, S. Rossell

P-16-018  
Clinical studies of biomarkers of the indolic hypermethylation in human perception alterations  
Jorge Ciprian Ollivier, Argentina  
A. Vitale, E. Romero, M. Vitale, A. Pomilio

P-16-019  
D-cell hypothesis of schizophrenia: Link of NSC hypothesis to dopamine hypothesis  
Keiko Ikemoto, Japan

P-16-020  
Does cortical thickness act as a mediator between childhood sexual trauma and transition to psychosis in young individuals at ultra-high risk of psychosis?  
Eleni Canella, Australia  

P-16-021  
Effect of carbonyl stress on cognitive impairment in schizophrenia patients  
Akiko Kobori, Japan  

P-16-022  
Enhancing cognitive functions in schizophrenia: A randomized controlled yoga trial  
Ruben Gur, India  
T. Bhatia, S. Mazumdar, J. Wood, F. He, R. Gur, V. Nimgaonkar, S. Deshpande

P-16-023  
Investigation of the neurobiology of effort valuation impairments in schizophrenia in a virtual environment  
George Foussias, Canada  

P-16-024  
Lipid profile in schizophrenia and first-episode psychosis: About a Tunisian population  
Ahmed Mhalla, Tunisia  
R. Mensi, A. Messaoud, I. Azizi, W. Douki, F. Najjar, L. Gaha

P-16-025  
Long-term improvements in auditory verbal hallucinations: Clinician vs. patient perspectives  
In Won Chung, Republic of Korea  

P-16-026  
Maternal immune activation at the precise times of pregnancy causes social deficits and decreased prefrontal cortex BDNF levels in rat offspring  
Eliza Koros, Germany  
H. Rosenbrock

P-16-028  
Peripheral blood markers of dopamine level and oxidative stress in schizophrenia, South India  
Mahalaxmi Iyer, India  
G. Mohan, A. Meyyazhagan, G. Changrathil, S. Keshavarao, D. S.N., B. Vellingiri

P-16-029  
Frontal brain activation during emotional stroop task in individuals at risk for schizophrenia and bipolar disorder using functional near-infrared spectroscopy  
Aleksandra Aleksandrowicz, Switzerland  
E. Hagenmuller, H. Haker Rössler, K. Heekeren, A. Theodoridou, S. Walitza, W. Rüssler, W. Kavohl

P-17  
POSTER PRESENTATION  
12:45 – 14:15 Muses Foyer  
Personality Disorders/Violence/Suicide/Forensic Psychiatry  
Chair: Athanasios Douzenis, Greece  
Co-Chair: George Kiosterakis, Greece

P-17-001  
A French cohort of paraphilic sex offenders: Preliminary results  
Sandrine Lamy, France  
V. Olivier, E. Houivet, J. Benichou, H. Delavenne, F. Thibault
P-17-002  
Neural processing of erotic adult and naked child pictures in pedophilic patients and healthy controls  
Inka Ristow, Germany  
S. Li, L. R. Demenesescu, M. Walter, H. Walter, K. Beier, B. Schiffer, J. Ponsseti, T. Kruger

P-17-003  
Antisocial personality disorder: Neurobiological aspects and therapeutic approaches  
Emilce Blanc, Argentina

P-17-004  
Behavioral improvement in women in prison with ADHD treated with atomoxetine  
Oscar Sanz-Garcia, Spain  
M. P. Ibáñez, A. Muro

P-17-009  
Melatonin levels as a marker of the neuroticism dimension of personality  
Armando Luis Morera-Fumero, Spain  
P. Abreu-Gonzalez, E. Diaz-Mesa

P-17-010  
Involuntary interference in emotion dysregulation: Hyper-modulation of brain networks by the amygdala and orbitofrontal cortex  
Kristy Abraham, USA  
V. Diwadkar, P. Soloff

P-17-011  
Contextual modulation of the connectivity of the brain’s episodic memory pathways by affect: A framework for understanding emotional dysregulation in psychiatric disease  
Sonya Sandhu, USA  
P. Soloff, V. Diwadkar

P-17-012  
From anxiolytics to antipsychotics in a patient with a borderline personality structure  
Marija Vucic Petl, Croatia  
J. Proloscic, D. Petric, S. Blazevic Zelic

P-17-013  
Axis I comorbidity in borderline personality disorder  
M Teresa Bel Villar, Spain  
I. Frigola de Vehi, V. Fabregat Navarro, R. Borrego Leal, C. Conesa Lopez, A. Corominas Diaz

P-17-014  
Association between neuroticism and 5-HTTLPR  
Hernan Silva, Chile  
J. Villarroel, S. Jerez, C. Montes

P-17-015  
Personality traits and fibromyalgia  
Maria Del Pino Ordovás González, Spain  
E. Rodríguez Jiménez, C. Castaño Díaz

P-17-016  
Cholesterol and inflammatory markers may predict schizoid personality traits among Japanese university students  
Noriaki Sagata, Japan  

P-17-017  
Suicide and testosterone: Neurobiological hypotheses concerning suicide in young and old men  
Leo Sher, USA  
T. Rice

P-17-018  
Impact of anxiety and depression on the suicide ideation and its correlation with clinical characteristics in Korean patients with coronary artery disease after percutaneous coronary interventions: An observational cross-sectional study  
Sang Yeol Lee, Republic of Korea  
H. J. Lee

P-17-019  
Contemporary patterns of formation of suicidal behavior in patients with depressive disorders  
Volodymyr Korostiy, Ukraine  
H. Kozhyna, K. Zelenska

P-17-020  
Emotion regulation and adolescent suicide: Proposals for specialist and nonspecialist physician education  
Leo Sher, USA  
T. Rice

P-17-021  
Prevention of homicidal behavior in men with psychiatric disorders  
Leo Sher, USA  
T. Rice

P-17-022  
Preventing school shootings: Importance of a developmental approach to at-risk adolescents  
Timothy Rice, USA  
L. Hoffman
<table>
<thead>
<tr>
<th>P-18-001</th>
<th>Thalamic shape and cognitive performance in amnestic mild cognitive impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changtae Hahn, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>C.-U. Lee</td>
<td></td>
</tr>
<tr>
<td>P-18-002</td>
<td>An exploratory study to reveal the neural basis of visual cognitive dysfunction in Alzheimer’s disease</td>
</tr>
<tr>
<td>Taku Yoshida, Japan</td>
<td></td>
</tr>
<tr>
<td>T. Mori, N. Sonobe, H. Shimizu, T. Matsumoto, S.-I. Ueno</td>
<td></td>
</tr>
<tr>
<td>P-18-003</td>
<td>Platelet APP ratio in AD patients treated with donepezil</td>
</tr>
<tr>
<td>Jessyka Maria de Franca Bram, Brazil</td>
<td></td>
</tr>
<tr>
<td>P-18-004</td>
<td>Prevalence of alcohol, tobacco and psychoactive substances in a cohort of 700 pregnant women—GTOX study: Preliminary results</td>
</tr>
<tr>
<td>Sandrine Lamy, France</td>
<td></td>
</tr>
<tr>
<td>H. Delavenne, E. Houivet, J. Benichou, S. Marret, F. Thibaut</td>
<td></td>
</tr>
<tr>
<td>P-18-005</td>
<td>Hair steroid analysis in postpartum mothers: An increased ratio of hair cortisol/hair cortisone is associated with postpartum depression</td>
</tr>
<tr>
<td>Thorsten Mikoteit, Switzerland</td>
<td></td>
</tr>
<tr>
<td>S. Brand, G. Meinschmidt, N. Buerki, I. Hoesli, E. Holsboer-Trachsler</td>
<td></td>
</tr>
<tr>
<td>P-18-006</td>
<td>Alterations of the cortisol and dehydroepiandrosterone in perinatal depression</td>
</tr>
<tr>
<td>Ho-Suk Suh, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>R.-S. Ahn, C.-H. Kim, K.-S. Lee</td>
<td></td>
</tr>
<tr>
<td>P-18-007</td>
<td>Biochemical markers and symptoms of depression in postpartum women</td>
</tr>
<tr>
<td>Maria Radziwon-Zaleska, Poland</td>
<td></td>
</tr>
<tr>
<td>P-18-008</td>
<td>Postpartum depression is associated with insomnia, decreased total sleep time and a lack in NREM S3 sleep duration</td>
</tr>
<tr>
<td>Thorsten Mikoteit, Switzerland</td>
<td></td>
</tr>
<tr>
<td>S. Brand, N. Buerki, I. Hoesli, E. Holsboer-Trachsler</td>
<td></td>
</tr>
<tr>
<td>P-18-009</td>
<td>Risks of antidepressants during pregnancy—a review</td>
</tr>
<tr>
<td>Margarida Viana Almeida Coelho, Portugal</td>
<td></td>
</tr>
<tr>
<td>A. R. Carvalho</td>
<td></td>
</tr>
<tr>
<td>P-18-010</td>
<td>Treating perinatal depression in low and middle-income countries: A systematic review</td>
</tr>
<tr>
<td>Amy Gajaria, Canada</td>
<td></td>
</tr>
<tr>
<td>T. da Silva, A. Ravindran</td>
<td></td>
</tr>
<tr>
<td>P-18-011</td>
<td>Antipsychotics in pregnancy: Safety and indications</td>
</tr>
<tr>
<td>Ana Rita Carvalho, Portugal</td>
<td></td>
</tr>
<tr>
<td>M. Coelho, R. Navarro</td>
<td></td>
</tr>
<tr>
<td>P-18-013</td>
<td>Cytokine profiles in ultra-high risk and first-episode schizophrenia and the effects of aripiprazole treatment</td>
</tr>
<tr>
<td>Yi-Ling Chien, Taiwan</td>
<td></td>
</tr>
<tr>
<td>C.-M. Liu, C.-C. Liu, H.-G. Hwu</td>
<td></td>
</tr>
<tr>
<td>P-18-014</td>
<td>Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood</td>
</tr>
<tr>
<td>Cécile Grudet, Sweden</td>
<td></td>
</tr>
<tr>
<td>J. Malm, Å. Westrin, L. Brundin</td>
<td></td>
</tr>
<tr>
<td>P-18-015</td>
<td>Altered immune repertoire in major depression</td>
</tr>
<tr>
<td>Kostas Patas, Germany</td>
<td></td>
</tr>
<tr>
<td>A. Willing, A. Agorastos, C. Demiralay, K. Wiedemann, S. Gold</td>
<td></td>
</tr>
<tr>
<td>P-18-016</td>
<td>Reduced frequency of blood CD8+ T lymphocytes expressing proinflammatory cytokines in mesial temporal lobe epilepsy patients</td>
</tr>
<tr>
<td>Daniela Rosa, Brazil</td>
<td></td>
</tr>
<tr>
<td>V. Rezende, B. Costa, M. Schutze, F. Mudado, L. Magno, M. Vasconcelos, D. Miranda, M. Romano-Silva</td>
<td></td>
</tr>
<tr>
<td>P-18-017</td>
<td>Proinflammatory cytokines and oxidative stress reduces the dopamine precursor tyrosine uptake in human skin fibroblasts: Role of antioxidants as adjuvants</td>
</tr>
<tr>
<td>Rani Yumma, Sweden</td>
<td></td>
</tr>
<tr>
<td>J. Johansson, N. Venizelos</td>
<td></td>
</tr>
<tr>
<td>P-18-019</td>
<td>Olfactory cravings and cytokine-mediated nociception in vulnerability to substance abuse</td>
</tr>
<tr>
<td>Tatyana Nevidimova, Russia</td>
<td></td>
</tr>
<tr>
<td>E. Batukhtina, N. Bokhan</td>
<td></td>
</tr>
<tr>
<td>P-18-021</td>
<td>Biomarkers of brain insulin resistance and neuroimaging correlates in early AD</td>
</tr>
<tr>
<td>Dimitrios Kapogiannis, USA</td>
<td></td>
</tr>
<tr>
<td>A. Willette, R. Mullins, M. Mustapic, E. Eitan, M. Mattson, E. Goetzl</td>
<td></td>
</tr>
<tr>
<td>P-19-002</td>
<td>Postnatal exposure to moderate noise impaired behavior, learning and memory in adult female rat</td>
</tr>
<tr>
<td>P-19-003</td>
<td>Role of the neurometabolites in emotional processing</td>
</tr>
<tr>
<td>P-19-004</td>
<td>Spontaneous behavior and oxidative stress of male adult rats exposed to moderate noise</td>
</tr>
<tr>
<td>P-19-005</td>
<td>fMRI reveals abnormalities in neural processing of reward prediction errors in pathological gambling</td>
</tr>
<tr>
<td>P-19-006</td>
<td>Depressive symptoms and cognitive functioning in coronary artery disease patients: Effect of triiodothyronine</td>
</tr>
<tr>
<td>P-19-007</td>
<td>A pilot study in cytogenetic biomarkers and molecular study of Phospholipase D3 (PLD3) gene in Alzheimer’s disease</td>
</tr>
<tr>
<td>P-19-008</td>
<td>Analysis of chromosomal abnormalities and ube3a gene mutation in angelman syndrome (AS) coiatatore population</td>
</tr>
</tbody>
</table>

**P-19-009**

**Association between depression and polymorphisms of the tryptophan hydroxylase (TPH) and the 5,10-methylene-tetrahydrofolate reductase (MTHFR) genes in the Tunisian population**


**P-19-010**

**Association study of 45 SNPs in Russian patients with Alzheimer’s disease**

Anna Bocharova, Russia  A. Marusin, N. Zhukova, V. Alifirova, I. Zhukova, V. Stepanov

**P-19-011**

**Epistatic interaction study between comt, 5-htr2a and nrg1 gene variants on schizophrenia**

Shiau Foon Tee, Malaysia  P. Y. Tang, T. J. Chow

**P-19-012**

**Exome sequencing identifies a novel risk variant in a dopamine regulation gene in familial schizophrenia**

Thelma Bittienda Kutappa, India  J. John, J. Jibin, N. V. L., D. S. N.

**P-19-013**

**Gene expression and psychiatric analysis of 100 Iranian methamphetamine addicted individuals**

Arvin Haghhatfard, Iran

**P-19-014**

**Prevalence of 22q11.2 deletions in a Chilean population with schizophrenia**

Aida Ruiz, Chile  P. John, R. Murray, E. Miranda, P. Sham, F. Benavides, G. Repetto

**P-19-015**

**Automatic classification of first episode psychosis obtained with gray matter thickness**


**P-19-016**

**Basal ganglia imaging (DaTscan): Association with antipsychotic treatment in elderly patients**


**P-19-017**

**Changes in brain volume and cognitive function in middle adulthood: A framework for investigating neurodegeneration in schizophrenia**

Rizwan Ahmed, USA  M. Bellani, G. Rambalde, R. White, V. Diwatkar, P. Brambilla
P-19-019
Differential modulation by working memory performance on regional brain activation in schizophrenia patients
Leila Shayegan, Germany
Y. Fukuda, T. Katthagen, L. Deserno, J. Kaminski, F. Schlagenauf

P-19-020
Gray matter and white matter structural changes in obsessive compulsive disorder from the aspect of heterogeneity
Keisuke Ikari, Japan

P-19-021
Investigating the predictive value of brain metabolism in the identification of laterality in temporal lobe epilepsy: A pattern classification approach
Manuel Schutze, Brazil
D. Rosa, M. Mamede, B. Costa, D. Miranda, M. Brammer, M. Romano-Silva

P-19-023
Neuroanatomical correlates of schizo-obsessive disorder
Dhanya Raveendranathan, India

P-20-001
SLC1A1 gene polymorphism and SRI response association in obsessive compulsive disorder
Tulika Shukla, India

P-20-002
Relationship between dopaminergic genes polymorphisms and metabolic syndrome components in schizophrenic patients treated with antipsychotics
Aurora Arrue, Spain

P-20-003
Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides
Mariko Takeda, Japan
N. Kamei, T. Shingaki, Y. Kanayama, Y. Watanabe

P-20-004
The neuroprotective role of rivastigmine during the treatment with amitriptyline on animal model
Dragos Marinescu, Romania
T. Udristoiu, L. Mogoanta, I. Marinescu

P-20-005
Cognition-enhancing and anxiety-like behavior of the novel 1,4-dihydropiridine derivative in female Alzheimer’s disease model-mice
Baiba Jansone, Latvia
I. Kadish, T. van Groen, U. Beitnere, A. Plotniece, K. Pajuste, V. Klusa

P-20-006
Right side transcranial magnetic stimulation for the treatment of anxious depression
Daniela White, USA
K. Mcdermott

P-20-008
Cognitive function of an adolescent patient with schizophrenia treated with modified electroconvulsive therapy: A case report
Rie Kuge, Japan
A. Yokota, Y. Morino, J. Ozaki, Y. Kikuchi, T. Ookura
**Scientific Programme | Thursday, 18 June 2015**

**PL-04**

**PLENARY LECTURE**

10:00 – 10:45  
Trianti Hall

Chair: Martin Hatzinger, Switzerland

**PL-04-001**
Neurobiological correlates of fear and anxiety and their clinical implications  
Kerry Ressler, USA

**S-46**

**SYMPOSIUM**

08:30 – 10:00  
Trianti Hall

Combining TMS with CBT or medications to boost response  
Michael Thase, USA

The latest advances in understanding TMS antidepressant neurobiology  
Shinsuke Kito, Japan

**S-47**

**SYMPOSIUM**

08:30 – 10:00  
Skalkotas Hall

Defining and re-defining the boundaries of psychotic disorders using neuroimaging  
Chair: Christos Pantelis, Australia  
Co-Chair: Eva Meisenzahl, Germany

Decomposing schizophrenia into intermediate imaging phenotypes identified by multiple system mapping  
Hennik Walter, Germany

Identifying neuroanatomical signatures of schizophrenia phenotypes using novel imaging methods  
Christos Davatzikos, USA

Stratifying schizophrenia according to outcome using MRI-based pattern classification methods  
Paola Dazzan, United Kingdom

Commonalities and differences between schizophrenia and neurodegenerative disorders elucidated by neuroimaging  
Dennis Velakoulis, Australia

**S-48**

**SYMPOSIUM**

08:30 – 10:00  
MC 3 Room

Understanding psychiatric disorders: Recent advances in postmortem research  
Chair: Brian Dean, Australia  
Co-Chair: Elizabeth Scarr, Australia

Structural and molecular alterations of the hippocampus in schizophrenia  
Peter Falkai, Germany

Roles for immune-regulated genes and neurotransmitter receptors in the pathophysiology of psychiatric disorders  
Brian Dean, Australia

---

**T16: GENETICS**

**S-45**

**SYMPOSIUM**

08:30 – 10:00  
Trianti Hall

Advances in genetics of affective disorders  
Chair: George N. Papadimitriou, Greece

**S-45-001**
Update on genetics of affective disorders  
Dimitris Dikeos, Greece

**S-45-002**
Pharmacogenetics of antidepressants  
Alessandro Serretti, Italy  
C. Fabbri

**S-45-003**
Organization and administration of a multinational project on pharmacogenetics  
Daniel Surrey, Belgium

**S-45-004**
Overview of the field and critical appraisals  
Thomas Schulze, Germany

**T44: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-46**

**SYMPOSIUM**

08:30 – 10:00  
Mitropoulos Hall

The latest international findings regarding TMS for treating depression  
Chair: Paul Fitzgerald, Australia  
Co-Chair: Mark George, USA

**S-46-001**
New data on acute phase treatments – dosing paradigms, improving speed of response, coil designs  
Paul Fitzgerald, Australia  
Z. J. Daskalakis

**S-46-002**
How durable are TMS antidepressant effects? New data  
Mark Demitrack, USA

---

**T40: SCHIZOPHRENIA: BASIC/CLINICAL**

**S-47**

**SYMPOSIUM**

08:30 – 10:00  
Skalkotas Hall

Defining and re-defining the boundaries of psychotic disorders using neuroimaging  
Chair: Christos Pantelis, Australia  
Co-Chair: Eva Meisenzahl, Germany

Decomposing schizophrenia into intermediate imaging phenotypes identified by multiple system mapping  
Hennik Walter, Germany

Identifying neuroanatomical signatures of schizophrenia phenotypes using novel imaging methods  
Christos Davatzikos, USA

Stratifying schizophrenia according to outcome using MRI-based pattern classification methods  
Paola Dazzan, United Kingdom

Commonalities and differences between schizophrenia and neurodegenerative disorders elucidated by neuroimaging  
Dennis Velakoulis, Australia

**T22: NEUROPATHOLOGY**

**S-48**

**SYMPOSIUM**

08:30 – 10:00  
MC 3 Room

Understanding psychiatric disorders: Recent advances in postmortem research  
Chair: Brian Dean, Australia  
Co-Chair: Elizabeth Scarr, Australia

Structural and molecular alterations of the hippocampus in schizophrenia  
Peter Falkai, Germany

Roles for immune-regulated genes and neurotransmitter receptors in the pathophysiology of psychiatric disorders  
Brian Dean, Australia
S-48-003
The syndrome of schizophrenia: Progress towards potential biomarkers
Elizabeth Scarr, Australia

S-48-004
Autophagy as future treatment target for schizophrenia: Lessons from activity-dependent neuroprotective protein
Ilana Gozes, Israel

T38: PSYCHOPATHOLOGY

S-49 SYMPOSIUM
08:30 – 10:00 MC 2 Room
Psychobiology of men’s mental health
Chair: Leo Sher, USA
Co-Chair: Zoltan Rihmer, Hungary

S-49-001
The WFSBP Men’s Mental Health Task Force: Rationale for a neuroendocrine-focused approach to men’s mental health
Timothy Rice, USA

S-49-002
Depression in men: Clinical and phenomenological aspects
Wolfgang Rutz, Sweden

S-49-003
Suicide in men: Hormonal and neurobiological correlates
Zoltan Rihmer, Hungary

S-49-004
Testosterone, violence and homicide
Leo Sher, USA

T32: PHARMACOLOGY

S-50 SYMPOSIUM
08:30 – 10:00 Kokkali Room
The importance of pharmacovigilance in psychiatric inpatient populations
Chair: Stefan Bleich, Germany
Co-Chair: Anastasios Konstantinidis, Austria

S-50-001
Systematic pharmacovigilance in psychiatry – Is it necessary?
Sermin Toto, Germany

S-50-002
Suicidality during antidepressant treatment in a psychiatric inpatient population
Susanne Stübner, Germany

S-50-003
Restless legs syndrome induced by psychotropic treatment
Konstantinos Papageorgiou, Austria
A. Konstantinidis, S. Toto, R. Grohmann, S. Kasper

S-50-004
Polypharmacy in psychiatry – a risk factor for adverse events?
Anastasios Konstantinidis, Austria

T46: SUICIDE: BASIC/CLINICAL

S-51 SYMPOSIUM
11:00 – 12:30 Mitropoulos Hall
Molecular determinants of suicide
Chair: Ghanshyam Pandey, USA
Co-Chair: John Mann, USA

S-51-001
Imaging studies of suicidal behavior neural circuitry
John Mann, USA

S-51-002
Neuroinflammatory markers in suicide brain: Focus on cytokine receptors and toll-like receptors
Ghanshyam Pandey, USA

S-51-003
Epigenomic basis for astrocyte abnormalities in suicidal behavior
Gustavo Turecki, Canada

S-51-004
Role of microRNAs in the etiology and treatment of depressive disorder and suicide
Yogesh Dwivedi, USA

T6: BIPOLAR DISORDERS: BASIC/CLINICAL

S-06 SYMPOSIUM
11:00 – 12:30 Skalkotas Hall
Major controversies for the treatment of bipolar disorders
Chair: Gustavo Vazquez, Argentina
Co-Chair: Eduard Vieta, Spain

S-06-001
Novel treatments for bipolar disorders
Eduard Vieta, Spain

S-06-002
Optimal duration of atypical antipsychotic therapy for maintenance treatment
Lakshmi Yatham, Canada

S-06-003
Neuroprotective potential of mood stabilizers
Michael Berk, Australia

S-06-004
Use of antidepressants in bipolar disorders
Gustavo Vazquez, Argentina
L. Tondo, A. Forte, V. Selle, R. Baldessarini
T40: Schizophrenia: Basic/Clinical

S-53 SYMPOSIUM
11:00–12:30 MC 2 Room

The impact of tobacco and cannabis use on psychosis liability and illness long term outcome: Epidemiological evidence across Europe and Australia
Chair: Nikos C. Stefanis, Greece
Co-Chair: David Castle, Australia

T40: Schizophrenia: Basic/Clinical

S-53-001
Tobacco and cannabis long term impact on physical health and clinical outcomes in schizophrenia. Is discontinuation of substance use feasible?
David Castle, Australia
A. Waterreus, V. Morgan, N. Stefanis, A. Sankaranarayanan, S. Mancuso

S-53-002
Substance use brings forward the onset of non-affective psychosis: Potential biological mechanisms and clinical implications
Nikos C. Stefanis, Greece
M. Dragovic, B. D. Power, A. Jablensky, D. Castle, V. Morgan

S-53-003
Cannabis complexities and why they are important
Amir Englund, United Kingdom

T44: Stimulation Methods (ECT, TMS, VNS, DBS)

S-54 SYMPOSIUM
11:00–12:30 Kokkali Room

Recent research data in electroconvulsive therapy and how they inform state of the art clinical practice
Chair: Georgios Petrides, USA
Co-Chair: Declan McLoughlin, Ireland

S-54-001
Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): A pragmatic, randomised, non-inferiority trial
Declan McLoughlin, Ireland

S-54-002
Antidepressant efficacy of RUL-Ultra brief pulse ECT: Data from phase I of the PRIDE study
Charles Kellner, USA

T23: Neuroimaging: Genetic, Functional, Structural

S-56 SYMPOSIUM
15:00–16:30 Trianti Hall

Development of biomarkers for neuropsychiatric disorders: State-of-the-art and challenges ahead
Chair: Nikolaos Koutsouleris, Germany
Co-Chair: Christos Davatzikos, USA

S-56-002
Machine learning biomarkers for individualized outcome prediction in functional psychoses
Lena Palaniyappan, United Kingdom
S. Guo, G. Deshpande, P. Liddle
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-56-003</td>
<td>Genetic markers of autism-spectrum disorders</td>
<td>Christos Pantelis, Australia&lt;br&gt;E. Skafidas, R. Testa, D. Zamotoio, G. Chana, I. Everall</td>
</tr>
<tr>
<td>S-56-004</td>
<td>Diagnostic and prognostic imaging markers in neurodegenerative disorders</td>
<td>Jessica Peter, Germany&lt;br&gt;S. Klöppel</td>
</tr>
<tr>
<td>S-57</td>
<td>Microglia: A common target for diverse drugs preventing schizophrenia?</td>
<td>Ina Weiner, Israel</td>
</tr>
<tr>
<td>S-57-002</td>
<td>Prenatal elevation of the glia-derived neuromodulator kynurenic acid: A novel schizophrenia model</td>
<td>Robert Schwarz, USA&lt;br&gt;A. Pocivavsek</td>
</tr>
<tr>
<td>S-57-003</td>
<td>Inflammatory imbalance in the periphery signalled by kynurenines is correlated with wide-spread grey matter decrease in people with schizophrenia</td>
<td>Cynthia Shannon Weickert, Australia&lt;br&gt;K. Zavitsanou, C. K. Lim, G. J. Guillemin, R. Lenroot, J. Kindler, V. Catts, S. Catts, J. Bruggemann, T. Weickert</td>
</tr>
<tr>
<td>S-57-004</td>
<td>Astrocytic dopamine modulates neuronal network and cognitive functions in the prefrontal cortex</td>
<td>Jean-Pierre Mothet, France</td>
</tr>
<tr>
<td>S-58</td>
<td>Diagnostic and prognostic stratification of affective disorders based on inflammation biomarkers and immune related neurotransmitter pathways</td>
<td>Angelos Halaris, USA&lt;br&gt;Co-Chair: Aye-Mu Myint, Germany</td>
</tr>
<tr>
<td>S-58-001</td>
<td>Stratification and outcome prediction of depressed patients using panels of inflammation biomarkers</td>
<td>Angelos Halaris, USA</td>
</tr>
<tr>
<td>S-58-002</td>
<td>Can plasma levels of kynurenines assist in the stratification of mood disorders?</td>
<td>Aye-Mu Myint, Germany&lt;br&gt;B. Sperner-Unterweger, V. Arolt</td>
</tr>
<tr>
<td>S-58-004</td>
<td>Biomarker and therapeutic potential of the endocannabinoid system in neuroinflammation-related psychoses</td>
<td>Rafael Franco, Spain&lt;br&gt;G. Navarro, I. Reyes-Resina</td>
</tr>
<tr>
<td>S-59</td>
<td>Dysregulation of tyrosine transport influence dopamine function and cause cognitive deficits in schizophrenia</td>
<td>Nikolaos Venizelos, Sweden&lt;br&gt;Co-Chair: Lenna Flyckt, Sweden</td>
</tr>
<tr>
<td>S-59-001</td>
<td>Aberrant tyrosine transport in fibroblast from patients with schizophrenia and bipolar-I disorders</td>
<td>Nikolaos Venizelos, Sweden</td>
</tr>
<tr>
<td>S-59-002</td>
<td>Aberrant tyrosine transport in fibroblast from patients with schizophrenia—indication of maternal inheritance</td>
<td>Lenna Flyckt, Sweden</td>
</tr>
</tbody>
</table>
S-59-003
Proinflammatory cytokines and oxidative stress decreases the dopamine precursor tyrosine uptake in human skin fibroblasts
Ravi Vumma, Sweden
J. Johansson, N. Venizelos

S-59-004
A comparative genomic meta-analysis study focused on genes and mechanisms involved in amino acid transport in schizophrenic and bipolar disorder patients
Fragiskos Kolisis, Greece
N. Venizelos, A. Chatziioannou, O. Papadodima, M. Logotheti

S-60-001
Neural oscillations: Optogenetic studies in mice
Robert McCarley, USA

S-60-002
Findings of auditory steady-state responses in psychiatric disorders
Toshiaki Onitsuka, Japan

S-60-003
Neural dynamics with simultaneous EEG and fMRI measurement
Hiroaki Mizuhara, Japan

S-60-004
NMDA-R hypofunctioning and dysregulated high-frequency oscillations in schizophrenia
Peter Uhlhaas, United Kingdom

T1: ADDICTIVE DISORDERS

TG-07-001
New developments in pharmacotreatment of opioid dependence
Michael Soyka, Switzerland

TG-07-002
New evidence-based treatment guidelines for alcohol use disorders
Karl Mann, Germany

TG-07-003
Genetics and pharmacogenetics of alcoholism: Recent developments
Victor Hesselbrock, USA
**ES-03**

**EDUCATIONAL SESSION**

09:00 – 13:00  
MC 3.3 Room

**Session 3 on brain stimulation methods**  
Chair: Mark George, USA  
Co-Chair: Shirley Fecteau, Canada

**ES-03-001**

TDCS (transcranial Direct Current Stimulation) and TMS (repetitive Transcranial Magnetic Stimulation)  
Shirley Fecteau, Canada  
Jerome Brunelin, France  
Emmanuel Poulet, France  
Zafiris J. Daskalakis, Canada

**ES-03-002**

Deep brain stimulation  
Thomas Schlaepfer, Germany

**ES-03-003**

ECT (electroconvulsive therapy)  
Mark George, USA

**FC-19**

**FREE COMMUNICATIONS**

08:30 – 10:00  
Conference Room 1

**Anxiety Disorders**  
Chair: Soraya Seedat, South Africa  
Co-Chair: Ioannis Papakostas, Greece

**FC-19-002**

Sex differences in kappa opioid receptor-mediated negative affective states in rats  
Maria Mavrikaki, USA  
J. Mays, D. Puttick, E. Chartoff

**FC-19-003**

Mitochondria as pharmacological targets for anxiolytic treatment  
Michaela Filiou, Germany  
M. Nussbaumer, L. Teplytska, M. Murphy, R. Landgraf, C. Turck

**FC-19-004**

A month and 10-year follow-up PTSD study of children exposed to a mass shooting incident  
Ruby Castilla-Puentes, USA  
T. Falcone, S. Castilla-Puentes, W. Castilla-Puentes, C. Sanchez-Russi, J. Gomez Morad, M. Habeych

**FC-19-005**

Molecular alterations in neuronal plasticity, immune response, and apoptosis in posttraumatic stress disorder  
Anna Boyajyan, Armenia  
D. Avetyan, L. Hovhannisyan, G. Mkrtchyan

**FC-19-006**

The cumulative effect of childhood trauma on adult mental and physical health: Results from the Marine Resiliency Study  
Agorastos Agorastos, Germany  
J. O. E. Pittman, A. C. Angkaw, C. M. Nievergelt, S. A. Parisi, D. G. Baker

**FC-19-007**

The role of increased CRP levels and CRP genetic variation in PTSD  
Vasiliki Michopoulos, USA  
T. Jovanovic, K. Ressler

**FC-20**

**FREE COMMUNICATIONS**

13:00 – 14:30  
Mitropoulos Hall

**Schizophrenia**  
Chair: Janusz Rybakowski, Poland  
Co-Chair: Elias Angelopoulos, Greece

**FC-20-001**

A longitudinal study evaluating social cognition of patients with schizophrenia during the symptomatic and remission phases  
Vijaya Lakshmi, India  
R. Nehra, S. Grover

**FC-20-002**

Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia  
Helena Fatouros-Bergman, Sweden  
S. Cervenka, L. Flyckt, G. Edman, L. Farde

**FC-20-004**

Treatment of neurocognitive dysfunction in schizophrenia: Effects of atypical antipsychotics on emotion processing  
Gabriele Sachs, Austria  
A. Erlen

**FC-20-005**

Cognitive function in schizophrenia and its association with socio-demographics factors  
Bharti Talreja, India  
S. Shah, L. Kataaria

**FC-20-006**

The impact of genetic counselling for severe mental disorders: A meta-analysis  
Ramona Moldovan, Romania  
D. Cozman, R. Popp, V. Pop, J. Austin
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Chair/Co-Chair</th>
<th>Speaker(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FC-21</td>
<td>Schizophrenia</td>
<td>Takashi Kudo, Japan</td>
<td>Sergei Potanin, Russia, D. Burminsky, M. Morozova, N. Baymeeva, A. Platova, L. Miroshnichenko</td>
</tr>
<tr>
<td></td>
<td>FC-21-001 The relationship between optimal plasma concentration of antipsychotics and early treatment response in patients with acute schizophrenia</td>
<td>George Moussas, Greece</td>
<td>W.-Y. Chen, Shih-Ku Lin, Taiwan, D. Burminsky, M. Morozova, N. Baymeeva, A. Platova, L. Miroshnichenko</td>
</tr>
<tr>
<td></td>
<td>FC-21-002 Comparison of first generation and second generation long-acting injectable antipsychotics in the treatment of schizophrenia</td>
<td>George Moussas, Greece</td>
<td>W.-Y. Chen, Shih-Ku Lin, Taiwan, D. Burminsky, M. Morozova, N. Baymeeva, A. Platova, L. Miroshnichenko</td>
</tr>
<tr>
<td></td>
<td>FC-21-004 Peony-Glycyrrhiza decoction, an herbal preparation against antipsychotic-induced hyperprolactinemia: From bedside to bench</td>
<td>George Moussas, Greece</td>
<td>W.-Y. Chen, Shih-Ku Lin, Taiwan, D. Burminsky, M. Morozova, N. Baymeeva, A. Platova, L. Miroshnichenko</td>
</tr>
<tr>
<td></td>
<td>FC-22</td>
<td>Schizophrenia</td>
<td>E. Mohandas, India</td>
</tr>
<tr>
<td></td>
<td>FC-22-001 Different frontal brain activation during verbal fluency test in individuals at risk for schizophrenia and bipolar disorder: A functional near-infrared spectroscopy study</td>
<td>E. Mohandas, India</td>
<td>Gottfried R. S. Treviranus, Switzerland, Linda Marie Kai, Denmark</td>
</tr>
<tr>
<td></td>
<td>FC-22</td>
<td>Schizophrenia</td>
<td>Alexandros Vgonzas, Greece</td>
</tr>
<tr>
<td></td>
<td>FC-22-002 Evidence for a transient clozapine-mediated gaba regulation of mesocorticolimbic and perforant pathway transmission in schizophrenia</td>
<td>Panos Gregoriou, Greece</td>
<td>Gottfried R. S. Treviranus, Switzerland, Linda Marie Kai, Denmark</td>
</tr>
<tr>
<td></td>
<td>FC-22-003 Familiar risk for psychosis influence the association between neuroticism and happy facial emotion recognition</td>
<td>Panos Gregoriou, Greece</td>
<td>Gottfried R. S. Treviranus, Switzerland, Linda Marie Kai, Denmark</td>
</tr>
<tr>
<td></td>
<td>FC-23</td>
<td>Depression</td>
<td>Victoria Valdez de Vuibert, Ecuador</td>
</tr>
<tr>
<td></td>
<td>FC-23-001 Appropriative cycles within in a syllogistic classic T-A-M-space as framework for anxio-affective disorders generating natural language maybe through thalamo- and insulo-cortical loops modulated by mast cells</td>
<td>Panos Gregoriou, Greece</td>
<td>Panos Gregoriou, Greece, Gottfried R. S. Treviranus, Switzerland, Linda Marie Kai, Denmark</td>
</tr>
<tr>
<td></td>
<td>FC-23-002 Meditation as a means of therapy of depression</td>
<td>Panos Gregoriou, Greece</td>
<td>Panos Gregoriou, Greece, Gottfried R. S. Treviranus, Switzerland, Linda Marie Kai, Denmark</td>
</tr>
<tr>
<td></td>
<td>FC-23-004 Sound profile and gene expression: Characteristics of a rat model of depression</td>
<td>Panos Gregoriou, Greece</td>
<td>Panos Gregoriou, Greece, Gottfried R. S. Treviranus, Switzerland, Linda Marie Kai, Denmark</td>
</tr>
</tbody>
</table>
FC-23-006
Attitudes and behavior of healthcare providers at a general hospital towards deliberate self-harm and suicide
Lakshitha Iroshan Ranasinghe, Sri Lanka
P. S. Ginge

FC-23-007
Suicide in military agents in Peru 2010-2012
Freddy Vasquez, Peru
W. Vargas, Y. Nicolas, S. Falconi, V. Vite

FC-24 FREE COMMUNICATIONS
13:00 – 14:30 Kokkali Room
Bipolar Disorder
Chair: Thomas Schulze, Germany
Co-Chair: Dimitris Dikeos, Greece

FC-24-001
A prospective study of the association of testosterone levels and future suicide attempts in women with bipolar disorder
Leo Sher, USA
M. Grunebaum, G. Sullivan, A. Burke, T. Cooper, J. Mann, M. Oquendo

FC-24-002
Gray matter anormalities in childhood maltreated bipolar type I patients: A voxel based morphometric study
Dante Duarte, Brazil
M. Neves, F. Neves, R. Nicolato, M. Albuquerque, F. Duran, G. Busatto, C. Humberto

FC-24-003
Schneiderian first-rank symptoms in bipolar disorder
Arindam Chakrabarty, India

FC-24-004
How often do persons with major depression convert to bipolar disorder on prospective follow-up? A systematic review and meta-analysis
Aswin Ratheesh, Australia
S. Cotton, S. Hetrick, C. Davey, M. Alvarez, P. McGorry, M. Berk

FC-24-005
Temperament profile predicts the polarity index of maintenance treatment for bipolar disorder and mixed features major depressive disorder in a naturalistic setting
Panagiotis Ferentinos, Greece
E. Pich, C. Christodoulou, D. Margaritis, I. Kotsioumpa, D. Dikeos, A. Douzenis

FC-25 FREE COMMUNICATIONS
13:00 – 14:30 Conference Room 1
Violence
Chair: Philippe Courtet, France
Co-Chair: Athanasios Douzenis, Greece

FC-25-001
Human aggression: The interaction of MAOA-Genotype, environment and dopamine
Ingo Vernaleken, Germany

FC-25-002
Impact of childhood abuse on emotion regulation during mother-child-interaction and associated neural correlates
Corinne Neukel, Germany

FC-25-004
The possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder (ASPD)
Borwin Bandelow, Germany

FC-25-005
Brain anatomy in schizophrenia patients with a history of community violence
Unn Kristin Hauvik, Norway

FC-25-006
Clinical and neurosurgical management of treatment-resistant severe violent and aggressive behavior
Ricardo Bueno Vargas, Mexico
M. Hernandez Salazar, L. A. Ledesma Torres, O. Meneses Luna, M. G. Ochoa Madrigal, F. J. Valencia Granados
## FC-26 FREE COMMUNICATIONS

**15:00 – 16:30**  
Conference Room 1

### Pharmacogenetics

**Chair:** Alessandro Serretti, Italy  
**Co-Chair:** Despina Sanoudou, Greece

**FC-26-001**  
Clinical and genetic markers to predict a rapid and strong weight gain during psychotropic treatment  
Frederik Vandenberghe, Switzerland  
N. Saigi Morgui, A. Delacrețaz, L. Quteineh, M. Ghomamrezaee, A. von Gunten, P. Conus, C. B. Eap

**FC-26-002**  
Impact of HSD11B1 polymorphisms on body mass index and components of the metabolic syndrome in patients with psychotropic treatments  
Lina Quteineh, Switzerland  

**FC-26-003**  
Influence of MCHR2 and MCHR2-A51 genetic polymorphisms on body mass index in psychiatric patients and in subjects from the general population with present or past atypical depression  
Aurélie Delacrétaz, Switzerland  

**FC-26-004**  
Influence of weighted genetic risk score on BMI in Swiss psychiatric cohorts  
Núria Saigi-Morgui, Switzerland  

**FC-26-005**  
Genetic variation in multi-drug resistance 1 and catechol-O-methyltransferase genes may influence antipsychotic response in schizophrenia and related disorders  
Rosa Catalán, Spain  
A. González-Rodríguez, M. J. Arranz, R. Penadés, B. Gutiérrez, F. Pérez Blanco, M. Bernardo

**FC-26-007**  
The need to improve current psychopharmacotherapy before developing new drugs  
Eva Ceskova, Czech Republic  
M. Mayerova

## P-21 POSTER PRESENTATION

**12:45 – 14:15**  
Muses Foyer

### Addictive Disorders/Anxiety Disorders/Stress/Psychopathology/Childhood and Adolescent Disorders

**Chair:** Nikos Vaidakis, Greece  
**Co-Chair:** George Konstantakopoulos, Greece

**P-21-001**  
What is „Food Addiction“: The classification issue revisited  
Liliana Castro, Portugal  
C. Raposo-Lima

**P-21-004**  
Varenicline and manic symptoms  
Esteban Rodríguez Jiménez, Spain  
J. Alcalá Partera, M. d. Pino Ordovás González

**P-21-005**  
Current opinions on alcohol-related aggression  
Eleftherios Mellos, Greece  
T. Paparrigopoulos, D. Tsaklakidou, E. Méllos, E. Tzavellas, I. Liappas, T. Paparrigopoulos

**P-21-006**  
Medical cannabis: Pros and cons  
Dimitrios Panteleakis, Greece  
D. Karaikos, D. Tsaklakidou, E. Mellos, E. Tzavellas, I. Liappas, T. Paparrigopoulos

**P-21-007**  
Conversion disorder  
Yacov Rofe, Israel

**P-21-008**  
Cognitive impairment and global functioning in schizophrenic and schizoaffective disorder patients with comorbid anxiety  
Aurora Sabau, Romania  
K. Wild, D. Podea

**P-21-009**  
Salivary cortisol level as a biomarker in anxiety disorders  
Krzysztof Rutkowski, Poland  
E. Dembinska, K. Tokarz, J. Sobanski, K. Cyranka, L. Młdner-Nieckowski, M. Mielimaka

**P-21-010**  
C-reactive protein level and psychological function of treatment seeking obese patients. A case-control study  
Kavitha Subramaniam, Malaysia  
W.-Y. Low, K. Chinna, K.-F. Chinna, S. Krishnaswamy

**P-21-011**  
Anxiety: A new clinical neuroconnective phenotype  
Andrea Bulbena-Cabre, USA  
A. Bulbena-Vilarrasa
P-21-012
Advancing pharmacological treatment of hoarding disorder
Vlasios Brakoulias, Australia

P-21-013
Regulation-focused psychotherapy for children: Illustrations of a research domain criteria-compatible psychodynamic intervention for youth with externalizing behaviors
Timothy Rice, USA
L. Hoffman

P-21-014
The therapeutic role of oxytocin in child and adolescent mental health problems
Evdokia Davilla, Greece
N. M. Voudouri, K. Apostolopoulou, N. Vasilakopoulou, C. Polychronidis, D. Georgiades, E. Tsalamanios

P-21-015
Depressive disorders at teenagers in places of freedom deprivation
Volodymyr Korostiy, Ukraine
H. Kozhyna, A. Cherkasova

P-21-016
TS-eurotrain: European wide investigation of the etiology and pathophysiology of Gilles de la Tourette syndrome and related disorders
Ahmad Seif Kanaan, Germany
N. Forde, P. Paschou

P-21-017
Psychiatric aspects of Addison’s disease (case report in a poster)
Rumyana Trendafilova, Bulgaria
Z. Yaneva

P-21-018
Preventing school shootings: Importance of a development approach to at-risk adolescents
Timothy Rice, USA
L. Hoffman

P-21-019
Psychiatric features of body integrity identity disorder
Bernd Kraemer, Switzerland
L. M. Hilti, J. Hänggi, P. Brugger

P-21-021
Is it possible to discriminate affective and non affective first episode psychosis based on their verbal pragmatic abilities?
Paolo Brambilla, Italy

P-21-022
Psychopathology, ways of coping with stress and quality of life in nursing staff of public hospitals
Panagiota Voskou, Greece
E. Kararizou, A. Douzenis, M. Economou, M. Cinieri-Coccosis, I. Evdokimidis

P-21-023
Gender differences in persistent delusional disorder: Retrospective chart review from a tertiary care centre in India
Karishma Kulkarni, India
R. Arasappa, K. Prasad, A. Zutshi, P. Chand, M. S. Keshavan, P. Murthy

P-21-024
Hair cortisol and subjective stress in patients with schizophrenia and bipolar disorder
Fabian Streit, Germany

P-21-025
Transcriptional activation of non-LTR retrotransposons specific transcripts in rats
Somnath Mukherjee, India
K. C. Upadhya, D. Sharma

P-21-026
Influence of meditation on the regulatory systems in the human body
Evgeniy Zakharov, Russia

P-22
POSTER PRESENTATION
12:45 – 14:15 Muses Foyer

Bipolar Disorders/Depression/Suicide
Chair: Georgios Moussas, Greece
Co-Chair: Evgenia Daskalopoulou, Greece

P-22-002
Use of personality measures and heart rate variability for subthreshold depressive symptoms of bipolar disorder in remission
Saejeong Lee, Republic of Korea
S. Park, Y. Joo

P-22-003
A manic episode following sexual enhancement supplement use
Andrea Bulbena-Cabre, USA
N. Ramos Dunn, R. Gorman Swift

P-22-005
Altered auditory steady-state magnetic fields in bipolar disorders: A source localization study
Oda Yuku, Japan
N. Hironaga, H. Shogo, R. Tsuchimoto, T. Maekawa, T. Onitsuka, S. Tobimatsu, S. Kanba

P-22-006
Designing a new therapeutic intervention for cognitive impairments in bipolar disorders: From a theoretical construct to a clinical illustration
Clémence Isaac, France
M.-C. Castillo, S. Braha-Zeitoun, A. Faivre, N. Bouaziz, D. Januel
P-22-007
From nails, via the lymphatic cauldron to brain: Mast cells, their particles and conduits take the lead beyond fluid psychoneuroimmunology
Gottfried R. S. Tre vir anus, Switzerland

P-22-008
Psychometrical scales in the bipolar I disorder
David Alberca, Spain
N. Corominas Castell

P-22-009
Differential expression of microRNA in peripheral blood of bipolar disorder I manic patient under asenapine and risperidone treatment
Lim Chor Hong, Malaysia
N. Z. Zainal, S. Kanagasundram, Z. Mohamed

P-22-010
Development of somatogenic depression
Volodymyr Mykhaylov, Ukraine
A. Kognya, A. Kognya

P-22-011
Severe post-partum depression with catatonic features as the presentation of neuropsychiatric systemic lupus erythematosus
Adam Wysokinski, Poland
R. Magierski, M. Partyka, I. Kloszewska

P-22-013
The role of zinc in elder people depression
Michal Skalski, Poland

P-22-014
Therapeutic drug monitoring of depression: Augmentation by magnesium ions
Maria Radziwon-Zaleska, Poland

P-22-015
Efficacy and tolerability of venlafaxine switch in serotonin selective reuptake inhibitors treated patients with partial response
Daniel Vasile, Romania
O. Vasiliu, D. G. Vasiliu, G. A. Sopterean, R. E. Bratu, F. Androne, F. Vasile

P-22-017
Comparison of cognitive function between early-onset and late-onset depression in euthymic people with late-life depression
Ying Chih Cheng, Taiwan
C.-C. Chiu, H.-C. Liu

P-22-018
Depression as the first symptom of haemochromatosis
Margarita Perez Fominaya, Spain
L. Muñoz Lorenzo, A. Rico Román

P-22-019
Depression associated to pathological condition
Kristina Zadorina, Ukraine

P-22-020
Looking into terrorists’ eyes: The sign of lower eye-white enlargement
Enrica Di Rosa, Italy
L. Ricciardi, M. Bologna, B. Demartini, A. Di Rosa

P-22-021
Neurofeedback training for depression: A case study
Sungwon Choi, Republic of Korea
H. Lim, S. Jeong

P-22-022
Lipidomics as a new tool in diagnosis of neuropsychiatric disorder
Wojciech Rachel, Poland
W. Piekoszewski, A. Grela

P-22-023
The impact of clinical and biological factors on dexamethasone suppression test result in psychiatric patients after a suicide attempt
Athanassia Papadopoulou, Greece
A. Douzenis, C. Christodoulou, R. Gournellis, C. Papageorgiou, M. Markianos

P-22-024
Work-related stress and suicidal ideation
Policarpo Rebolledo, Chile
N. Martini, P. González, C. Rebolledo
P-23 PoSter Presentation

Thursday, 18 June 2015 | Scientific Programme

12:45 – 14:15 Muses Foyer

Schizophrenia
Chair: Elias Angelopoulos, Greece
Co-Chair: Dimitra Pappa, Greece

P-23-001
Bridging the gap between biochemistry content and sensory process in schizophrenia and schizoaffective psychosis
Stephanie Fryar-Williams, Australia

P-23-002
Development of a novel animal model of clozapine-resistant schizophrenia: Behavioral and neurobiological characterization
Michal Taler, Israel
I. Gil-Ad, I. Tarasenko, A. Weizman, A. Krivoy

P-23-004
Frequency and type of somatic diseases in schizophrenic patients – correlation with antipsychotics treatment
Dzevad Begic, Bosnia and Herzegovina
S. Bise, O. Cemalovic, B. Kurtovic

P-23-006
Memory deficits in a ketamine-induced rat model of schizophrenia
Manuela Padurariu, Romania
M. Paulet, L. Hritcu, A. Ciobica, R. Lefter, D. Timofte

P-23-007
Myelination alterations in an animal model of schizophrenia-like symptoms and schizophrenia patients
Michaela Filiou, Germany

P-23-008
Neurological soft signs might be an endophenotype candidate for patients with deficit syndrome schizophrenia
Murat Beyazyü, Turkey
E. Soydas Akyol, Y. Albayrak, M. Kuloglu

P-23-009
Re-engineering case management processes to promote patients adherence to treatment
Margaret Mary Hendricks, Singapore
V. K. Swapna, K. L. Yow

P-23-011
Cognitive profile in schizophrenia and bipolar disorder: A study in Chilean patients
Aida Ruiz, Chile

P-23-013
Frontal assessment battery (FAB). A brief assessment of executive functions in schizophrenic patients
John Nimatoudis, Greece
A. Theofilidis

P-23-014
Paliperidone for the treatment of schizoaffective disorder
Christos Istikoglou, Greece
R. Malamou, E. Liapis, A. Aivatides, M. Economou, M. Vassiliadou, N. Polonis, P. Kanellos, I. Liappas, D. Vlissides

P-23-016
Reduced negative symptoms may distinguish the clinical profile of patients with psychosis following traumatic brain injury from schizophrenia/schizoaffective disorder
Rachel Batty, Australia
A. Francis, N. Thomas, M. Hopwood, J. Ponsford, S. Rossell

P-23-017
Smoking habits in psychotic patients in Greek population
Christos Istikoglou, Greece
E. Liapis, A. Aivatides, M. Economou, M. Vassiliadou, P. Kanellos, N. Polonis, I. Liappas, R. Malamou, V. Tziora

P-23-018
Social cognition in people with schizophrenia as seen in thematic apperception test
Ladislav Hosak, Czech Republic
K. Hosakova, M. Lechych

P-23-020
Treatment in first psychotic episodes: A case report
Esteban Rodríguez Jiménez, Spain
J. Alcalá Partera, M. d. Pino Ordovás González

P-23-021
International classification of functioning, disability and health (ICF) for schizophrenic patients
Oscar Pino, Spain
E. Rojo, G. Guiller, J. Gomez-Benito
P-24-001
A comparative study of serum Tau protein levels on intestinal endotoxemia among Alzheimer's disease rats and in Chinese sample of Alzheimer's disease patients and healthy controls
Bai Han, People's Republic of China
F. Wu, Q. Sun, Y. Gao, L. Ma, X. Shan

P-24-002
Alterations in hippocampal cholinergic system of Samarian rats are similar to those observed in early stages of Alzheimer's disease
Zdenka Kristofikova, Czech Republic
A. Stuchlik, T. Petrasek, M. Skurlova, K. Vales, D. Ripova

P-24-003
A comparative study of serum NO levels on intestinal endotoxemia among Alzheimer's disease rats and in Chinese sample of Alzheimer's disease patients and healthy controls
Bai Han, People's Republic of China
F. Wu, Q. Sun, Y. Gao, L. Ma, X. Shan

P-24-005
Study on serum BDNF levels on intestinal endotoxemia on Alzheimer's disease rats and in Chinese sample of Alzheimer's disease patients and healthy controls
Bai Han, People's Republic of China
F. Wu, Q. Sun, Y. Gao, L. Ma, X. Shan

P-24-006
Associated symptoms with eating disorders among mothers and subjects with ED
María Del Pino Ordovás González, Spain
E. Rodríguez Jiménez, T. Guijarro Granados, P. Martín Borrego

P-24-007
Negative correlation between skin conductance response and the severity in patients with bulimia nervosa
Noriko Numata, Japan
Y. Hirano, M. Nakazato

P-24-008
Obesity and eating attitude of medical, surgical and service group resident and intern physicians
Beomwoo Nam, Republic of Korea
J. S. Seo

P-24-009
Factors associated with high risk for eating disorders in Korean adolescents
Young-Eun Jung, Republic of Korea

P-24-010
Elevated body temperature: A symptom of malignant neuroleptic syndrome or of a distinct excited delirium syndrome in the course of the treatment of psychosis
Gordana Rubesa, Croatia
L. Gudeli, I. Skarpa Usman, S. Blazevic Zelic

P-24-011
Psychiatric emergency: Factors associated with the decision of hospitalization
Kilani Hajji, Tunisia
I. Marrag, R. Ben Soussia, L. Zarrouk, M. Nasr

P-24-012
The doctor-patient relationship and medication adherence in chronic psychiatric illness: A mixed-model study
Gayatri Devasthali, India
S. Chakrabarti, A. K. Misra

P-24-013
Devising the neuroscience in clinical adolescent and young adult psychiatry study
Konstantinos Ioannidis, United Kingdom
R. Kelvin, I. Goodyer

P-24-015
Correlation of psychiatry disorders with full moon and new moon
Meraj Quadri, India
P. Rathi

P-24-016
Impact of belief in Jinnie and black magic in psychiatric patients
Meraj Quadri, India
A. Quadri

P-24-018
Cytokine-behavior links in lewis lung carcinoma (LLC)-bearing mice and effects of a new anticancer agent
Anna Tallerova, Russia
O. Kuznetsova, S. Nikitin, L. Kovalenko

P-24-019
Effects of a new 5-pyrimidinol derivative (SNK-411) on tumor growth and depressive-like behavior in LLC-bearing mice
Olga Kuznetsova, Russia
A. Tallerova, D. Shatsky, S. Nikitin, L. Kovalenko
P-24-020
Translational research of chronic pain patients using human blood-induced microglia-like (iMG) cells
Masahiro Ohgidani, Japan
T. Kato, M. Hosoi, R. Iwaki, N. Sudo, S. Kanba

P-24-022
Hephaestus revisited: The heritability of lifelong premature ejaculation
Paddy Janssen, The Netherlands
F. van der Heijden

P-24-024
Impact of non-apnea sleep disorders on diabetic control and metabolic outcome – a longitudinal cohort study
Ying Chuan Hung, Taiwan
Y.-C. Lin, H.-M. Hsieh, H.-C. Chiu

P-24-025
The quality of life in patients with nonorganic insomnia
Michal Skalski, Poland
A. Król, A. Silka, M. Zarzycki

P-24-026
BDNF concentrations in patients with somatization disorder before and after treatment
Mal Rye Choi, Republic of Korea
J.-C. Yang, S.-K. Chung, D.-J. Kim, Y.-K. Kim

P-24-027
1) Psychogenic nonepileptic seizures in an epilepsy center in Colombia: A diagnosis challenge 2) Quality of life in patients with epilepsy and psychogenic NmN-epileptic seizures in a Colombian neurological centre
Maria Alejandra Velez Aguirre, Colombia

P-24-028
Acute adjustment disorders: A descriptive study of 93 patients
Kilani Hajji, Tunisia
I. Marrag, W. Chebbi, R. Ben Soussia, M. Nasr

P-25-002
Predictors of weight gain during antipsychotic treatment of schizophrenia
Adam Wysokinski, Poland
R. Magierski, I. Kloszewska, T. Sobów

P-25-003
Efficacy of quetiapine on psychotic symptoms and cognition in Parkinson’s disease
Gorana Sulejmanpasic-Arslanagic, Bosnia and Herzegovina
S. Fisekovic, A. Kucukalic, S. Ler

P-25-005
Safety profile and weight gain of treatment with risperidone in patients with schizophrenia
Alma Bravo-Mehmedbasic, Bosnia and Herzegovina
A. Kucukalic, A. Dzubur Kulenovic, S. Kucukalic

P-25-006
Psychiatric pharmacogenomics: A stride in human genetics and a bridge for individualized treatment
Leslie Kiraly, Canada
Z. Elbaz

P-25-007
Agmatine rescued ASD like behavior in valproic acid induced animal model of autism: New implication for the ASD
Ji-Woon Kim, Republic of Korea

P-25-008
Drug induced body weight gain and metabolic syndrome in patient with schizophrenia and bipolar disorder
Kyungphil Kwak, Republic of Korea
T. Kim

P-25-009
Influence streptozotocin-induced diabetes on behavioral activity of offspring and it’s correction of afobazole
Victoria Zabrodina, Russia
E. Shreder, O. Shreder, A. Durnev

P-25-010
The interaction between decreased short-term spatial memory and increased oxidative stress in a scopolamine-induced rat model of Alzheimer’s disease
Manuela Paduraru, Romania
R. Lefter, A. Ciobica, E. Anton

P-25-011
Psychosis as a side effect of raltegravir
Jose M. Lopez-Santin, Spain
P. Alvaro Seron
P-25-012
Case report: A patient with restless legs syndrome associated with the co-administration of duloxetine and paroxetine
Kalliopi Nikolaou, Greece
R. Gournellis, I. Michopoulos, C. Papazahos, C. Papageorgiou, A. Douzenis

P-25-013
Serotonin syndrome in a patient with autism spectrum disorder
Kalliopi Nikolaou, Greece
R. Gournellis, I. Michopoulos, G. Dervenoulas, A. Douzenis

P-25-014
Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: A case of severe manic catatonia
Mirko Manchia, Italy
M. Pinna, G. Pillai, P. Salis, G. Minnai

P-25-015
Prolonged postictal delirium following electroconvulsive therapy
Suet Yee Chee, Singapore
N. Kathirvel, N. Ravichandran

P-25-016
High frequency left prefrontal transcranial magnetic stimulation (TMS) in the treatment of depressive stupor: A case report
Takashi Hasegawa, Japan
A. Takamiya, T. Nakajima, S. Kito

P-26-001
Development of an algorithm for the differential diagnosis of organic psychotic disorders
Olivier Bonnot, France
J. Torres Martin, S. Kolb

P-26-002
Subjective cognition across psychiatric disorders: Gone with the wind?
Valerie Tourjman, Canada
S. Potvin, S. Purdon, A. Djouini

P-26-003
Effects of alcohol on decision-making in healthy woman
Marina Kunchulia, Georgia

P-26-005
Cognitive disorders, associated with epilepsy
Volodymyr Korostiy, Ukraine
A. Dubenko, M. Ivenskaya

P-26-006
Epidemiology of PANDAS in children at the Far East of Russia
Alina Martynova, Russia

P-26-007
Depression and anxiety disorders in child and adolescent populations in low and middle income countries: A review
Swetha Yatham, Canada
A. Ravindran

P-26-009
Epidemiology of obsessive-compulsive disorders on data of the Far East of Russia
Alina Martynova, Russia
A. Shwedova

P-26-010
Transcultural psychiatry working with migrants in everyday clinical
Solmaz Golsabahi-Broclawski, Germany
A. Broclawski

P-26-011
Sex-related differences of relationships between 2nd to 4th digit ratio and EEG coherence in patients with schizophrenia compared with controls
Yu Sang Lee, Republic of Korea
B.-H. Choi

P-26-012
Two case-reports providing evidence for a new phenotype of SHANK3 alterations
Stéphanie Vesperini, France
S. Serret, F. Askenazy, S. Thummler, A. Santos, E. Dor

P-26-013
Investigating gene pathways involved in the aetiology of Gilles de la Tourette syndrome
John Alexander, Greece
F. Tsetsos, P. Drineas, P. Paschou

P-26-014
The role of genes in the psychotherapeutic treatment of psychiatric disorders (therapugenetics)
Niki Maria Voudouri, Greece
E. Tsalamanios, K. Apostolopoulou, E. Davilla, D. Georgiadis

P-26-015
Whole exome sequencing of consanguineous family with psychosis in northwest Algeria
Aicha Dahdouh Guermouche, Algeria
M. Guipponi, J. Prados, M. Taleb, B. Semaoune, S. Antonarakis
Screening of marker chromosome and mutational study of shank3 in ADHD patients compared with serotonin level
Subramaniam Mohana Devi, India
V. Balachandar, M. Arun, K. Sasikala

Resting state functional connectivity pattern-classification as a tool for the identification of clinical high risk for psychosis
Maria F. Urquijo, Germany
L. Kambeitz-ilankovic, C. Cabral, N. Koutsouleris

Changes in the oxyhemoglobin levels and reaction time during the game of rock, paper, scissors taking with the responses after the opponent’s – Comparison between schizophrenic patients and healthy controls
Mamoru Sato, Japan

Single emotional load event-related changes in cerebral oxyhemoglobin using shiritori task in patients with schizophrenia: Comparison with healthy subjects
Yoshihisa Shoji, Japan

Single word evoked changes in cerebral oxyhemoglobin using shiritori task in patients with schizophrenia: Comparison with healthy subjects
Ryo Fujiki, Japan

Single-event-related changes in oxy-hb during verbal discrimination tasks in schizophrenic patients
Youhei Ishii, Japan
Y. Shoji, K. Morita, R. Fujiki, K. Mori, N. Uchimura

Using magnetoencephalography (MEG) to evaluate neurocognitive models of auditory verbal hallucinations
Susan Rossell, Australia
M. Hughes, W. Woods, S. Lancaster, N. Thomas, P. Michie

Utilizing mutual information analysis to explore the relationship between gray and white matter structural pathologies in first episode schizophrenia
Amanda Lyall, USA

CLOSING CEREMONY
16:30 – 17:30  Trianti Hall

WFSBP Poster Awards
presented by the Chair of the ISPC:
Florence Thibaut, France

Invitation to the
13th WFSBP Congress 2017 Copenhagen, Denmark

Farewell message
CONGRESS VENUE
Megaron Athens International Conference Centre

Congress Entrance
Entrance B, left from main Music Hall entrance
Leoforos Vasilissis Sofias and Kokkali 1
Athens 115 21, Greece

CONGRESS REGISTRATION COUNTER
All congress materials will be available at the congress registration located in Mitropoulos Foyer of the Megaron. The Mitropoulos Foyer is located right hand side when entering the congress venue through the congress entrance B on ground floor.

Opening Hours
Sunday, 14 June 2015 12:00 – 19:00
Monday, 15 June 2015 07:30 – 18:00
Tuesday, 16 June 2015 08:00 – 18:00
Wednesday, 17 June 2015 08:00 – 18:00
Thursday, 18 June 2015 08:00 – 17:00

During these hours the congress registration counter can be reached at Phone: +30 – 210 – 7282651

NAME BADGES
All participants are kindly requested to wear their name badge at all times during the congress including the Opening Ceremony and Welcome Reception.

The colours of the name badge have the following significance:
Congress delegate: blue
Exhibitor: green
Staff: red

CONGRESS LANGUAGE
The official language of the Congress will be English. Simultaneous translation will not be provided. No simultaneous translation will be provided.

CERTIFICATE OF ATTENDANCE/CME CERTIFICATES
For certificates of attendance and CME certificates please use the terminals located in the registration area. From 24 June following to the congress you can also print your CME certificate online at www.wfsbp-congress.org by accessing with your participant number on your badge or with your personal login data of the congress website.

FINAL PROGRAMME
The Final Programme is inserted in your congress bag.

CO CONGRESS ONLINE®
Congress Information system
For the 12th WFSBP Congress 2015, the web based Congress Information System CO CONGRESS ONLINE® has been installed: www.wfsbp-congress.org

CO CONGRESS ONLINE® will provide information on:
- Updated scientific programme
- Programme by day
- Programme by formats with accepted abstracts
- Programme by topics with accepted abstracts
- Programme search
- List of participants (who is who)
- List of exhibitors and sponsors
- General congress information
- City of Athens
- Travel information
- Private mailbox

WIRELESS LAN/WI-FI
Wireless LAN / Wi-Fi is installed free of charge from Monday, 15 June until Thursday, 18 June 2015 in the Muses Foyer. A password is not required in order to access the wireless LAN.

TECHNICAL EXHIBITION
The WFSBP Congress will be accompanied by a technical exhibition taking place in the Muses Foyer, ground floor, of the Megaron Athens International Conference Centre. Coffee bars will be located in the technical exhibition.

Opening Hours
Monday, 15 June 2015 09:00 – 17:00
Tuesday, 16 June 2015 09:00 – 17:00
Wednesday, 17 June 2015 09:00 – 17:00

WFSBP 2015 APP CONGRESS MOBILE®
Get the WFSBP 2015 Congress App for your smartphone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The App is completely free for congress participants and provides iPhone/iPad, Android Smartphone users at the WFSBP Congress 2015 in Athens with on-the-go access to the congress.
Congress Information

The WFSBP 2015 Congress App is powered by GLOBIT’s acclaimed CONGRESS MOBILE® software.

Further information is given at www.wfsbp-congress/app.

SPEAKERS CENTRE

The Speakers Centre is located in Room MC 3.2 at Level -1/Conference Suites 2 Foyer. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before but at the latest 90 minutes prior to the presentation.

The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Several PC working stations are provided in the speakers centre where speakers can also work on their PC charts in a quiet area. Technical staff will be glad to assist.

operated by Estensis GmbH
the Conference Company

Opening Hours

Sunday, 14 June 2015 12:00 – 19:00
Monday, 15 June 2015 07:30 – 18:00
Tuesday, 16 June 2015 08:00 – 18:00
Wednesday, 17 June 2015 08:00 – 18:00
Thursday, 18 June 2015 08:00 – 17:00

POSTER EXHIBITION

The poster exhibition is located in the Muses Foyer on ground level of the Megaron.

Posters are allocated to 26 guided poster tours (P-01 to P-26). Posters will be changed daily and are on display for the entire day of the according poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster exhibition times for P-01 to P-06
Monday, 15 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Poster exhibition times for P-07 to P-13
Tuesday, 16 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Poster exhibition times for P-14 to P-20
Wednesday, 17 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Poster exhibition times for P-21 to P-26
Thursday, 18 June 2015 09:00 – 17:00
Guided Poster Tours 12:45 – 14:15

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set-up and dismantling times for posters

Posters need to be set up and dismantled on the day of the respective poster tour within the following times:

Set-up: 08:00 – 09:00
Dismantling: 17:00 – 18:00

Posters which have not been removed will be disposed off. Poster material to put up the poster is available at the poster service desk in the poster area.

BEST POSTER AWARDS

All posters will be evaluated on site by the WFSBP Prize Committee. The best poster of each poster tour will be moved to the best poster area in the Muses Foyer where they are displayed throughout the congress. Out of these the 10 best posters of young investigators under 40 years will be awarded with a poster prize. The awards will be handed out during the Closing Ceremony on Thursday, 18 June 2015.

PROGRAMME CHANGES

The organizers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances.

SNACK BARS/VENUE RESTAURANT

The congress provides snack bars in the exhibition area in the Muses Foyer. Beverages and snacks can be purchased there. In addition, the Allegro restaurant of the Megaron Athens International Conference Centre, next to the congress registration counter, offers cold and warm dishes.

CLOAKROOM

A cloakroom can be used free of charge from Sunday, 14 June through Thursday, 18 June 2015. Delegates can also store their luggage there.
CASH MACHINE
An ATM/cash machine is located in the passway from the congress registration machine to conference room 4 (in the foyer of the main Megaron Entrance A).

FIRST AID
In case of emergency, please contact the registration counter.

MOBILE PHONES
Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

CURRENCY
The Greek currency is the Euro. The Euro is freely convertible on world currency markets. The exchange rate fluctuates daily depending on the money market.

VISA
The entry formalities for Greece vary according to the country of origin. The Ministry of Foreign Affairs of Greece advises on its website a list of countries that do not and that do require a visa to enter the country. Please visit the website www.mfa.gr

OFFICIAL ITALIAN AGENCY
AIM Group International - AIM Education S.r.l. has been appointed as the Italian Official Agency for AIFA submission. Italian pharmaceutical companies which require specific authorization from the Italian Health Ministry have been advised to contact:

AIM Group International – AIM Education S.r.l.
Raffaella Figerio / Cristina Ghidoli
Via G. Ripamonti, 129 l 20141 Milan, Italy
Phone: +39 – 02 – 56601.288/360
Fax: +39 – 02 – 70048585
Email: aifa@aimgroup.eu
www.aimgroupinternational.com

INSURANCE
Please notice that the congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is strongly recommended and will need to be purchased in the country of origin.

FORCE MAJEURE
For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any natural disaster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond its control) that have an impact on the arrangements, timetables or planning of the 12th World Congress of Biological Psychiatry (WFSBP 2015) and its corresponding activities in Athens, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

GENERAL CONDITIONS
The conditions published in the web will apply. www.wfsbp-congress.org

CLIMATE
The city of Athens is located in a Mediterranean climate. The average temperature for the month of June is 28°C/82°F and it can drop down to 20°C/68°F.

The sun shines 13 hours a day. The sun’s rays are strong and it is recommended to use sun-cream and to wear a hat and sunglasses. A bottle of water should be taken with you every time you go outside to keep yourself appropriately hydrated. In average it rains 4 days in the month of June.

HOUSING
For the 12th WFSBP Congress in Athens, the hotel accommodation for the participants is managed by our on-site partner company AFEA.

AFEA S.A.
39-41 Lykavittou Str.
10672 Athens, Greece
Email: wfsbp2015@afea.gr
Phone: +30-210 366 8800
Contact: Martha Kornarou

Booking conditions and information can be found on the congress website www.wfsbp-congress.org.

ATHENS INFORMATION COUNTER
An Athens counter is located at the registration counter and open during the congress. Please contact the staff for city information on Athens or reservations.
HOW TO GET TO THE MEGARON ATHENS INTERNATIONAL CONFERENCE CENTRE

Airport
The Athens-Eleftherios Venizelos Airport (ATH) is the international airport of the city of Athens. It is named after the premier Eleftherios Venizelos (1864 – 1936) and is the biggest and most important airport of Greece. The airport functions as an intersection for the Middle East and the Balkans. More than 13 million travelers transfer via the ATH yearly. It is 25 kilometers away from the city center and part of the commune Spata.

Transport between airport and city / between city and Megaron Athens International Conference Centre
The metro M3 takes about 30 minutes from the airport to the Megaron Athens International Conference Centre (metro station “Megaron Moussikis” on metro line 3, blue line). Please visit the website www.ametro.gr for more information about the prices and departure times.

CAR PARK
The Megaron Athens International Conference Centre’s three-level underground parking facility has spaces for 750 cars. It is open every day. The facility is fully signed for the convenience of drivers and pedestrians, and has 15 dedicated spaces for persons with special needs on each level. The facility is open from 6 a.m. to 2 a.m. every day.

The charge is EUR 3 for the first three hours, and EUR 1 for each extra hour. The parking fee is not included in the congress registration fee.

TAXIS
Taxis can stop right in front of the Megaron. Even though, there is no permanent taxi stand in front of the building, taxis can be stopped with hand signs easily. The appropriate price for a taxi from Athens-Eleftherios Venizelos Airport (ATH) to the Megaron Athens International Conference Centre is approx. EUR 35 – 40.

SAFETY
Athens is a city where inhabitants and visitors can safely stroll in the streets at any time of day and night. As a recommendation, please do not wear your badge and take your bag as you might be identified as a tourist.

CITY OF ATHENS
Located in the very southeast of Europe, Greece – ‘Hellas’ – is one of the oldest cultural spot within Europe. With a total population of around 11,3 million people, more than a third – 4 million people – live in Athens, the Capital. Athens is located in the Attica prefecture, in particular in the Attica basin, which is framed by Mount Aegaleo, Mount Parnitha, Mount Penteli and Mount Hymettos.

Athens has been founded more than 5,000 years ago and therefore is – unchallenged – the oldest and most ancient capital in Europe. But not only is the age a measure. Nowadays Athens is a very special spot in the world where ancient culture meets the challenges and advantages of today’s life.

This was proved very successfully by the Olympic summer games in 2004. Athens has come up with infrastructure, facilities and services that meet global standards – so far the 12th World Congress of Biological Psychiatry will become another successful global event in a global environment.

Next to the most famous sites of Athens, such as the Acropolis, the National Archaeological Museum of Athens, the Museum of the Acropolis, the Plaka area, also known as the god’s neighborhood. Athens is very famous for the attic light, a unique yellow golden light which has been described since ancient times.

Also in scientific terms, Greece and especially Athens have much going for: Nine universities are located in Athens. In the 20th century, two Nobel Prize of Literature awardees were born in Greece: Odysseas Elytis (1911-1996), received the prize in 1979 – and Giorgos Seferis (1900-1971), who was the awardee of 1963.
**EXHIBITION FLOOR PLAN**
(as per May 2015)

**EXHIBITOR LIST**

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actelion Pharmaceuticals Ltd.</td>
<td>3</td>
</tr>
<tr>
<td>Brainsway</td>
<td>7</td>
</tr>
<tr>
<td>ECNP – European College of Neuropsychopharmacology 2015</td>
<td>9</td>
</tr>
<tr>
<td>Ferrer</td>
<td>4</td>
</tr>
<tr>
<td>Informa PLC</td>
<td>12</td>
</tr>
<tr>
<td>Karger Verlag</td>
<td>8</td>
</tr>
<tr>
<td>MagVenture A/S</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroelectrics</td>
<td>6</td>
</tr>
<tr>
<td>Neuronetics</td>
<td>13</td>
</tr>
<tr>
<td>Pharmaserve Lilly S.A.C.I.</td>
<td>1</td>
</tr>
<tr>
<td>REMED TMS – TSIMPOS</td>
<td>1B</td>
</tr>
<tr>
<td>Wisepress Ltd.</td>
<td>11</td>
</tr>
<tr>
<td>WFSBP</td>
<td>2</td>
</tr>
<tr>
<td>WPA</td>
<td>10</td>
</tr>
</tbody>
</table>
Acknowledgements

The organizers of the 12th World Congress of Biological Psychiatry gratefully acknowledge the support of the following companies (as per May 2015)

SPONSORS

- Actelion Pharmaceuticals Ltd.
- Brainsway
- Ferrer
- Informa PLC
- MagVenture A/S
- MSD K.K.
- Neuroelectrics
- Neuronetics
- Pharmaserve Lilly S.A.C.L.
- REMED TMS-TSIMPOS
- Sumitomo Dainippon Pharma Co., Ltd.
- Wisepress Ltd.
**SUNDAY, 14 JUNE 2015**

**SA-01  INDUSTRY SPONSORED SYMPOSIUM**

16:00 – 17:30  Trianti Hall

**Bipolar disorder as metabolic inflammatory disorder: Implications for disease modeling and interventional priorities**
Chair: Joseph R. Calabrese, USA

**SA-01-001**

Bipolar disorder and metabolic disorder: Implications of depressive symptoms for cognitive function  
Roger S. McIntyre, Canada

**SA-01-002**

Gene expression changes in animal models of mood disorders: The effect of pharmacological intervention  
Marco Andrea Riva, Italy

supported by an educational grant from Sumitomo Dainippon Pharma Co. Ltd.

---

**MONDAY, 15 JUNE 2015**

**SA-02  INDUSTRY SPONSORED SYMPOSIUM**

17:00 – 18:30  Trianti Hall

**Orexin receptor antagonist and sleep disorder**
Chair: Masatoshi Takeda, Japan

**SA-02-001**

Solving the mysteries of sleep and wakefulness: from the discovery of orexin to forward genetics  
Masashi Yanagisawa, Japan

supported by an educational grant from MSD K.K.

---

**TUESDAY, 16 JUNE 2015**

**SA-03  INDUSTRY SPONSORED SYMPOSIUM**

13:30 – 15:00  Skalkotas Hall

**Managing behavioral emergencies**
Chair: Konstantinos Fountoulakis, Greece

**SA-03-001**

Management of behavioral emergencies in Europe: The French model  
Pierre-Michel Llorca, France

**SA-03-002**

Experience with inhaled route of administration in behavioral emergencies  
Andreas Erlfurth, Austria

supported by an educational grant from MSD K.K.

---

**WEDNESDAY, 17 JUNE 2015**

**SA-04  INDUSTRY SPONSORED SYMPOSIUM**

13:30 – 15:00  Skalkotas Hall

**Could it be Niemann-Pick disease Type C? A differential diagnosis of organic psychoses**
Chair: Hans-Hermann Klünemann, Germany

**SA-04-001**

Making the correct diagnosis: How to recognise a rare disease  
Hans-Hermann Klünemann, Germany

**SA-04-002**

Identifying disorders with organic psychoses: Revolutionising differential diagnosis  
Olivier Bonnot, France

**SA-04-003**

Novel approaches to screening, diagnosis and disease management in NP-C  
Mark Roberts, United Kingdom

supported by an educational grant from Actelion
List of Chairpersons and Presenters

B

Baadrup, L. .......................... 41
Babie, D. .............................. 41
Baca García, E. ...................... 58
Bacevic, A. ............................ 52
Bada Math, S. ......................... 58
Badouar, F. ............................ 41
Bae, K-V. ............................... 67
Bae, S-M. ............................... 66
Baez, M. T. ......................... 64
Bagalot, T. R. ......................... 50
Bai, Y-M. ............................... 51
Baque, M. G. ......................... 79
Balachandar, V. ................. 72, 89
Balachandar, S. ..................... 56
Balamurali Krishnan, B. ........ 72
Balasubramiam, B. ............. 38, 50
Balasundar, R. ..................... 71
Balderstone, P. ..................... 31
Balikova, M. ......................... 57
Ballarino, M. C. .................... 39
Banati, R. ......................... 49
Bandelov, B. ......................... 30
Bar, H. ............................... 63
Barclay, M. ......................... 65
Barclay, V. ............................ 45
Barcz, A. .............................. 66
Baron, S. .............................. 35
Barrantes, R. ....................... 55
Barrero, A. .......................... 73
Bartholomeusz, C. .............. 30, 38
Barrett, T. ......................... 40, 49, 69
Bartošková, I. ....................... 37
Bartova, I. ......................... 67
Batsherez, R. ....................... 78
Batstherreche, N. ............... 73
Bau, D. .............................. 56, 57
Bau, M. ............................... 64
Batukhina, E. ....................... 71
Bauer, M. .............................. 46
Bauer, B. .............................. 49, 58
Baus, C. ............................... 64
Bawor, M. ............................ 46
Baym, N. ............................... 77
Beaurel, S. .......................... 29, 36, 62, 63
Beck, J. ............................... 37
Beccue, S. ......................... 32
Beer-Sandtner, B. ............. 77
Begic, D. ......................... 52, 85
Behere, R. ............................ 40
Bien, K. ............................... 70
Beitiner, U. ......................... 39
Bellani, M. .......................... 41, 53, 72
Beli, M. ............................... 68
Ayhan, Y. ............................ 35
Ayis, M. ............................... 46
Azizi, I. ............................. 68, 69

A

Abdel-Aziz, H. ...................... 54
Ahner, E. ............................ 32
Abraham, G. ....................... 51
Abraham, R. ....................... 33, 70
Abreu-Gonzalez, P ................ 70
Abo-Akel, A. ......................... 30, 40
Abuhogazy, H. ..................... 48
Abujath, C. ......................... 60
Achab, S. ............................. 63
Achar, O. ............................. 72
Achuta, V. S. ....................... 48
Adamczyk, M. ...................... 61
Adelom, K. ........................... 38
Adriana, F-M. ...................... 38
Agapi, E. ............................. 41
Agart, I. .............................. 33, 41, 81
Agawal, S. M. ...................... 35
Aigd, O. ............................... 69
Agarastos, A. ...................... 32, 65, 71, 79
Ahern, E. ............................. 67
Ahmed, R. ............................ 72
Ahn, J. ............................... 66
Ahn, R-S. ............................ 71
Ahn, Y-M. ............................ 36, 37, 63
Ain, N. ............................... 66
Aizatides, A. ......................... 67, 85
Aizenstein, H. ...................... 32
Akel, H. .............................. 35
Akkus, M. ............................ 53
Albus, N. .............................. 53
Albayrak, Y. ........................ 53, 58, 85
Alberca, D. ......................... 84
Alberich, S. ......................... 67
Albuquerque, M. .................. 56, 81
Alcalá Partera, J. ................. 39, 64, 82, 85
Aleksandrovic, A. .............. 52, 69, 80
Alevizaki, M. ....................... 36
Alexander, J. ....................... 88
Alexiou, P. ........................... 50
Alifirova, V. ......................... 72
Allan, H. .............................. 40
Allott, K. ............................. 30
Allergi, R. ............................ 67
Alglunander, C. ................... 48, 60
Allott, K. ............................. 30, 38, 40
Almeida, O. ......................... 64
Alonso Zuñiga, E. ................. 56, 57
Altamura, C. ....................... 27, 32, 43, 51
Altorder, M. ......................... 56
Alvarez, M. ......................... 81
Alvarez, X. ........................... 38
Alvaresero, M. .................... 87
Alves Samo, T. ..................... 71
Alves, T. M. ......................... 53
Alvim-Soares, A. .................. 38
Aliyorg, U. ........................... 60
Ambras, L. ........................... 37
Ameis, S. ............................. 46
Ameixi, G. ............................ 52
Ammer, P. ............................ 38
Anamori, M. ......................... 29
Angagostoli, M. .................. 56
Anani, S. ............................. 29
Andersen, C. ....................... 55, 64
Andreasen, O. A. .................. 33, 41, 81
Andric, S. ............................ 32, 80
Andrere, F. ........................... 67, 84
Androutsos, G. .................... 49
Androutsos, G. .................... 47
Angelopoulou, E. ................. 23, 54, 79
Angkaw, A. C. ..................... 79
Angrisano, T. ....................... 69
An, S. K. ............................. 52
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
</tbody>
</table>
List of Chairpersons and Presenters

Kim, K.-S.  40
Kim, K. W.  51
Kim, K. W.  41
Kim, K. H.  36
Kim, S. H.  36, 52, 69
Kim, S.-H.  50
Kim, S. M.  66
Kim, S.-W.  38, 87
Kim, T.  78, 87
Kim, T. Y.  67
Kim, Y.  36, 50, 66
Kim, Y. J.  41
Kim, Y.-K.  87
Kim, Y. S.  52, 69
Kineller, J.  77
Kinosita, A.  80
Kioterakis, G.  35, 69
Kiral, L.  57, 87
Kircher, T.  24
Kirschaum, C.  64, 83
Kisielewski, J.  65
Kito, S.  74
Kisielewski, J.  65
Klauser, P.  49
Kloiber, S.  40
Klein, M.  53
Klein, H.  34
Kleber, S.  40
Klöppel, S.  77
Klozewski, L.  84, 87
Klönemann, H.-H.  65, 97
Klunk, W.  32
Klusa, V.  73
Knapp, R.  76
Knecht, B.  76
Knoth, F. K.  47
Kobori, A.  52, 69
Kodama, T.  37
Kogkas, A.  68
Kogna, A.  40
Kohl, C.  77
Koike, S.  56
Kokars, N.  64, 72, 73
Kokal, J.  53
Kokal, S.  40, 51, 54
Kohli, S.  88
Kokoske, L. G.  35
Kolios, F.  78
Kolios, R.  51
Kollermann, S.  41
Korczaszynski, A.  33
Korczaszynski, A.  33
Konadina, M. R.  33
Konezewska, B.  37
Kong, J.  31
Konstantopoulos, G.  82
Konstantinidis, A.  75
Konstantinidou, A.  48
Konstantinopoljsky, M.  35
Kopelman, T.  41
Koomacker, J.  37
Koone, C.  61
Korostylev, V.  67, 70, 83, 84, 88
Korostynski, M.  35
Kosic, J.  48
Kotsnaja, I.  40
Kow, K.  60
Koumoula, A.  38, 48
Koussouleris, N.  76, 80, 89
Kovaleski, L.  86
Kozhanova, H.  67, 70, 83
Kraemer, B.  41, 83
Kraft, K.  40
Krähenmann, R.  59
Kranz, G.  33, 40
Kratz, O.  24
Kraus, A.  56
Kraus, C.  24
Kreh, M.-O.  25
Krishnan, p.  50
Krishnasamy, S.  82
Kristofikova, Z.  21
Krivov, A.  68, 85
Kröl, A.  87
Kronbichler, M.  55, 72
Kruiger, T.  70
Krona, P.  44
Kubik, M.  44, 89
Kühnbock, M.  40
Kubo, H.  40
Kuckelkoch, A.  41, 34, 87
Kuckelkoch, S.  87
Kudo, T.  78, 80
Kuge, R.  73
Kukuljan, M.  52
Kulkarni, K.  73, 83
Kuloglu, M.  52, 85
Kumar, S.  28
Kunchula, M.  88
Kunjitpathapatham, G.  57, 67
Kurtovic, B.  52, 85
Kushner, S.  42
Kusumi, I.  26
Kutalk, Z.  82
Kuwano, M.  73
Kuznetsova, O.  86
Kwak, K.  87
Kwon, Y.  50
Kweon, Y.-S.  50
Kwon, Y.  68
Lachance, I.  54
Lachmann, I.  37
Lagergren, J.  34
Lagergren, K.  34
Lahaye, M.  60
Laiz, O.  31
Laksmhi, V.  79
Lammert, F.  64
Lammertz, A.  39, 65
Lamp, R. W.  46
Lamy, S.  69, 71
Lancaster, S.  89
Landgraf, R.  79
Landowski, J.  65
Lane, H.-Y.  26
Lange, E.  41
Lang, M.  50, 64, 83
Lamna, C.  38
Lan, T.-H.  66
Lanzenberger, R.  24, 27, 30
Lara, C.  31, 33, 40
Larach, V.  46
Larson, J.  66
Lasalvá, A.  71
Lasdun, J.  68
László, P.  34
Laucht, M.  26
Lawrence, A.  66
Lazarevic, D.  52
Le Bail, M.  27
Lebedeva, E.  67
Lee, K.  54
Lee, M.  43
Lebron-Mladk, K.  25
Lecene, C.  64, 65, 80
Ledesma Torres, L. A.  81
Lee, C.  56
Lee, C.-D.  56
Lee, C.-T.  50
Lee, C. U.  37, 56, 63
Lee, N.-U.  71
Lee, C.-W.  72
Lee, D.  51
Lee, H.-C.  50, 51
Lee, H. J.  36, 70
Lee, H.-K.  50
Lee, I.  44
Lee, I.-J.  50
Lee, J.  36
Lee, J.-S.  51
Lee, K.  33
Lee-Kardaschjan, L.  66
Lee, K. J.  53
Lee, K.-S.  71
Lee, K.-U.  50
Lee, M.-S.  63
Lee, P.  38
Lee, A.  80
Lehtimaki, T.  44
Levental, N.  37
Lemenager, T.  72
Lemes, J. A.  35
Leng, M.  35
Lenroot, R.  76, 77
Lepage, M.  34
Le Pen, G.  67
Let, S.  54, 87
Lesch, K.-P.  56
Lesch, O.-H.  42
Le Strat, Y.  25
Leszek, J.  32
Levchuk, L.  67
Levinson, A.  37
Levkovitz, H.  40
Levkovitz, Y.  60
Lewczuk, P.  37, 45
Li, X.  70
Li, Y.  84
Li, H.-C.  36
Li, S.-L.  83
Liu, J.  51
Liu, X.  50
Lukina, M. R.  53
Löw, W.-Y.  42
Lublin, H.  47
Ludie, S.  40
Lukingue, S.  68
Lu, M.-K.  84
Lu, M.-L.  36, 39
Luna Muñoz, J.  56
Lutz, P.-E.  60
Lyall, A.  89
Lykleman, C.  30, 58
Maite, C.-S.  69
Macdonald, A.  56
Machado-Viera, R.  36, 65
Madisen, H.  66
Madurak, A.  38
Maekawa, T.  83
Maeng, S.  25
Maes, M.  54
Maesta, F.  62
Maggiore, B.  32
Magrini, E.  51
Magier, R.  84
Magno, L.  71
Mago, R.  32, 54
Maher, M.  36
Maligno, L.  71
Malspach, A.  72
Malamou, R.  67, 85
Malan-Müller, S.  56
Malan-Müller, S.  50
Marsushko, A.  72
Marsushko, A.  72
Marsmur, D.  32
Markad, M.  76
Markad, M.  76
Markad, M.  76
Marsushko, A.  72
Marsushko, A.  72
List of Chairpersons and Presenters

Malhadas Martins, J. .................................. 49
Malthota, S. ......................................... 56, 57
Malla, A. .................................................. 34
Maller, L. .............................................. 36, 41
Malm, J. .................................................... 71
Malpighi, C. ........................................... 48
Malta Vacas, S. ........................................ 80
Malt, A. .................................................... 37
Malky, S. ................................................ 41
Mamede, M. ........................................... 73
Mamo, D. .................................................. 39
Manchia, M. ............................................ 55, 88
Mancke, F. ............................................... 33
Mancuso, S. ............................................ 57
Mann, J. ............................................... 75, 81
Mané, A. .................................................. 38
Mancuso, S. ............................................ 76
Mamo, D. ................................................ 39
McCorry, P. ............................................. 30, 38, 40, 41
McGuire, P. ............................................. 44
McIntosh, A. .......................................... 56
McIntyre, R. S. ........................................ 97
Mackay, M. ............................................. 51, 68
McKenna, J. ........................................... 44, 78
McLaughlin, D. ....................................... 76
McNally, J. ............................................. 44, 78
Meaney, M. J. ......................................... 60
Meinschmidt, G. ..................................... 71
Meisenzahl, E. ......................................... 74, 80
Melchior, T. ........................................... 57
Melle, I. .................................................. 33, 41, 81
Meltzer-Brody, S. ................................... 42
Menjí, A. ................................................. 64, 83
Mendlewicz, J. ........................................ 31
Meneses Luna, O. .................................. 81
Meneses, A. K. ........................................ 53
Menéndez, F. .......................................... 68, 69
Meraner, V. .......................................... 77
Merz, C. .................................................. 24
Mes planning-Cately, R. ......................... 89
Messanaid, A. ......................................... 68, 69
Metcalfe, M. .......................................... 57
Meyer-Lindenberg, A. ............................ 43
Meyyazhan, A. ...................................... 38, 50
Mihalla, A. ............................................. 68, 69, 72
Miller, C. ............................................... 60
Michal, B. ............................................. 34
Michaels, S. .......................................... 60
Miculek, R. ............................................ 84
Milch, C. ................................................. 48
Micochopoulos, I. .................................. 66, 70
Miculčíková, P. .................................... 55
Mickovius, N. ........................................ 52, 66
Mieliski, M. ......................................... 64, 82
Mihalev, M. ........................................... 32, 80
Miškiv, K. .............................................. 36
Min, K. ................................................... 36
Minnai, G. ............................................. 88
Miranda, D. ......................................... 38, 71, 73
Miranda, E. .......................................... 72, 85
Miranda-Letras, E. .................................. 40
Mispel, I. .............................................. 56
Mitschukhov, D. .................................... 80
Mitsou, D. ............................................ 51
Misra, A. K. .......................................... 86
Mital, A. K. ............................................ 30
Mitchell, J. ............................................ 35
Mietlman, S. .......................................... 26
Mitterhauer, M. ..................................... 33
Miyamoto, T. ........................................ 26
Miyashita, M. ........................................ 52, 69
Miura, H. .............................................. 78
Mizuta, N. ............................................. 37
Mjirchyan, G. ........................................ 32, 79
Miýinec, K. .......................................... 84
Modi, M. .............................................. 79
Mohler, E. .......................................... 64, 81
Moguunta, L. ........................................ 68, 73
Mohammed, Z. ....................................... 84
Mohammadkhani Shali, S. .................... 33
Mohana Devi, S. .................................. 89
Mohandas, E. ........................................ 60
Mohan, G. ............................................. 69
Moha ou Maati, H. ................................ 31
Moldovan, R. ........................................ 79
Mølendijk, J. ........................................ 58
Molina-Andreu, D. ................................ 49
Mollenhauer, H. .................................... 45
Möller, H. J. .......................................... 80
Möll, G. .................................................. 34
Molteni, M. .......................................... 38
Mondelli, V. .......................................... 39
Montes, C. ........................................... 52, 70
Montgomery, S. ..................................... 31
Moons, T. .............................................. 32
Morallata, R. ........................................ 24, 48
Moreno, S. ............................................ 31
Moreno-Fueyo, A. I. ......................... 30, 55
Morgan, C. ........................................... 76
Morgan, V. ........................................... 76
Mor, K. .................................................. 89
Morinaga, S. ......................................... 80
Moris, O. .............................................. 55
Mortensen, J. K. .................................... 56
Mortensen, P. B. .................................... 53
Moscato, P. .......................................... 56
Mosoidek, A. ......................................... 56
Mora, E. ................................................. 83
Mota, C. .................................................. 66
Mothet, J.-P. .......................................... 27, 77
Motomura, K. ....................................... 56
Mottaghy, F. ........................................... 81
Musial, V. .............................................. 47
Musial, T. .............................................. 43
Musiaux, C. .......................................... 51, 80, 83
Madr, A. .................................................. 68
Mucci, A. ................................................. 58
Mudado, F. ............................................ 71
Mueller, J. ............................................ 54
Mueler, M. ............................................ 76
Muik, K. .................................................. 47
Mukherjee, S. ........................................ 83
Muldner-Niekewski, L. ................. 64, 82
Mühle, D. .............................................. 47
Müller, J. .............................................. 45
Müller, U. .............................................. 27
Mullin, R. .............................................. 71
Mulsant, B. ........................................... 36, 39
Mummo, J. ............................................ 35
Müller, L. .............................................. 37
Müller, M. .............................................. 76
Müller, R. .............................................. 76
Munoz, D. ............................................. 38
Munk-Olsen, T. ..................................... 37, 42
Munoz, D. ............................................. 38
Munoz-Lorenzo, L. ......................... 33, 42
Murayama, K. ....................................... 73
Murphy, M. .......................................... 79
Murphy, M. .......................................... 79
Murphy, R. ........................................... 53, 72
Murphy, U. ............................................ 81
Musalek, M. ........................................... 61
Mush 시, K. ........................................... 63
Mushiti, D. ............................................ 63
Mushiti, H. ............................................ 45
Musler, K. ............................................ 37
Mustaphic, M. ........................................ 37
Mutalik, N. R. ........................................ 30
Moez, E. ................................................. 64
Myint, A.-M. ......................................... 77
Mykhallov, E. ...................................... 66
Mykhaliov, V. ........................................ 84
Myung, W. .......................................... 66
Na, C. ......................................................... 36, 66
Na, R. ......................................................... 52
Nadekall, R. K. ...................................... 40
Nagpal, R. .......................................... 28
Nagy, K. ................................................. 33
Nahas, Z. ............................................. 55
Najar, F. ............................................ 68, 69, 72
Nakae, A. ............................................. 60
Nakajima, A. ........................................ 39
Nakajima, S. ......................................... 39
Nakajim, T. .......................................... 88
Nakamae, T. ........................................ 47
Nakamura, M. ....................................... 34, 60
Nakao, K. .............................................. 45, 54
Nakao, T. ............................................. 47, 73
Nakazato, M. ......................................... 86
Nakazawa, K. ....................................... 45, 54
Nakovic, H. .......................................... 41
Na, J.-S. .................................................. 66
Nalvarte, I. .......................................... 51
Nam, B. .................................................. 86
Nam, J. Y. .............................................. 37
Napolitano, F. ........................................ 69
Naarmalalage, H. ................................. 39
Narayanaswamy, J. ............................. 35, 73
Nasar, M. ............................................. 51, 53, 67, 86, 87
Nathan, D. ............................................ 55
Nayar, A. ............................................. 71
Nawara, L. A. ..................................... 55
Nebes, R. ............................................. 32
Neffati, F. ............................................ 72
Nehra, R. ............................................. 79
Neill, E. ............................................... 30, 55
Nelson, R. ............................................ 49, 69
Nenadic, I. ........................................... 30
Nerland, S. ........................................... 33, 41
Nesvág, R. .......................................... 33
Neufeld, N. .......................................... 27
Neukel, C. .......................................... 81
Neura, E. .............................................. 81
Nevre, F. ............................................... 81
Nevre, M. ............................................ 56, 81
Nevidimova, T. ................................... 71
Nielckowski, L. .................................. 40
Nickell, T. ............................................. 45
Nicola, B. ............................................. 55
Nicola, Y. ............................................. 81
Nicola, R. ............................................ 49, 56, 81
Nicolai, R. ............................................ 44
Nielsen, R. E. ...................................... 47
Niernberg, A. ....................................... 51
Nieto, R. ............................................... 52
Nievergelt, C. M. .................................... 79
Nikolic, G. ............................................ 48
Nimatod, J. .......................................... 31, 85
Nimpa, B. ............................................. 49, 69
Nimrody, T. ......................................... 50
Nishimura, Y. ....................................... 30
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oberguggenberger, A.</td>
<td>77</td>
</tr>
<tr>
<td>Oakeley, E.</td>
<td>56</td>
</tr>
<tr>
<td>Nobska, T.</td>
<td>68</td>
</tr>
<tr>
<td>Nöthen, M.</td>
<td>79</td>
</tr>
<tr>
<td>Nutt, D.</td>
<td>65</td>
</tr>
<tr>
<td>Odebrecht, S.</td>
<td>36</td>
</tr>
<tr>
<td>Odebrecht, H.</td>
<td>36</td>
</tr>
<tr>
<td>Oluyadi, F.</td>
<td>50</td>
</tr>
<tr>
<td>Olazabal, N.</td>
<td>73</td>
</tr>
<tr>
<td>Okochi, M.</td>
<td>37</td>
</tr>
<tr>
<td>Okamura, M.</td>
<td>65</td>
</tr>
<tr>
<td>Ortiz-Garcia de la Foz, V.</td>
<td>74</td>
</tr>
<tr>
<td>O'Rourke, S.</td>
<td>38</td>
</tr>
<tr>
<td>Oskuro, F.</td>
<td>71</td>
</tr>
<tr>
<td>Oskuro, F.</td>
<td>71</td>
</tr>
<tr>
<td>Oosthuizen, K.</td>
<td>35</td>
</tr>
<tr>
<td>Oubel, M.</td>
<td>67</td>
</tr>
</tbody>
</table>

### P

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Padberg, F.</td>
<td>59</td>
</tr>
<tr>
<td>Padmanabhaikumar, S. S.</td>
<td>41</td>
</tr>
<tr>
<td>Padmasree, M.</td>
<td>97</td>
</tr>
<tr>
<td>Pae, C. L.</td>
<td>54</td>
</tr>
<tr>
<td>Pagida, M.</td>
<td>48</td>
</tr>
<tr>
<td>Paik, I. H.</td>
<td>37</td>
</tr>
<tr>
<td>Paik, J-W.</td>
<td>41, 63</td>
</tr>
<tr>
<td>Paik, Y.</td>
<td>54</td>
</tr>
<tr>
<td>Painold, A.</td>
<td>36</td>
</tr>
<tr>
<td>Paiva, A.</td>
<td>49</td>
</tr>
<tr>
<td>Pajute, K.</td>
<td>73</td>
</tr>
<tr>
<td>Palacios Escalona, S.</td>
<td>56</td>
</tr>
<tr>
<td>Palaniyappan, A.</td>
<td>76</td>
</tr>
<tr>
<td>Palencsar, T.</td>
<td>57, 59</td>
</tr>
<tr>
<td>Palma, H.</td>
<td>66</td>
</tr>
<tr>
<td>Panayotopoulos, M.</td>
<td>48, 55</td>
</tr>
<tr>
<td>Pandey, G.</td>
<td>23, 75</td>
</tr>
<tr>
<td>Panon, D.</td>
<td>33</td>
</tr>
<tr>
<td>Panteleakis, D.</td>
<td>41</td>
</tr>
<tr>
<td>Pantelis, C.</td>
<td>23, 30, 36</td>
</tr>
<tr>
<td>Papadamitriou, G. N.</td>
<td>51, 61, 74</td>
</tr>
<tr>
<td>Papadodima, O.</td>
<td>31, 78</td>
</tr>
<tr>
<td>Papadopoulou, A.</td>
<td>52, 84</td>
</tr>
<tr>
<td>Papageorgiou, C.</td>
<td>34, 52, 84, 88</td>
</tr>
<tr>
<td>Papageorgiou, G.</td>
<td>39, 87</td>
</tr>
<tr>
<td>Papageorgiou, K.</td>
<td>34, 75</td>
</tr>
<tr>
<td>Papageorgiou, S.</td>
<td>32, 56</td>
</tr>
<tr>
<td>Papakosta, J.</td>
<td>71</td>
</tr>
<tr>
<td>Papale, N.</td>
<td>36</td>
</tr>
<tr>
<td>Paparrigopoulos, T.</td>
<td>35, 64, 65, 82</td>
</tr>
<tr>
<td>Papazahos, C.</td>
<td>88</td>
</tr>
<tr>
<td>Pappa, D.</td>
<td>72, 85</td>
</tr>
<tr>
<td>Paquet, Ph.D. J.</td>
<td>36</td>
</tr>
<tr>
<td>Paradis, I.</td>
<td>54</td>
</tr>
<tr>
<td>Pardo, M.</td>
<td>38</td>
</tr>
<tr>
<td>Parellada, E.</td>
<td>24</td>
</tr>
<tr>
<td>Pariante, C.</td>
<td>23, 43</td>
</tr>
<tr>
<td>Parikh, S.</td>
<td>29, 43</td>
</tr>
<tr>
<td>Parisi, S. A.</td>
<td>71</td>
</tr>
<tr>
<td>Park, C.</td>
<td>67</td>
</tr>
<tr>
<td>Park, H-J.</td>
<td>52</td>
</tr>
<tr>
<td>Park, J-I.</td>
<td>51</td>
</tr>
<tr>
<td>Park, K.</td>
<td>52</td>
</tr>
<tr>
<td>Park, S. Y.</td>
<td>36, 63</td>
</tr>
<tr>
<td>Park, S. Y.</td>
<td>66</td>
</tr>
<tr>
<td>Park, T. W.</td>
<td>51</td>
</tr>
<tr>
<td>Partyka, M.</td>
<td>84</td>
</tr>
<tr>
<td>Paschali, M.</td>
<td>53</td>
</tr>
<tr>
<td>Paschou, P.</td>
<td>41, 83, 88</td>
</tr>
<tr>
<td>Passarelli Giroud, J. H.</td>
<td>53, 71</td>
</tr>
<tr>
<td>Paternak, O.</td>
<td>44</td>
</tr>
<tr>
<td>Pantazis, K.</td>
<td>30, 71</td>
</tr>
<tr>
<td>Patel, J.</td>
<td>67</td>
</tr>
<tr>
<td>Pathak, S.</td>
<td>42</td>
</tr>
<tr>
<td>Pattet, J.</td>
<td>34</td>
</tr>
<tr>
<td>Patterson Silver Wolf, D. A.</td>
<td>66</td>
</tr>
<tr>
<td>Paulet, M.</td>
<td>53, 85</td>
</tr>
<tr>
<td>Paul, I.</td>
<td>35</td>
</tr>
<tr>
<td>Paul, P.</td>
<td>40</td>
</tr>
<tr>
<td>Pauls, W.</td>
<td>74</td>
</tr>
<tr>
<td>Pawlzen, M.</td>
<td>39, 65</td>
</tr>
<tr>
<td>Pawluk, D.</td>
<td>32</td>
</tr>
<tr>
<td>Pawlowski, M.</td>
<td>61</td>
</tr>
<tr>
<td>Paz, R.</td>
<td>54</td>
</tr>
<tr>
<td>Pecciniuji, E.</td>
<td>80</td>
</tr>
<tr>
<td>Pedersen, C. B.</td>
<td>53</td>
</tr>
</tbody>
</table>

### Q

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quadri, A.</td>
<td>86</td>
</tr>
<tr>
<td>Quadri, M.</td>
<td>86</td>
</tr>
<tr>
<td>Quartaz, R.</td>
<td>29</td>
</tr>
<tr>
<td>Quattrocchi, C. C.</td>
<td>83</td>
</tr>
<tr>
<td>Quetein, L.</td>
<td>82</td>
</tr>
</tbody>
</table>

### R

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel, W.</td>
<td>84</td>
</tr>
<tr>
<td>Radziwon-Zaleska, M.</td>
<td>68, 71</td>
</tr>
<tr>
<td>Rapot, S.</td>
<td>41</td>
</tr>
<tr>
<td>Rai, H.</td>
<td>49, 68</td>
</tr>
<tr>
<td>Rajesh, J.</td>
<td>57</td>
</tr>
<tr>
<td>Raja, T.</td>
<td>80</td>
</tr>
<tr>
<td>Ralphs, C.</td>
<td>34</td>
</tr>
<tr>
<td>Ramalingam, J.</td>
<td>56, 72</td>
</tr>
<tr>
<td>Ramaseshan, K.</td>
<td>41, 51, 53, 57, 68</td>
</tr>
<tr>
<td>Rambaladelli, C.</td>
<td>72</td>
</tr>
<tr>
<td>Rami-Mark, C.</td>
<td>33</td>
</tr>
<tr>
<td>Ramos Dunn, N.</td>
<td>39, 83</td>
</tr>
<tr>
<td>Ramez, N.</td>
<td>25, 27</td>
</tr>
</tbody>
</table>
WFSBP Congress 2017

13th World Congress of Biological Psychiatry

18 – 22 June 2017
Bella Center | Copenhagen, Denmark

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry
The congress at your fingertips:

WFSBP GLOBAL HEADQUARTERS
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49–40–670 882 90
Fax: +49–40–670 328 82 91
Email: info@wfsbp.org
www.wfsbp.org